{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:11:57Z","timestamp":1777889517519,"version":"3.51.4"},"reference-count":935,"publisher":"Bentham Science Publishers Ltd.","issue":"11","funder":[{"DOI":"10.13039\/501100001871","name":"FCT - Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["LA\/P\/0058\/2020"],"award-info":[{"award-number":["LA\/P\/0058\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT - Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04539\/2020"],"award-info":[{"award-number":["UIDB\/04539\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT - Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDP\/04539\/2020"],"award-info":[{"award-number":["UIDP\/04539\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT - Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/QUI-OUT\/32243\/2017"],"award-info":[{"award-number":["PTDC\/QUI-OUT\/32243\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT - Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/149709\/2019"],"award-info":[{"award-number":["SFRH\/BD\/149709\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2022,11]]},"abstract":"\nAbstract:<\/jats:title>\nNeurodegenerative diseases affect over 30 million people worldwide with an ascending\ntrend. Most individuals suffering from these irreversible brain damages belong to the elderly population,\nwith onset between 50 and 60 years. Although the pathophysiology of such diseases is partially\nknown, it remains unclear upon which point a disease turns degenerative. Moreover, current\ntherapeutics can treat some of the symptoms but often have severe side effects and become less effective\nin long-term treatment. For many neurodegenerative diseases, the involvement of G proteincoupled\nreceptors (GPCRs), which are key players of neuronal transmission and plasticity, has become\nclearer and holds great promise in elucidating their biological mechanism. With this review,\nwe introduce and summarize class A and class C GPCRs, known to form heterodimers or oligomers\nto increase their signalling repertoire. Additionally, the examples discussed here were shown to display\nrelevant alterations in brain signalling and had already been associated with the pathophysiology\nof certain neurodegenerative diseases. Lastly, we classified the heterodimers into two categories\nof crosstalk, positive or negative, for which there is known evidence.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570159x20666220327221830","type":"journal-article","created":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T18:34:48Z","timestamp":1648406088000},"page":"2081-2141","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Class A and C GPCR Dimers in Neurodegenerative Diseases"],"prefix":"10.2174","volume":"20","author":[{"given":"Irina S.","family":"Moreira","sequence":"first","affiliation":[{"name":"University of Coimbra, Department of Life Sciences, Cal\u00e7ada\nMartim de Freitas, 3000-456 Coimbra, Portugal"},{"name":"Center for Neuroscience and Cell Biology, Center for Innovative Biomedicine\nand Biotechnology, 3004-504 Coimbra, Portugal"}]},{"given":"Ana B.","family":"Caniceiro","sequence":"additional","affiliation":[{"name":"Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal"}]},{"given":"Beatriz","family":"Bueschbell","sequence":"additional","affiliation":[{"name":"PhD Programme in\nExperimental Biology and Biomedicine, Institute for Interdisciplinary Research (IIIUC), University of Coimbra, Casa\nCosta Alem\u00e3o, 3030-789 Coimbra, Portugal"}]},{"given":"Anke C.","family":"Schiedel","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical & Medicinal Chemistry, Pharmaceutical\nInstitute, University of Bonn, D-53121 Bonn, Germany"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3390\/cells9020506","volume":"9","author":"Azam S.","year":"2020","unstructured":"Azam S.; Haque M.E.; Jakaria M.; Jo S.H.; Kim I.S.; Choi D.K.; G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative Disorders and Associated Cognitive Deficits. Cells 2020,9(2),506","journal-title":"Cells"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1172\/JCI200317522","volume":"111","author":"Przedborski S.","year":"2003","unstructured":"Przedborski S.; Vila M.; Jackson-Lewis V.; Neurodegeneration: what is it and where are we? J Clin Invest 2003,111(1),3-10","journal-title":"J Clin Invest"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3390\/antiox8090348","volume":"8","author":"Jakaria M.","year":"2019","unstructured":"Jakaria M.; Azam S.; Cho D.Y.; Haque M.E.; Kim I.S.; Choi D.K.; The methanol extract of Allium cepa L. Protects inflammatory markers in LPS-induced BV-2 microglial cells and upregulates the antiapoptotic gene and antioxidant enzymes in N27-A cells. Antioxidants 2019,8(9),348","journal-title":"Antioxidants"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.3390\/jcm8111789","volume":"8","author":"Jakaria M.","year":"2019","unstructured":"Jakaria M.; Azam S.; Jo S.H.; Kim I.S.; Dash R.; Choi D.K.; Potential therapeutic targets of quercetin and its derivatives: its role in the therapy of cognitive impairment. J Clin Med 2019,8(11),1789","journal-title":"J Clin Med"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.coph.2017.02.001","volume":"32","author":"Huang Y.","year":"2017","unstructured":"Huang Y.; Todd N.; Thathiah A.; The role of GPCRs in neurodegenerative diseases: Avenues for therapeutic intervention. Curr Opin Pharmacol 2017,32,96-110","journal-title":"Curr Opin Pharmacol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.31887\/DCNS.2013.15.4\/sarlt","volume":"15","author":"Arlt S.","year":"2013","unstructured":"Arlt S.; Non-Alzheimer\u2019s disease-related memory impairment and dementia. Dialogues Clin Neurosci 2013,15(4),465-473","journal-title":"Dialogues Clin Neurosci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1172\/JCI24761","volume":"115","author":"Bertram L.","year":"2005","unstructured":"Bertram L.; Tanzi R.E.; The genetic epidemiology of neurodegenerative disease. J Clin Invest 2005,115(6),1449-1457","journal-title":"J Clin Invest"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"786","DOI":"10.2174\/1570159X16666180308161642","volume":"16","author":"Lemos A.","year":"2018","unstructured":"Lemos A.; Melo R.; Preto A.J.; Almeida J.G.; Moreira I.S.; Dias Soeiro Cordeiro M.N.; \nIn silico\nstudies targeting G-protein coupled receptors for drug research against Parkinson\u2019s disease.\n Curr Neuropharmacol 2018,16(6),786-848","journal-title":"Curr Neuropharmacol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"Serrano-Pozo A.","year":"2011","unstructured":"Serrano-Pozo A.; Frosch M.P.; Masliah E.; Hyman B.T.; Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011,1(1),a006189","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=10","volume":"17","author":"Lopez OL","year":"2011","unstructured":"Lopez OL; The growing burden of Alzheimer\u2019s disease. Am J Manag Care 2011,17(Suppl 1)","journal-title":"Am J Manag Care"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/cercor\/bhn113","volume":"19","author":"Dickerson B.C.","year":"2009","unstructured":"Dickerson B.C.; Bakkour A.; Salat D.H.; Feczko E.; Pacheco J.; Greve D.N.; Grodstein F.; Wright C.I.; Blacker D.; Rosas H.D.; Sperling R.A.; Atri A.; Growdon J.H.; Hyman B.T.; Morris J.C.; Fischl B.; Buckner R.L.; The cortical signature of Alzheimer\u2019s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex 2009,19(3),497-510","journal-title":"Cereb Cortex"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"Kalia L.V.","year":"2015","unstructured":"Kalia L.V.; Lang A.E.; Parkinson\u2019s disease. Lancet 2015,386(9996),896-912","journal-title":"Lancet"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s12031-016-0799-3","volume":"60","author":"Yassi N.","year":"2016","unstructured":"Yassi N.; Desmond P.M.; Masters C.L.; Magnetic resonance imaging of vascular contributions to cognitive impairment and dementia. J Mol Neurosci 2016,60(3),349-353","journal-title":"J Mol Neurosci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00401-016-1571-z","volume":"131","author":"Kalaria R.N.","year":"2016","unstructured":"Kalaria R.N.; Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer\u2019s disease. Acta Neuropathol 2016,131(5),659-685","journal-title":"Acta Neuropathol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"f4827","DOI":"10.1136\/bmj.f4827","volume":"347","author":"Warren J.D.","year":"2013","unstructured":"Warren J.D.; Rohrer J.D.; Rossor, MN Frontotemporal dementia. BMJ 2013,347(123),f4827","journal-title":"BMJ"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2217\/nmt.11.9","volume":"1","author":"Jicha G.A.","year":"2011","unstructured":"Jicha G.A.; Nelson P.T.; Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options. Neurodegener Dis Manag 2011,1(2),141-156","journal-title":"Neurodegener Dis Manag"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"Ross C.A.","year":"2014","unstructured":"Ross C.A.; Aylward E.H.; Wild E.J.; Langbehn D.R.; Long J.D.; Warner J.H.; Scahill R.I.; Leavitt B.R.; Stout J.C.; Paulsen J.S.; Reilmann R.; Unschuld P.G.; Wexler A.; Margolis R.L.; Tabrizi S.J.; Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 2014,10(4),204-216","journal-title":"Nat Rev Neurol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/ng0893-398","volume":"4","author":"Andrew S.E.","year":"1993","unstructured":"Andrew S.E.; Goldberg Y.P.; Kremer B.; Telenius H.; Theilmann J.; Adam S.; Starr E.; Squitieri F.; Lin B.; Kalchman M.A.; The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington\u2019s disease. Nat Genet 1993,4(4),398-403","journal-title":"Nat Genet"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1523\/JNEUROSCI.19-07-02522.1999","volume":"19","author":"Gutekunst C.A.","year":"1999","unstructured":"Gutekunst C.A.; Li S.H.; Yi H.; Mulroy J.S.; Kuemmerle S.; Jones R.; Rye D.; Ferrante R.J.; Hersch S.M.; Li X.J.; Nuclear and neuropil aggregates in Huntington\u2019s disease: relationship to neuropathology. J Neurosci 1999,19(7),2522-2534","journal-title":"J Neurosci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"a023705","DOI":"10.1101\/cshperspect.a023705","volume":"9","author":"Hinz F.I.","year":"2017","unstructured":"Hinz F.I.; Geschwind D.H.; Molecular genetics of neurodegenerative dementias. Cold Spring Harb Perspect Biol 2017,9(4),a023705","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/WCO.0b013e32833be924","volume":"23","author":"Dickson D.W.","year":"2010","unstructured":"Dickson D.W.; Ahmed Z.; Algom A.A.; Tsuboi Y.; Josephs K.A.; Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol 2010,23(4),394-400","journal-title":"Curr Opin Neurol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","volume":"70","author":"Braak H.","year":"2011","unstructured":"Braak H.; Thal D.R.; Ghebremedhin E.; Del Tredici K.; Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. J Neuropathol Exp Neurol 2011,70(11),960-969","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/NEN.0000000000000046","volume":"73","author":"Dugger B.N.","year":"2014","unstructured":"Dugger B.N.; Hentz J.G.; Adler C.H.; Sabbagh M.N.; Shill H.A.; Jacobson S.; Caviness J.N.; Belden C.; Driver-Dunckley E.; Davis K.J.; Sue L.I.; Beach T.G.; Clinicopathological outcomes of prospectively followed normal elderly brain bank volunteers. J Neuropathol Exp Neurol 2014,73(3),244-252","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"a028035","DOI":"10.1101\/cshperspect.a028035","volume":"9","author":"Dugger B.N.","year":"2017","unstructured":"Dugger B.N.; Dickson D.W.; Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol 2017,9(7),a028035","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.sbi.2019.03.022","volume":"55","author":"Jabeen A.","year":"2019","unstructured":"Jabeen A.; Ranganathan S.; Applications of machine learning in GPCR bioactive ligand discovery. Curr Opin Struct Biol 2019,55,66-76","journal-title":"Curr Opin Struct Biol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"522","DOI":"10.2174\/1389450120666181105152439","volume":"20","author":"Saikia S.","year":"2019","unstructured":"Saikia S.; Bordoloi M.; Sarmah R.; Established and in-trial GPCR families in clinical trials: A review for target selection. Curr Drug Targets 2019,20(5),522-539","journal-title":"Curr Drug Targets"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/bs.mcb.2017.07.011","author":"Sensoy O.","year":"2017","unstructured":"Sensoy O.; Almeida J.G.; Shabbir J.; Moreira I.S.; Morra G.; Methods in Cell Biology 2017,205-245","journal-title":"Methods in Cell Biology"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuint.2016.09.005","volume":"101","author":"Guerram M.","year":"2016","unstructured":"Guerram M.; Zhang L.Y.; Jiang Z.Z.; G-protein coupled receptors as therapeutic targets for neurodegenerative and cerebrovascular diseases. Neurochem Int 2016,101,1-14","journal-title":"Neurochem Int"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.biotechadv.2013.08.017","volume":"31","author":"Heng B.C.","year":"2013","unstructured":"Heng B.C.; Aubel D.; Fussenegger M.; An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases. Biotechnol Adv 2013,31(8),1676-1694","journal-title":"Biotechnol Adv"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature08144","volume":"459","author":"Rosenbaum D.M.","year":"2009","unstructured":"Rosenbaum D.M.; Rasmussen S.G.F.; Kobilka B.K.; The structure and function of G-protein-coupled receptors. Nature 2009,459(7245),356-363","journal-title":"Nature"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1124\/mol.63.6.1256","volume":"63","author":"Fredriksson R.","year":"2003","unstructured":"Fredriksson R.; Lagerström M.C.; Lundin L.G.; Schiöth H.B.; The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 2003,63(6),1256-1272","journal-title":"Mol Pharmacol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"617176","DOI":"10.3389\/fmolb.2021.617176","volume":"8","author":"Jabeen A.","year":"2021","unstructured":"Jabeen A.; Vijayram R.; Ranganathan S.; BIO-GATS: A tool for automated GPCR template selection through a biophysical approach for homology modeling. Front Mol Biosci 2021,8,617176","journal-title":"Front Mol Biosci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"11669","DOI":"10.1038\/s41598-020-68355-x","volume":"10","author":"Miyagi H.","year":"2020","unstructured":"Miyagi H.; Asada H.; Suzuki M.; Takahashi Y.; Yasunaga M.; Suno C.; Iwata S.; Saito J.I.; The discovery of a new antibody for BRIL-fused GPCR structure determination. Sci Rep 2020,10(1),11669","journal-title":"Sci Rep"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1371\/journal.pcbi.0020029","volume":"2","author":"Zhang Y.","year":"2006","unstructured":"Zhang Y.; DeVries M.E.; Skolnick J.; Correction: Structure modeling of all identified G protein-coupled receptors in the human genome. PLOS Comput Biol 2006,2(3),e29","journal-title":"PLOS Comput Biol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nrd.2017.178","volume":"16","author":"Hauser A.S.","year":"2017","unstructured":"Hauser A.S.; Attwood M.M.; Rask-Andersen M.; Schiöth H.B.; Gloriam D.E.; Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov 2017,16(12),829-842","journal-title":"Nat Rev Drug Discov"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.febslet.2015.05.007","volume":"589","author":"Huang Y.","year":"2015","unstructured":"Huang Y.; Thathiah A.; Regulation of neuronal communication by G protein-coupled receptors. FEBS Lett 2015,589(14),1607-1619","journal-title":"FEBS Lett"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.pneurobio.2012.01.009","volume":"96","author":"Betke K.M.","year":"2012","unstructured":"Betke K.M.; Wells C.A.; Hamm H.E.; GPCR mediated regulation of synaptic transmission. Prog Neurobiol 2012,96(3),304-321","journal-title":"Prog Neurobiol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1146\/annurev.bi.48.070179.003543","volume":"48","author":"Snyder S.H.","year":"1979","unstructured":"Snyder S.H.; Innis R.B.; Peptide neurotransmitters. Annu Rev Biochem 1979,48,755-782","journal-title":"Annu Rev Biochem"},{"key":"ref=39","author":"Lodish H.","year":"2000","unstructured":"Lodish H.; Berk A.; Zipursky S.L.E.A.; 2000"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.semcdb.2003.12.017","volume":"15","author":"Hall R.A.","year":"2004","unstructured":"Hall R.A.; β-adrenergic receptors and their interacting proteins. Semin Cell Dev Biol 2004,15(3),281-288","journal-title":"Semin Cell Dev Biol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.33549\/physiolres.931903","volume":"60","author":"Pytliak M.","year":"2011","unstructured":"Pytliak M.; Vargová V.; Mechírová V.; Fel\u0161öci M.; Serotonin receptors - from molecular biology to clinical applications. Physiol Res 2011,60(1),15-25","journal-title":"Physiol Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1002\/cbdv.201200288","volume":"9","author":"Hoyer D.","year":"2012","unstructured":"Hoyer D.; Bartfai T.; Neuropeptides and neuropeptide receptors: drug targets, and peptide and non-peptide ligands: A tribute to Prof. Dieter Seebach. Chem Biodivers 2012,9(11),2367-2387","journal-title":"Chem Biodivers"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nrd4295","volume":"13","author":"Kruse A.C.","year":"2014","unstructured":"Kruse A.C.; Kobilka B.K.; Gautam D.; Sexton P.M.; Christopoulos A.; Wess J.; Muscarinic acetylcholine receptors: novel opportunities for drug development. Nat Rev Drug Discov 2014,13(7),549-560","journal-title":"Nat Rev Drug Discov"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.2174\/1389557511313130010","volume":"13","author":"Vaidya A.","year":"2013","unstructured":"Vaidya A.; Jain S.; Jain A.K.; Agrawal A.; Kashaw S.K.; Jain S.K.; Agrawal R.K.; Metabotropic glutamate receptors: A review on prospectives and therapeutic aspects. Mini Rev Med Chem 2013,13(13),1967-1981","journal-title":"Mini Rev Med Chem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1124\/pr.110.002642","volume":"63","author":"Beaulieu J.M.","year":"2011","unstructured":"Beaulieu J.M.; Gainetdinov R.R.; The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011,63(1),182-217","journal-title":"Pharmacol Rev"},{"key":"ref=46","first-page":"410","volume":"10","author":"Emerson G.M.","year":"1973","unstructured":"Emerson G.M.; Emerson studies on growth hormone effects in the Norway rat. Ala J Med Sci 1973,10(4),410-416","journal-title":"Ala J Med Sci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejphar.2010.12.024","volume":"660","author":"Marston O.J.","year":"2011","unstructured":"Marston O.J.; Garfield A.S.; Heisler L.K.; Role of central serotonin and melanocortin systems in the control of energy balance. Eur J Pharmacol 2011,660(1),70-79","journal-title":"Eur J Pharmacol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.neubiorev.2010.02.001","volume":"35","author":"Ikemoto S.","year":"2010","unstructured":"Ikemoto S.; Brain reward circuitry beyond the mesolimbic dopamine system: A neurobiological theory. Neurosci Biobehav Rev 2010,35(2),129-150","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"R222","DOI":"10.1152\/ajpregu.00556.2010","volume":"300","author":"Rinaman L.","year":"2011","unstructured":"Rinaman L.; Hindbrain noradrenergic A2 neurons: diverse roles in autonomic, endocrine, cognitive, and behavioral functions. Am J Physiol Regul Integr Comp Physiol 2011,300(2),R222-R235","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"162","DOI":"10.5603\/AIT.2015.0015","volume":"47","author":"Iwa\u0144czuk W.","year":"2015","unstructured":"Iwa\u0144czuk W.; Guźniczak P.; Neurophysiological foundations of sleep, arousal, awareness and consciousness phenomena. Part 1. Anaesthesiol Intensive Ther 2015,47(2),162-167","journal-title":"Anaesthesiol Intensive Ther"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.neubiorev.2016.03.008","volume":"64","author":"Trofimova I.","year":"2016","unstructured":"Trofimova I.; Robbins T.W.; Temperament and arousal systems: A new synthesis of differential psychology and functional neurochemistry. Neurosci Biobehav Rev 2016,64,382-402","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1177\/088307389701200802","volume":"12","author":"Bittigau P.","year":"1997","unstructured":"Bittigau P.; Ikonomidou C.; Glutamate in neurologic diseases. J Child Neurol 1997,12(8),471-485","journal-title":"J Child Neurol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3109\/00207454.2010.483651","volume":"120","author":"Werner F.M.","year":"2010","unstructured":"Werner F.M.; Coveñas R.; Classical neurotransmitters and neuropeptides involved in major depression: A review. Int J Neurosci 2010,120(7),455-470","journal-title":"Int J Neurosci"},{"key":"ref=54","first-page":"6","author":"Mehta T.R.","year":"2019","unstructured":"Mehta T.R.; Monegro A.; Nene Y.; Fayyaz M.; Bollu P.C.; Current Developmental Disorders Reports 2019,6","journal-title":"Current Developmental Disorders Reports"},{"key":"ref=55","first-page":"45","volume":"12","author":"Khalifeh S.","year":"2021","unstructured":"Khalifeh S.; Pour M.S.; Ghermezian A.; Behvarmanesh A.; Moghtadaei M.; Ashabi G.; Introduction to neurocircuitry and neurobiology of anxiety. Arch Adv Biosci 2021,12(1),45-51","journal-title":"Arch Adv Biosci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.physbeh.2007.05.021","volume":"92","author":"Meister B.","year":"2007","unstructured":"Meister B.; Neurotransmitters in key neurons of the hypothalamus that regulate feeding behavior and body weight. Physiol Behav 2007,92(1-2),263-271","journal-title":"Physiol Behav"},{"key":"ref=57","author":"Li Y.","year":"2021","unstructured":"Li Y.; Wang X.; Ge, SN; Wang, XL\nAlterations in neurotransmitters targeted metabolomics from the key nuclei of brain reward circuits in cocaine-induced behavioral sensitization for selfadministering rats 2021","journal-title":"Ge, SN; Wang, XL\nAlterations in neurotransmitters targeted metabolomics from the key nuclei of brain reward circuits in cocaine-induced behavioral sensitization for selfadministering rats"},{"key":"ref=58","first-page":"2231","volume":"141","author":"Palkovits M.","year":"2000","unstructured":"Palkovits M.; The brain and the pain: neurotransmitters and neuronal pathways of pain perception and response. Orv Hetil 2000,141(41),2231-2239","journal-title":"Orv Hetil"},{"key":"ref=59","first-page":"494","volume":"47","author":"Shetty D.N.","year":"2002","unstructured":"Shetty D.N.; Pathak S.S.; Correlation between plasma neurotransmitters and memory loss in pregnancy. J Reprod Med 2002,47(6),494-496","journal-title":"J Reprod Med"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3389\/fneur.2015.00052","volume":"6","author":"Dobryakova E.","year":"2015","unstructured":"Dobryakova E.; Genova H.M.; DeLuca J.; Wylie G.R.; The dopamine imbalance hypothesis of fatigue in multiple sclerosis and other neurological disorders. Front Neurol 2015,6(MAR),52","journal-title":"Front Neurol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"e1007045","DOI":"10.1371\/journal.pgen.1007045","volume":"13","author":"Fernández M.V.","year":"2017","unstructured":"Fernández M.V.; Kim J.H.; Budde J.P.; Black K.; Medvedeva A.; Saef B.; Deming Y.; Del-Aguila J.; Ibañez L.; Dube U.; Harari O.; Norton J.; Chasse R.; Morris J.C.; Goate A.; Cruchaga C.; Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease. PLoS Genet 2017,13(11),e1007045","journal-title":"PLoS Genet"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ygcen.2004.12.018","author":"Schiöth H.B.","year":"2005","unstructured":"Schiöth H.B.; Fredriksson R.; In: General and Comparative Endocrinology 2005,94-101","journal-title":"In: General and Comparative Endocrinology"},{"key":"ref=63","author":"Alexander","year":"2019","unstructured":"Alexander ; SPH G protein-coupled receptors 2019","journal-title":"SPH G protein-coupled receptors"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1111\/bph.14748","volume":"176","author":"Alexander S.P.H.","year":"2019","unstructured":"Alexander S.P.H.; Christopoulos A.; Davenport A.P.; Kelly E.; Mathie A.; Peters J.A.; Veale E.L.; Armstrong J.F.; Faccenda E.; Harding S.D.; Pawson A.J.; Sharman J.L.; Southan C.; Davies J.A.; The concise guide to pharmacology 2019\/20: g protein-coupled receptors. Br J Pharmacol 2019,176(S1)(Suppl. 1),S21-S141","journal-title":"Br J Pharmacol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"15495","DOI":"10.1038\/s41598-017-15707-9","volume":"7","author":"Hu G.M.","year":"2017","unstructured":"Hu G.M.; Mai T.L.; Chen C.M.; Visualizing the GPCR network: classification and evolution. Sci Rep 2017,7(1),15495","journal-title":"Sci Rep"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/protein\/7.2.195","volume":"7","author":"Attwood T.K.","year":"1994","unstructured":"Attwood T.K.; Findlay J.B.C.; Fingerprinting G-protein-coupled receptors. Protein Eng 1994,7(2),195-203","journal-title":"Protein Eng"},{"key":"ref=67","first-page":"1","volume":"2","author":"Kolakowski L.F.","year":"1994","unstructured":"Kolakowski L.F.; GCRDb: A G-protein-coupled receptor database. Receptors Channels 1994,2(1),1-7","journal-title":"Receptors Channels"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/acs.jmedchem.6b01453","volume":"61","author":"Lee Y.","year":"2018","unstructured":"Lee Y.; Basith S.; Choi S.; Recent advances in structure-based drug design targeting class A G protein-coupled receptors utilizing crystal structures and computational simulations. J Med Chem 2018,61(1),1-46","journal-title":"J Med Chem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fphar.2018.00128","volume":"9","author":"Basith S.","year":"2018","unstructured":"Basith S.; Cui M.; Macalino S.J.Y.; Park J.; Clavio N.A.B.; Kang S.; Choi S.; \nExploring G protein-coupled receptors (GPCRs) ligand space\nvia \ncheminformatics approaches: Impact on rational drug design.\n Front Pharmacol 2018,9,128","journal-title":"Front Pharmacol"},{"key":"ref=70","first-page":"31","volume":"177","author":"Zöllner C.","year":"2007","unstructured":"Zöllner C.; Stein C.; Opioids. Handb. Exp. Pharmacol 2007,177(177),31-63","journal-title":"Pharmacol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bbagen.2013.08.027","volume":"1840","author":"Moreira I.S.","year":"2014","unstructured":"Moreira I.S.; Structural features of the G-protein\/GPCR interactions. Biochim Biophys Acta 2014,1840(1),16-33","journal-title":"Biochim Biophys Acta"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3390\/ph5050417","volume":"5","author":"Somvanshi R.K.","year":"2012","unstructured":"Somvanshi R.K.; Kumar U.; Pathophysiology of GPCR homo- and heterodimerization: special emphasis on somatostatin receptors. Pharmaceuticals (Basel) 2012,5(5),417-446","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1124\/pr.113.008052","volume":"66","author":"Ferré S.","year":"2014","unstructured":"Ferré S.; Casadó V.; Devi L.A.; Filizola M.; Jockers R.; Lohse M.J.; Milligan G.; Pin J.P.; Guitart X.; G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev 2014,66(2),413-434","journal-title":"Pharmacol Rev"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"55-74","DOI":"10.1007\/978-94-007-7423-0_4","author":"Mondal S.","year":"2014","unstructured":"Mondal S.; Khelashvili G.; Johner N.; Weinstein H.; How the dynamic properties and functional mechanisms of GPCRs are modulated by their coupling to the membrane environment 2014,55-74","journal-title":"How the dynamic properties and functional mechanisms of GPCRs are modulated by their coupling to the membrane environment"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1111\/j.1742-4658.2005.04730.x","volume":"272","author":"Filizola M.","year":"2005","unstructured":"Filizola M.; Weinstein H.; The study of G-protein coupled receptor oligomerization with computational modeling and bioinformatics. FEBS J 2005,272(12),2926-2938","journal-title":"FEBS J"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3389\/fnmol.2019.00230","volume":"12","author":"Borroto-Escuela D.O.","year":"2019","unstructured":"Borroto-Escuela D.O.; Fuxe K.; Oligomeric receptor complexes and their allosteric receptor-receptor interactions in the plasma membrane represent a new biological principle for integration of signals in the CNS. Front Mol Neurosci 2019,12,230","journal-title":"Front Mol Neurosci"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3389\/fphar.2018.00829","volume":"9","author":"Borroto-Escuela D.O.","year":"2018","unstructured":"Borroto-Escuela D.O.; Rodriguez D.; Romero-Fernandez W.; Kapla J.; Jaiteh M.; Ranganathan A.; Lazarova T.; Fuxe K.; Carlsson J.; Mapping the interface of a GPCR Dimer: A structural model of the A2A Adenosine and D2 dopamine receptor heteromer. Front Pharmacol 2018,9,829","journal-title":"Front Pharmacol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.3390\/ijms20071686","volume":"20","author":"Wouters E.","year":"2019","unstructured":"Wouters E.; Marín A.R.; Dalton J.A.R.; Giraldo J.; Stove C.; Distinct dopamine D2 receptor antagonists differentially impact D2 receptor oligomerization. Int J Mol Sci 2019,20(7),1686","journal-title":"Int J Mol Sci"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.phrs.2017.01.008","volume":"117","author":"Farran B.","year":"2017","unstructured":"Farran B.; An update on the physiological and therapeutic relevance of GPCR oligomers. Pharmacol Res 2017,117,303-327","journal-title":"Pharmacol Res"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"714","DOI":"10.2174\/1568026618666180604082610","volume":"18","author":"Schiedel A.C.","year":"2018","unstructured":"Schiedel A.C.; Köse M.; Barreto C.; Bueschbell B.; Morra G.; Sensoy O.; Moreira I.S.; Prediction and targeting of interaction interfaces in g-protein coupled receptor oligomers. Curr Top Med Chem 2018,18(8),714-746","journal-title":"Curr Top Med Chem"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"BSR20160547","DOI":"10.1042\/BSR20160547","volume":"37","author":"Guo H.","year":"2017","unstructured":"Guo H.; An S.; Ward R.; Yang Y.; Liu Y.; Guo X-X.; Hao Q.; Xu T.R.; Methods used to study the oligomeric structure of G-protein-coupled receptors. Biosci Rep 2017,37(2),BSR20160547","journal-title":"Biosci Rep"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2174\/092986712803414259","volume":"19","author":"Fuxe K.","year":"2012","unstructured":"Fuxe K.; Borroto-Escuela D.O.; Marcellino D.; Romero-Fernandez W.; Frankowska M.; Guidolin D.; Filip M.; Ferraro L.; Woods A.S.; Tarakanov A.; Ciruela F.; Agnati L.F.; Tanganelli S.; GPCR heteromers and their allosteric receptor-receptor interactions. Curr Med Chem 2012,19(3),356-363","journal-title":"Curr Med Chem"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.1016\/j.jmb.2020.06.009","volume":"432","author":"Yang J.","year":"2020","unstructured":"Yang J.; Gong Z.; Lu Y.B.; Xu C.J.; Wei T.F.; Yang M.S.; Zhan T.W.; Yang Y.H.; Lin L.; Liu J.; Tang C.; Zhang W.P.; FLIM-FRET-based structural characterization of a class-A GPCR dimer in the cell membrane. J Mol Biol 2020,432(16),4596-4611","journal-title":"J Mol Biol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.sbi.2019.04.005","volume":"55","author":"Townsend-Nicholson A.","year":"2019","unstructured":"Townsend-Nicholson A.; Altwaijry N.; Potterton A.; Morao I.; Heifetz A.; Computational prediction of GPCR oligomerization. Curr Opin Struct Biol 2019,55,178-184","journal-title":"Curr Opin Struct Biol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature20566","volume":"540","author":"Pin J-P.","year":"2016","unstructured":"Pin J-P.; Bettler B.; Organization and functions of mGlu and GABA receptor complexes. Nature 2016,540(7631),60-68","journal-title":"Nature"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s41048-017-0036-9","volume":"3","author":"Møller T.C.","year":"2017","unstructured":"Møller T.C.; Moreno-Delgado D.; Pin J-P.; Kniazeff J.; Class C G protein-coupled receptors: reviving old couples with new partners. Biophys Rep 2017,3(4),57-63","journal-title":"Biophys Rep"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s41589-020-0566-1","volume":"16","author":"Möller J.","year":"2020","unstructured":"Möller J.; Isbilir A.; Sungkaworn T.; Osberg B.; Karathanasis C.; Sunkara V.; Grushevskyi E.O.; Bock A.; Annibale P.; Heilemann M.; Schütte C.; Lohse M.J.; Single-molecule analysis reveals agonist-specific dimer formation of µ-opioid receptors. Nat Chem Biol 2020,16(9),946-954","journal-title":"Nat Chem Biol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s12013-017-0829-y","volume":"76","author":"Kasai R.S.","year":"2018","unstructured":"Kasai R.S.; Ito S.V.; Awane R.M.; Fujiwara T.K.; Kusumi A.; The class-A GPCR dopamine D2 receptor forms transient dimers stabilized by agonists: Detection by single-molecule tracking. Cell Biochem Biophys 2018,76(1-2),29-37","journal-title":"Cell Biochem Biophys"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22063241","volume":"22","author":"Lazim R.","year":"2021","unstructured":"Lazim R.; Suh D.; Lee J.W.; Vu T.N.L.; Yoon S.; Choi S.; Structural characterization of receptor-receptor interactions in the allosteric modulation of G protein-coupled receptor (Gpcr) dimers. Int J Mol Sci 2021,22(6),1-20","journal-title":"Int J Mol Sci"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/BF02769180","volume":"7","author":"Zoli M.","year":"1993","unstructured":"Zoli M.; Agnati L.F.; Hedlund P.B.; Li X.M.; Ferré S.; Fuxe K.; Receptor-receptor interactions as an integrative mechanism in nerve cells. Mol Neurobiol 1993,7(3-4),293-334","journal-title":"Mol Neurobiol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nchembio0309-131","volume":"5","author":"Ferré S.","year":"2009","unstructured":"Ferré S.; Baler R.; Bouvier M.; Caron M.G.; Devi L.A.; Durroux T.; Fuxe K.; George S.R.; Javitch J.A.; Lohse M.J.; Mackie K.; Milligan G.; Pfleger K.D.; Pin J.P.; Volkow N.D.; Waldhoer M.; Woods A.S.; Franco R.; Building a new conceptual framework for receptor heteromers. Nat Chem Biol 2009,5(3),131-134","journal-title":"Nat Chem Biol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"942","DOI":"10.4161\/psb.4.10.9530","volume":"4","author":"Tuteja N.","year":"2009","unstructured":"Tuteja N.; Signaling through G protein coupled receptors. Plant Signal Behav 2009,4(10),942-947","journal-title":"Plant Signal Behav"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-1-60327-333-6_3","author":"Moreira I.S.","year":"2010","unstructured":"Moreira I.S.; Shi L.; Freyberg Z.; Ericksen S.S.; Weinstein H.; Javitch J.A.; In: The Dopamine Receptors 2010,47-73","journal-title":"In: The Dopamine Receptors"},{"key":"ref=94","author":"Vauquelin G.","unstructured":"Vauquelin G.; Van Liefde I.; G protein-coupled receptors: A count of 1001 conformations. In: Fundamental and Clinical Pharmacology; John Wiley & Sons, Ltd, 2005; 19, pp. 45-56."},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"e56742","DOI":"10.1371\/journal.pone.0056742","volume":"8","author":"Latek D.","year":"2013","unstructured":"Latek D.; Pasznik P.; Carlomagno T.; Filipek S.; Towards improved quality of GPCR models by usage of multiple templates and profile-profile comparison. PLoS One 2013,8(2),e56742","journal-title":"PLoS One"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.tips.2014.11.001","volume":"36","author":"Isberg V.","year":"2015","unstructured":"Isberg V.; de Graaf C.; Bortolato A.; Cherezov V.; Katritch V.; Marshall F.H.; Mordalski S.; Pin J.P.; Stevens R.C.; Vriend G.; Gloriam D.E.; Generic GPCR residue numbers - aligning topology maps while minding the gaps. Trends Pharmacol Sci 2015,36(1),22-31","journal-title":"Trends Pharmacol Sci"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/S1043-9471(05)80049-7","volume":"25","author":"Ballesteros J.A.","year":"1995","unstructured":"Ballesteros J.A.; Weinstein H.; Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci 1995,25(C),366-428","journal-title":"Methods Neurosci"},{"key":"ref=98","first-page":"8","volume":"8","author":"Zhou Q.","year":"2019","unstructured":"Zhou Q.; Yang D.; Wu M.; Guo Y.; Guo W.; Zhong L.; Cai X.; Dai A.; Jang W.; Shakhnovich E.I.; Liu Z.J.; Stevens R.C.; Lambert N.A.; Babu M.M.; Wang M.W.; Zhao S.; Common activation mechanism of class A GPCRs. eLife 2019,8,8","journal-title":"eLife"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"10445","DOI":"10.1074\/jbc.273.17.10445","volume":"273","author":"Ballesteros J.","year":"1998","unstructured":"Ballesteros J.; Kitanovic S.; Guarnieri F.; Davies P.; Fromme B.J.; Konvicka K.; Chi L.; Millar R.P.; Davidson J.S.; Weinstein H.; Sealfon S.C.; Functional microdomains in G-protein-coupled receptors. The conserved arginine-cage motif in the gonadotropin-releasing hormone receptor. J Biol Chem 1998,273(17),10445-10453","journal-title":"J Biol Chem"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1124\/jpet.109.163220","volume":"333","author":"Schneider E.H.","year":"2010","unstructured":"Schneider E.H.; Schnell D.; Strasser A.; Dove S.; Seifert R.; Impact of the DRY motif and the missing “ionic lock” on constitutive activity and G-protein coupling of the human histamine H4 receptor. J Pharmacol Exp Ther 2010,333(2),382-392","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"29171","DOI":"10.1074\/jbc.M103747200","volume":"276","author":"Ballesteros J.A.","year":"2001","unstructured":"Ballesteros J.A.; Jensen A.D.; Liapakis G.; Rasmussen S.G.F.; Shi L.; Gether U.; Javitch J.A.; Activation of the β 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem 2001,276(31),29171-29177","journal-title":"J Biol Chem"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1038\/s41467-017-02257-x","volume":"8","author":"Schönegge A.M.","year":"2017","unstructured":"Schönegge A.M.; Gallion J.; Picard L.P.; Wilkins A.D.; Le Gouill C.; Audet M.; Stallaert W.; Lohse M.J.; Kimmel M.; Lichtarge O.; Bouvier M.; Evolutionary action and structural basis of the allosteric switch controlling βAR functional selectivity. Nat Commun 2017,8(1),2169","journal-title":"Nat Commun"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"10327","DOI":"10.1073\/pnas.1810316115","volume":"115","author":"Alhadeff R.","year":"2018","unstructured":"Alhadeff R.; Vorobyov I.; Yoon H.W.; Warshel A.; Exploring the free-energy landscape of GPCR activation. Proc Natl Acad Sci USA 2018,115(41),10327-10332","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.tips.2014.10.009","volume":"35","author":"Jacobson K.A.","year":"2014","unstructured":"Jacobson K.A.; Costanzi S.; Paoletta S.; Computational studies to predict or explain G protein coupled receptor polypharmacology. Trends Pharmacol Sci 2014,35(12),658-663","journal-title":"Trends Pharmacol Sci"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nchembio.2371","volume":"13","author":"Feng X.","year":"2017","unstructured":"Feng X.; Ambia J.; Chen K.M.; Young M.; Barth P.; Computational design of ligand-binding membrane receptors with high selectivity. Nat Chem Biol 2017,13(7),715-723","journal-title":"Nat Chem Biol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/nchembio.2490","volume":"13","author":"Roth B.L.","year":"2017","unstructured":"Roth B.L.; Irwin J.J.; Shoichet B.K.; Discovery of new GPCR ligands to illuminate new biology. Nat Chem Biol 2017,13(11),1143-1151","journal-title":"Nat Chem Biol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/nsmb.3450","volume":"24","author":"Shihoya W.","year":"2017","unstructured":"Shihoya W.; Nishizawa T.; Yamashita K.; Inoue A.; Hirata K.; Kadji F.M.N.; Okuta A.; Tani K.; Aoki J.; Fujiyoshi Y.; Doi T.; Nureki O.; X-ray structures of endothelin ET receptor bound to clinical antagonist bosentan and its analog. Nat Struct Mol Biol 2017,24(9),758-764","journal-title":"Nat Struct Mol Biol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1038\/ncomms5733","volume":"5","author":"Yuan S.","year":"2014","unstructured":"Yuan S.; Filipek S.; Palczewski K.; Vogel H.; Activation of G-protein-coupled receptors correlates with the formation of a continuous internal water pathway. Nat Commun 2014,5,4733","journal-title":"Nat Commun"},{"key":"ref=109","first-page":"pp. 317-325","author":"Filizola M.","year":"2002","unstructured":"Filizola M.; Weinstein H.; Structural models for dimerization of G-protein coupled receptors: The opioid receptor homodimers. In: Biopolymers - Peptide Science Section; Biopolymers, 2002,pp. 317-325"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"E871","DOI":"10.1208\/aapsj070485","volume":"7","author":"Weinstein H.","year":"2006","unstructured":"Weinstein H.; Hallucinogen actions on 5-HT receptors reveal distinct mechanisms of activation and signaling by G protein-coupled receptors. AAPS J 2006,7(4),E871-E884","journal-title":"AAPS J"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S0076-6879(02)43145-X","volume":"343","author":"Visiers I.","year":"2002","unstructured":"Visiers I.; Ballesteros J.A.; Weinstein H.; Three-dimensional representations of G protein-coupled receptor structures and mechanisms. Methods Enzymol 2002,343,329-371","journal-title":"Methods Enzymol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1073\/pnas.0435715100","volume":"100","author":"Fritze O.","year":"2003","unstructured":"Fritze O.; Filipek S.; Kuksa V.; Palczewski K.; Hofmann K.P.; Ernst O.P.; Role of the conserved NPxxY(x)5,6F motif in the rhodopsin ground state and during activation. Proc Natl Acad Sci USA 2003,100(5),2290-2295","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.2174\/092986712799320556","volume":"19","author":"Trzaskowski B.","year":"2012","unstructured":"Trzaskowski B.; Latek D.; Yuan S.; Ghoshdastider U.; Debinski A.; Filipek S.; Action of molecular switches in GPCRs--theoretical and experimental studies. Curr Med Chem 2012,19(8),1090-1109","journal-title":"Curr Med Chem"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41467-019-08568-5","volume":"10","author":"Chen S.","year":"2019","unstructured":"Chen S.; Lu M.; Liu D.; Yang L.; Yi C.; Ma L.; Zhang H.; Liu Q.; Frimurer T.M.; Wang M.W.; Schwartz T.W.; Stevens R.C.; Wu B.; Wüthrich K.; Zhao Q.; Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography. Nat Commun 2019,10(1),638","journal-title":"Nat Commun"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nature19107","volume":"536","author":"Venkatakrishnan A.J.","year":"2016","unstructured":"Venkatakrishnan A.J.; Deupi X.; Lebon G.; Heydenreich F.M.; Flock T.; Miljus T.; Balaji S.; Bouvier M.; Veprintsev D.B.; Tate C.G.; Schertler G.F.; Babu M.M.; Diverse activation pathways in class A GPCRs converge near the G-protein-coupling region. Nature 2016,536(7617),484-487","journal-title":"Nature"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"8555","DOI":"10.1073\/pnas.0903545106","volume":"106","author":"Angel T.E.","year":"2009","unstructured":"Angel T.E.; Chance M.R.; Palczewski K.; Conserved waters mediate structural and functional activation of family A (rhodopsin-like) G protein-coupled receptors. Proc Natl Acad Sci USA 2009,106(21),8555-8560","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"36577","DOI":"10.1074\/jbc.M206223200","volume":"277","author":"Prioleau C.","year":"2002","unstructured":"Prioleau C.; Visiers I.; Ebersole B.J.; Weinstein H.; Sealfon S.C.; Conserved helix 7 tyrosine acts as a multistate conformational switch in the 5HT2C receptor. Identification of a novel “locked-on” phenotype and double revertant mutations. J Biol Chem 2002,277(39),36577-36584","journal-title":"J Biol Chem"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"14367","DOI":"10.1073\/pnas.0901074106","volume":"106","author":"Angel T.E.","year":"2009","unstructured":"Angel T.E.; Gupta S.; Jastrzebska B.; Palczewski K.; Chance M.R.; Structural waters define a functional channel mediating activation of the GPCR, rhodopsin. Proc Natl Acad Sci USA 2009,106(34),14367-14372","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature10361","volume":"477","author":"Rasmussen S.G.F.","year":"2011","unstructured":"Rasmussen S.G.F.; DeVree B.T.; Zou Y.; Kruse A.C.; Chung K.Y.; Kobilka T.S.; Thian F.S.; Chae P.S.; Pardon E.; Calinski D.; Mathiesen J.M.; Shah S.T.; Lyons J.A.; Caffrey M.; Gellman S.H.; Steyaert J.; Skiniotis G.; Weis W.I.; Sunahara R.K.; Kobilka B.K.; Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 2011,477(7366),549-555","journal-title":"Nature"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.sbi.2019.03.017","volume":"55","author":"Filipek S.","year":"2019","unstructured":"Filipek S.; Molecular switches in GPCRs. Curr Opin Struct Biol 2019,55,114-120","journal-title":"Curr Opin Struct Biol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"9928","DOI":"10.1073\/pnas.1601278113","volume":"113","author":"Wescott M.P.","year":"2016","unstructured":"Wescott M.P.; Kufareva I.; Paes C.; Goodman J.R.; Thaker Y.; Puffer B.A.; Berdougo E.; Rucker J.B.; Handel T.M.; Doranz B.J.; Signal transmission through the CXC chemokine receptor 4 (CXCR4) transmembrane helices. Proc Natl Acad Sci USA 2016,113(35),9928-9933","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.tips.2009.02.006","volume":"30","author":"Nygaard R.","year":"2009","unstructured":"Nygaard R.; Frimurer T.M.; Holst B.; Rosenkilde M.M.; Schwartz T.W.; Ligand binding and micro-switches in 7TM receptor structures. Trends Pharmacol Sci 2009,30(5),249-259","journal-title":"Trends Pharmacol Sci"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.tibs.2009.07.005","volume":"34","author":"Hofmann K.P.","year":"2009","unstructured":"Hofmann K.P.; Scheerer P.; Hildebrand P.W.; Choe H.W.; Park J.H.; Heck M.; Ernst O.P.A.; G protein-coupled receptor at work: the rhodopsin model. Trends Biochem Sci 2009,34(11),540-552","journal-title":"Trends Biochem Sci"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1124\/mol.117.110544","volume":"93","author":"Kaiser A.","year":"2018","unstructured":"Kaiser A.; Hempel C.; Wanka L.; Schubert M.; Hamm H.E.; Beck-Sickinger A.G.; G protein preassembly rescues efficacy of W 6.48 toggle mutations in neuropeptide Y 2 receptor. Mol Pharmacol 2018,93(4),387-401","journal-title":"Mol Pharmacol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.1074\/jbc.M109.064725","volume":"285","author":"Holst B.","year":"2010","unstructured":"Holst B.; Nygaard R.; Valentin-Hansen L.; Bach A.; Engelstoft M.S.; Petersen P.S.; Frimurer T.M.; Schwartz T.W.; A conserved aromatic lock for the tryptophan rotameric switch in TM-VI of seven-transmembrane receptors. J Biol Chem 2010,285(6),3973-3985","journal-title":"J Biol Chem"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s41048-018-0056-0","volume":"4","author":"Zhang X.C.","year":"2018","unstructured":"Zhang X.C.; Zhou Y.; Cao C.; Proton transfer during class-A GPCR activation: do the CWxP motif and the membrane potential act in concert? Biophys Rep 2018,4(3),115-122","journal-title":"Biophys Rep"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.pharmthera.2014.02.004","volume":"143","author":"Tehan B.G.","year":"2014","unstructured":"Tehan B.G.; Bortolato A.; Blaney F.E.; Weir M.P.; Mason J.S.; Unifying family A GPCR theories of activation. Pharmacol Ther 2014,143(1),51-60","journal-title":"Pharmacol Ther"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cell.2017.12.004","volume":"172","author":"Eddy M.T.","year":"2018","unstructured":"Eddy M.T.; Lee M.Y.; Gao Z.G.; White K.L.; Didenko T.; Horst R.; Audet M.; Stanczak P.; McClary K.M.; Han G.W.; Jacobson K.A.; Stevens R.C.; Wüthrich K.; Allosteric Coupling of Drug Binding and Intracellular Signaling in the A Adenosine Receptor. Cell 2018,172(1-2),68-80.e12","journal-title":"Cell"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"8223","DOI":"10.1073\/pnas.1700891114","volume":"114","author":"Ishchenko A.","year":"2017","unstructured":"Ishchenko A.; Wacker D.; Kapoor M.; Zhang A.; Han G.W.; Basu S.; Patel N.; Messerschmidt M.; Weierstall U.; Liu W.; Katritch V.; Roth B.L.; Stevens R.C.; Cherezov V.; Structural insights into the extracellular recognition of the human serotonin 2B receptor by an antibody. Proc Natl Acad Sci USA 2017,114(31),8223-8228","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41586-019-1337-6","volume":"572","author":"Kato H.E.","year":"2019","unstructured":"Kato H.E.; Zhang Y.; Hu H.; Suomivuori C.M.; Kadji F.M.N.; Aoki J.; Krishna Kumar K.; Fonseca R.; Hilger D.; Huang W.; Latorraca N.R.; Inoue A.; Dror R.O.; Kobilka B.K.; Skiniotis G.; Conformational transitions of a neurotensin receptor 1-G complex. Nature 2019,572(7767),80-85","journal-title":"Nature"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"232-236","DOI":"10.1126\/science.1219218","volume":"337","author":"Liu W.","year":"2012","unstructured":"Liu W.; Chun E.; Thompson A.A.; Chubukov P.; Xu F.; Katritch V.; Structural basis for allosteric regulation of GPCRS by sodium ions. Science (80) 2012,337((6091)),232-236","journal-title":"Science (80)"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"10112","DOI":"10.1002\/anie.201302244","volume":"52","author":"Yuan S.","year":"2013","unstructured":"Yuan S.; Vogel H.; Filipek S.; The role of water and sodium ions in the activation of the μ-opioid receptor. Angew Chem Int Ed Engl 2013,52(38),10112-10115","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nature12944","volume":"506","author":"Fenalti G.","year":"2014","unstructured":"Fenalti G.; Giguere P.M.; Katritch V.; Huang X.P.; Thompson A.A.; Cherezov V.; Roth B.L.; Stevens R.C.; Molecular control of δ-opioid receptor signalling. Nature 2014,506(7487),191-196","journal-title":"Nature"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.str.2017.11.013","volume":"26","author":"Vickery O.N.","year":"2018","unstructured":"Vickery O.N.; Carvalheda C.A.; Zaidi S.A.; Pisliakov A.V.; Katritch V.; Zachariae U.; Intracellular transfer of Na in an active-state G-protein-coupled receptor. Structure 2018,26(1),171-180.e2","journal-title":"Structure"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.tibs.2014.03.002","volume":"39","author":"Katritch V.","year":"2014","unstructured":"Katritch V.; Fenalti G.; Abola E.E.; Roth B.L.; Cherezov V.; Stevens R.C.; Allosteric sodium in class A GPCR signaling. Trends Biochem Sci 2014,39(5),233-244","journal-title":"Trends Biochem Sci"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.str.2017.12.013","volume":"26","author":"White K.L.","year":"2018","unstructured":"White K.L.; Eddy M.T.; Gao Z.G.; Han G.W.; Lian T.; Deary A.; Patel N.; Jacobson K.A.; Katritch V.; Stevens R.C.; Structural connection between activation microswitch and allosteric sodium site in GPCR signaling. Structure 2018,26(2),259-269.e5","journal-title":"Structure"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/s41467-018-03314-9","volume":"9","author":"Ye L.","year":"2018","unstructured":"Ye L.; Neale C.; Sljoka A.; Lyda B.; Pichugin D.; Tsuchimura N.; Larda S.T.; Pomès R.; García A.E.; Ernst O.P.; Sunahara R.K.; Prosser R.S.; Mechanistic insights into allosteric regulation of the A adenosine G protein-coupled receptor by physiological cations. Nat Commun 2018,9(1),1372","journal-title":"Nat Commun"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.str.2016.03.019","volume":"24","author":"Yuan S.","year":"2016","unstructured":"Yuan S.; Filipek S.; Vogel H.; A gating mechanism of the serotonin 5-HT3 receptor. Structure 2016,24(5),816-825","journal-title":"Structure"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1073\/pnas.1809251116","volume":"116","author":"Venkatakrishnan A.J.","year":"2019","unstructured":"Venkatakrishnan A.J.; Ma A.K.; Fonseca R.; Latorraca N.R.; Kelly B.; Betz R.M.; Asawa C.; Kobilka B.K.; Dror R.O.; Diverse GPCRs exhibit conserved water networks for stabilization and activation. Proc Natl Acad Sci USA 2019,116(8),3288-3293","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=140","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.69035","author":"Dorszewska J.","year":"2017","unstructured":"Dorszewska J.; Florczak-Wyspianska J.; Kowalska M.; Stanski M.; Kowalewska A.; Kozubski W.; Serotonin in neurological diseases Serotonin - A Chemical Messenger Between All Types of Living Cells; IntechOpen 2017","journal-title":"Serotonin - A Chemical Messenger Between All Types of Living Cells; IntechOpen"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"518","DOI":"10.2174\/1389202914666131210210241","volume":"14","author":"Dorszewska J.","year":"2013","unstructured":"Dorszewska J.; Prendecki M.; Oczkowska A.; Rozycka A.; Lianeri M.; Kozubski W.; Polymorphism of the COMT, MAO, DAT, NET and 5-HTT genes, and biogenic amines in Parkinson\u2019s disease. Curr Genomics 2013,14(8),518-533","journal-title":"Curr Genomics"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1365-2885.2008.00944.x","volume":"31","author":"Mohammad-Zadeh L.F.","year":"2008","unstructured":"Mohammad-Zadeh L.F.; Moses L.; Gwaltney-Brant S.M.; Serotonin: A review. J Vet Pharmacol Ther 2008,31(3),187-199","journal-title":"J Vet Pharmacol Ther"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.bbr.2008.03.020","volume":"195","author":"Hannon J.","year":"2008","unstructured":"Hannon J.; Hoyer D.; Molecular biology of 5-HT receptors. Behav Brain Res 2008,195(1),198-213","journal-title":"Behav Brain Res"},{"key":"ref=144","first-page":"D1006","volume":"48","author":"Armstrong J.F.","year":"2020","unstructured":"Armstrong J.F.; Faccenda E.; Harding S.D.; Pawson A.J.; Southan C.; Sharman J.L.; Campo B.; Cavanagh D.R.; Alexander S.P.H.; Davenport A.P.; Spedding M.; Davies J.A.; The IUPHAR\/ BPS Guide to PHARMACOLOGY in 2020: extending immunopharmacology content and introducing the IUPHAR\/MMV Guide to malaria pharmacology. Nucleic Acids Res 2020,48(D1),D1006-D1021","journal-title":"Nucleic Acids Res"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41586-021-03376-8","volume":"592","author":"Xu P.","year":"2021","unstructured":"Xu P.; Huang S.; Zhang H.; Mao C.; Zhou X.E.; Cheng X.; Simon I.A.; Shen D.D.; Yen H.Y.; Robinson C.V.; Harpsøe K.; Svensson B.; Guo J.; Jiang H.; Gloriam D.E.; Melcher K.; Jiang Y.; Zhang Y.; Xu H.E.; Structural insights into the lipid and ligand regulation of serotonin receptors. Nature 2021,592(7854),469-473","journal-title":"Nature"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"50708","DOI":"10.18632\/oncotarget.9367","volume":"7","author":"Kowalska M.","year":"2016","unstructured":"Kowalska M.; Prendecki M.; Kozubski W.; Lianeri M.; Dorszewska J.; Molecular factors in migraine. Oncotarget 2016,7(31),50708-50718","journal-title":"Oncotarget"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1046\/j.1535-7597.2003.03508.x","volume":"3","author":"Theodore W.H.","year":"2003","unstructured":"Theodore W.H.; Does serotonin play a role in epilepsy? Epilepsy Curr 2003,3(5),173-177","journal-title":"Epilepsy Curr"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000202825","volume":"59","author":"Hercigonja Novkovic V.","year":"2009","unstructured":"Hercigonja Novkovic V.; Rudan V.; Pivac N.; Nedic G.; Muck-Seler D.; Platelet serotonin concentration in children with attention-deficit\/hyperactivity disorder. Neuropsychobiology 2009,59(1),17-22","journal-title":"Neuropsychobiology"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"9828","DOI":"10.1523\/JNEUROSCI.1469-16.2016","volume":"36","author":"Whitney M.S.","year":"2016","unstructured":"Whitney M.S.; Shemery A.M.; Yaw A.M.; Donovan L.J.; Glass J.D.; Deneris E.S.; Adult brain serotonin deficiency causes hyperactivity, circadian disruption, and elimination of siestas. J Neurosci 2016,36(38),9828-9842","journal-title":"J Neurosci"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/00207450600754087","volume":"116","author":"Sandyk R.","year":"2006","unstructured":"Sandyk R.; Serotonergic mechanisms in amyotrophic lateral sclerosis. Int J Neurosci 2006,116(7),775-826","journal-title":"Int J Neurosci"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11302-020-09753-8","volume":"17","author":"Yang X.","year":"2021","unstructured":"Yang X.; Heitman L.H.; IJzerman A.P.; van der Es D.; Molecular probes for the human adenosine receptors. Purinergic Signal 2021,17(1),85-108","journal-title":"Purinergic Signal"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nrd1983","volume":"5","author":"Jacobson K.A.","year":"2006","unstructured":"Jacobson K.A.; Gao Z.G.; Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006,5(3),247-264","journal-title":"Nat Rev Drug Discov"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/978-3-540-89615-9_17","volume":"193","author":"Stone T.W.","year":"2009","unstructured":"Stone T.W.; Ceruti S.; Abbracchio M.P.; Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb Exp Pharmacol 2009,193(193),535-587","journal-title":"Handb Exp Pharmacol"},{"key":"ref=154","first-page":"1","author":"Ordway G.A.","year":"2007","unstructured":"Ordway G.A.; Schwartz M.A.; Frazer A.; Brain norepinephrine: neurobiology and therapeutics 2007,1-642","journal-title":"Brain norepinephrine: neurobiology and therapeutics"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0893-133X(98)00134-1","volume":"21","author":"Klimek V.","year":"1999","unstructured":"Klimek V.; Rajkowska G.; Luker S.N.; Dilley G.; Meltzer H.Y.; Overholser J.C.; Stockmeier C.A.; Ordway G.A.; Brain noradrenergic receptors in major depression and schizophrenia. Neuropsychopharmacology 1999,21(1),69-81","journal-title":"Neuropsychopharmacology"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1124\/mol.109.057307","volume":"76","author":"Gupta M.K.","year":"2009","unstructured":"Gupta M.K.; Papay R.S.; Jurgens C.W.D.; Gaivin R.J.; Shi T.; Doze V.A.; Perez D.M.; α1-Adrenergic receptors regulate neurogenesis and gliogenesis. Mol Pharmacol 2009,76(2),314-326","journal-title":"Mol Pharmacol"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2174\/1871524919666190719163632","volume":"19","author":"Nguyen P.V.","year":"2019","unstructured":"Nguyen P.V.; Connor S.A.; Noradrenergic regulation of hippocampus-dependent memory. Cent Nerv Syst Agents Med Chem 2019,19(3),187-196","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"ref=158","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.581098","author":"Perez D.M.","year":"2020","unstructured":"Perez D.M.; α1-adrenergic receptors in neurotransmission, synaptic plasticity, and cognition. Vol. 11, Frontiers in Pharmacology. Front Pharmacol 2020","journal-title":"Front Pharmacol"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.neuint.2010.03.019","volume":"57","author":"Hertz L.","year":"2010","unstructured":"Hertz L.; Lovatt D.; Goldman S.A.; Nedergaard M.; Adrenoceptors in brain: cellular gene expression and effects on astrocytic metabolism and [Ca()]i. Neurochem Int 2010,57(4),411-420","journal-title":"Neurochem Int"},{"key":"ref=160","first-page":"113(18), pp. 129-134","author":"Xiao R-P.","year":"2006","unstructured":"Xiao R-P.; The Adrenergic Receptors in the 21st Century. In: Circulation; Springer 2006,113(18), pp. 129-134"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fncel.2016.00294","volume":"10","author":"Kendall D.A.","year":"2017","unstructured":"Kendall D.A.; Yudowski G.A.; Cannabinoid receptors in the central nervous system: Their signaling and roles in disease. Front Cell Neurosci 2017,10,294","journal-title":"Front Cell Neurosci"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.drudis.2016.08.005","volume":"22","author":"Aizpurua-Olaizola O.","year":"2017","unstructured":"Aizpurua-Olaizola O.; Elezgarai I.; Rico-Barrio I.; Zarandona I.; Etxebarria N.; Usobiaga A.; Targeting the endocannabinoid system: future therapeutic strategies. Drug Discov Today 2017,22(1),105-110","journal-title":"Drug Discov Today"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1093\/brain\/awg224","volume":"126","author":"Pryce G.","year":"2003","unstructured":"Pryce G.; Ahmed Z.; Hankey D.J.R.; Jackson S.J.; Croxford J.L.; Pocock J.M.; Ledent C.; Petzold A.; Thompson A.J.; Giovannoni G.; Cuzner M.L.; Baker D.; Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003,126(Pt 10),2191-2202","journal-title":"Brain"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nri1602","volume":"5","author":"Klein T.W.","year":"2005","unstructured":"Klein T.W.; Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005,5(5),400-411","journal-title":"Nat Rev Immunol"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/sj.bjp.0707446","volume":"152","author":"Campbell V.A.","year":"2007","unstructured":"Campbell V.A.; Gowran A.; Alzheimer\u2019s disease; taking the edge off with cannabinoids? Br J Pharmacol 2007,152(5),655-662","journal-title":"Br J Pharmacol"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1098\/rstb.2011.0388","volume":"367","author":"Bilkei-Gorzo A.","year":"2012","unstructured":"Bilkei-Gorzo A.; The endocannabinoid system in normal and pathological brain ageing. Philos Trans R Soc Lond B Biol Sci 2012,367(1607),3326-3341","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1476-5381.2010.00735.x","volume":"160","author":"Scotter E.L.","year":"2010","unstructured":"Scotter E.L.; Abood M.E.; Glass M.; The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol 2010,160(3),480-498","journal-title":"Br J Pharmacol"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/j.1476-5381.2011.01365.x","volume":"163","author":"Fernández-Ruiz J.","year":"2011","unstructured":"Fernández-Ruiz J.; Moreno-Martet M.; Rodríguez-Cueto C.; Palomo-Garo C.; Gómez-Cañas M.; Valdeolivas S.; Guaza C.; Romero J.; Guzmán M.; Mechoulam R.; Ramos J.A.; Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol 2011,163(7),1365-1378","journal-title":"Br J Pharmacol"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/978-0-387-74349-3_10","author":"Marsicano G.","year":"2008","unstructured":"Marsicano G.; Kuner R.; In: Cannabinoids and the Brain 2008,161-201","journal-title":"In: Cannabinoids and the Brain"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.neubiorev.2018.12.026","volume":"98","author":"Jordan C.J.","year":"2019","unstructured":"Jordan C.J.; Xi Z.X.; Progress in brain cannabinoid CB receptor research: From genes to behavior. Neurosci Biobehav Rev 2019,98,208-220","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1365-2826.2008.01671.x","author":"Mackie K.","year":"2008","unstructured":"Mackie K.; Cannabinoid receptors: Where they are and what they do. J Neuroendocrinol 2008,10-14","journal-title":"J Neuroendocrinol"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2010.02.013","volume":"80","author":"Bosier B.","year":"2010","unstructured":"Bosier B.; Muccioli G.G.; Hermans E.; Lambert D.M.; Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. Biochem Pharmacol 2010,80(1),1-12","journal-title":"Biochem Pharmacol"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1124\/mol.116.104539","volume":"90","author":"Nogueras-Ortiz C.","year":"2016","unstructured":"Nogueras-Ortiz C.; Yudowski G.A.; The multiple waves of cannabinoid 1 receptor signaling. Mol Pharmacol 2016,90(5),620-626","journal-title":"Mol Pharmacol"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrn3876","volume":"16","author":"Di Marzo V.","year":"2015","unstructured":"Di Marzo V.; Stella N.; Zimmer A.; Endocannabinoid signalling and the deteriorating brain. Nat Rev Neurosci 2015,16(1),30-42","journal-title":"Nat Rev Neurosci"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1093\/brain\/awp239","volume":"132","author":"Palazuelos J.","year":"2009","unstructured":"Palazuelos J.; Aguado T.; Pazos M.R.; Julien B.; Carrasco C.; Resel E.; Sagredo O.; Benito C.; Romero J.; Azcoitia I.; Fernández-Ruiz J.; Guzmán M.; Galve-Roperh I.; Microglial CB2 cannabinoid receptors are neuroprotective in Huntington\u2019s disease excitotoxicity. Brain 2009,132(Pt 11),3152-3164","journal-title":"Brain"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.neuron.2016.06.015","volume":"91","author":"Yeh F.L.","year":"2016","unstructured":"Yeh F.L.; Wang Y.; Tom I.; Gonzalez L.C.; Sheng M.; TREM2 binds to apolipoproteins, including APOE and CLU\/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron 2016,91(2),328-340","journal-title":"Neuron"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12035-007-0004-3","volume":"36","author":"Sagredo O.","year":"2007","unstructured":"Sagredo O.; García-Arencibia M.; de Lago E.; Finetti S.; Decio A.; Fernández-Ruiz J.; Cannabinoids and neuroprotection in basal ganglia disorders. Mol Neurobiol 2007,36(1),82-91","journal-title":"Mol Neurobiol"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1523\/JNEUROSCI.4540-04.2005","volume":"25","author":"Ramírez B.G.","year":"2005","unstructured":"Ramírez B.G.; Blázquez C.; Gómez del Pulgar T.; Guzmán M.; de Ceballos M.L.; Prevention of Alzheimer\u2019s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005,25(8),1904-1913","journal-title":"J Neurosci"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0006-8993(80)90564-8","volume":"188","author":"Dockray G.J.","year":"1980","unstructured":"Dockray G.J.; Cholecystokinins in rat cerebral cortex: identification, purification and characterization by immunochemical methods. Brain Res 1980,188(1),155-165","journal-title":"Brain Res"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"6917","DOI":"10.1073\/pnas.77.11.6917","volume":"77","author":"Innis R.B.","year":"1980","unstructured":"Innis R.B.; Snyder S.H.; Distinct cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci USA 1980,77(11),6917-6921","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1177\/070674379003500115","volume":"35","author":"Bradwejn J.","year":"1990","unstructured":"Bradwejn J.; Koszycki D.; Meterissian G.; Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiatry 1990,35(1),83-85","journal-title":"Can J Psychiatry"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1515\/revneuro-2016-0088","volume":"28","author":"Ballaz S.","year":"2017","unstructured":"Ballaz S.; The unappreciated roles of the cholecystokinin receptor CCK(1) in brain functioning. Rev Neurosci 2017,28(6),573-585","journal-title":"Rev Neurosci"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1152\/ajpregu.2001.280.4.R1149","volume":"280","author":"Beglinger C.","year":"2001","unstructured":"Beglinger C.; Degen L.; Matzinger D.; D\u2019Amato M.; Drewe J.; Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. Am J Physiol \u2013 Regul Integr Comp Physiol 2001,280(4),49-54","journal-title":"Am J Physiol \u2013 Regul Integr Comp Physiol"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/MED.0b013e32834eb77d","volume":"19","author":"Dockray G.J.","year":"2012","unstructured":"Dockray G.J.; Cholecystokinin. Curr Opin Endocrinol Diabetes Obes 2012,19(1),8-12","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref=185","first-page":"587","volume":"3","author":"Beglinger C.","year":"2002","unstructured":"Beglinger C.; Overview. Cholecystokinin and eating. Curr Opin Investig Drugs 2002,3(4),587-588","journal-title":"Curr Opin Investig Drugs"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/jnen\/nlaa113","volume":"80","author":"Choi J.G.","year":"2021","unstructured":"Choi J.G.; Jeong M.; Joo B.R.; Ahn J.H.; Woo J.H.; Kim D.H.; Oh M.S.; Choi J.H.; Reduced levels of intestinal neuropeptides and neurotrophins in neurotoxin-induced Parkinson disease mouse models. J Neuropathol Exp Neurol 2021,80(1),15-20","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1474-4422(15)00007-1","volume":"14","author":"Fasano A.","year":"2015","unstructured":"Fasano A.; Visanji N.P.; Liu L.W.C.; Lang A.E.; Pfeiffer R.F.; Gastrointestinal dysfunction in Parkinson\u2019s disease. Lancet Neurol 2015,14(6),625-639","journal-title":"Lancet Neurol"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0165-0173(86)90001-9","volume":"396","author":"Everitt B.J.","year":"1986","unstructured":"Everitt B.J.; Meister B.; Hökfelt T.; Melander T.; Terenius L.; Rökaeus A.; Theodorsson-Norheim E.; Dockray G.; Edwardson J.; Cuello C.; The hypothalamic arcuate nucleus-median eminence complex: immunohistochemistry of transmitters, peptides and DARPP-32 with special reference to coexistence in dopamine neurons. Brain Res 1986,396(2),97-155","journal-title":"Brain Res"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/0306-4522(80)90127-X","volume":"5","author":"Hökfelt T.","year":"1980","unstructured":"Hökfelt T.; Skirboll L.; Rehfeld J.F.; Goldstein M.; Markey K.; Dann O.; A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing. Neuroscience 1980,5(12),2093-2124","journal-title":"Neuroscience"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bph.12906","volume":"172","author":"Beaulieu J.M.","year":"2015","unstructured":"Beaulieu J.M.; Espinoza S.; Gainetdinov R.R.; Dopamine receptors - IUPHAR Review 13. Br J Pharmacol 2015,172(1),1-23","journal-title":"Br J Pharmacol"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/0024-3205(78)90157-1","volume":"23","author":"Kebabian J.W.","year":"1978","unstructured":"Kebabian J.W.; Multiple classes of dopamine receptors in mammalian central nervous system: the involvement of dopamine-sensitive adenylyl cyclase. Life Sci 1978,23(5),479-483","journal-title":"Life Sci"},{"key":"ref=192","first-page":"155","volume":"19","author":"Spano P.F.","year":"1978","unstructured":"Spano P.F.; Govoni S.; Trabucchi M.; Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system. Adv Biochem Psychopharmacol 1978,19,155-165","journal-title":"Adv Biochem Psychopharmacol"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"E1196","DOI":"10.3390\/molecules24071196","volume":"24","author":"Bueschbell B.","year":"2019","unstructured":"Bueschbell B.; Barreto C.A.V.; Preto A.J.; Schiedel A.C.; Moreira I.S.; A complete assessment of dopamine receptor-ligand interactions through computational methods. Molecules 2019,24(7),E1196","journal-title":"Molecules"},{"key":"ref=194","first-page":"1","author":"Cokan K.B.","year":"2020","unstructured":"Cokan K.B.; Mavri M.; Rutland C.S.; Gli\u0161i\u0107 S.; Sen\u0107anski M.; Vrecl M.; Critical impact of different conserved endoplasmic retention motifs and dopamine receptor interacting proteins (Drips) on intracellular localization and trafficking of the d2 dopamine receptor (D2-r) isoforms 2020,1-18","journal-title":"Critical impact of different conserved endoplasmic retention motifs and dopamine receptor interacting proteins (Drips) on intracellular localization and trafficking of the d2 dopamine receptor (D2-r) isoforms"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1007\/s00018-008-8153-8","volume":"65","author":"Mitsukawa K.","year":"2008","unstructured":"Mitsukawa K.; Lu X.; Bartfai T.; Galanin, galanin receptors and drug targets. Cell Mol Life Sci 2008,65(12),1796-1805","journal-title":"Cell Mol Life Sci"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/0014-5793(83)80033-7","volume":"164","author":"Tatemoto K.","year":"1983","unstructured":"Tatemoto K.; Rökaeus A.; Jörnvall H.; McDonald T.J.; Mutt V.; Galanin - a novel biologically active peptide from porcine intestine. FEBS Lett 1983,164(1),124-128","journal-title":"FEBS Lett"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0196-9781(86)90060-4","volume":"7","author":"Ottlecz A.","year":"1986","unstructured":"Ottlecz A.; Samson W.K.; McCann S.M.; Galanin: evidence for a hypothalamic site of action to release growth hormone. Peptides 1986,7(1),51-53","journal-title":"Peptides"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2174\/187152707780619335","volume":"6","author":"Lu X.","year":"2007","unstructured":"Lu X.; Sharkey L.; Bartfai T.; The brain galanin receptors: targets for novel antidepressant drugs. CNS Neurol Disord Drug Targets 2007,6(3),183-192","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=199","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.npep.2004.12.024","author":"Hua X.Y.","year":"2005","unstructured":"Hua X.Y.; Salgado K.F.; Gu G.; Fitzsimmons B.; Kondo I.; Bartfai T.; Mechanisms of antinociception of spinal galanin: How does galanin inhibit spinal sensitization?. Neuropeptides 2005,211-216","journal-title":"Neuropeptides"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/0304-3940(87)90024-3","volume":"73","author":"Nordström O.","year":"1987","unstructured":"Nordström O.; Melander T.; Hökfelt T.; Bartfai T.; Goldstein M.; Evidence for an inhibitory effect of the peptide galanin on dopamine release from the rat median eminence. Neurosci Lett 1987,73(1),21-26","journal-title":"Neurosci Lett"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0165-6147(02)02074-6","volume":"23","author":"Liu H.X.","year":"2002","unstructured":"Liu H.X.; Hökfelt T.; The participation of galanin in pain processing at the spinal level. Trends Pharmacol Sci 2002,23(10),468-474","journal-title":"Trends Pharmacol Sci"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0278-5846(00)00156-1","volume":"25","author":"Wrenn C.C.","year":"2001","unstructured":"Wrenn C.C.; Crawley J.N.; Pharmacological evidence supporting a role for galanin in cognition and affect. Prog Neuropsychopharmacol Biol Psychiatry 2001,25(1),283-299","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/0304-3940(87)90088-7","volume":"83","author":"Hökfelt T.","year":"1987","unstructured":"Hökfelt T.; Wiesenfeld-Hallin Z.; Villar M.; Melander T.; Increase of galanin-like immunoreactivity in rat dorsal root ganglion cells after peripheral axotomy. Neurosci Lett 1987,83(3),217-220","journal-title":"Neurosci Lett"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.1073\/pnas.0304823101","volume":"101","author":"Elliott-Hunt C.R.","year":"2004","unstructured":"Elliott-Hunt C.R.; Marsh B.; Bacon A.; Pope R.; Vanderplank P.; Wynick D.; Galanin acts as a neuroprotective factor to the hippocampus. Proc Natl Acad Sci USA 2004,101(14),5105-5110","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1124\/mi.3.3.137","volume":"3","author":"Counts S.E.","year":"2003","unstructured":"Counts S.E.; Perez S.E.; Ginsberg S.D.; De Lacalle S.; Mufson E.J.; Galanin in Alzheimer disease. Mol Interv 2003,3(3),137-156","journal-title":"Mol Interv"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1111\/j.0953-816X.2004.03449.x","volume":"19","author":"Mazarati A.","year":"2004","unstructured":"Mazarati A.; Lu X.; Kilk K.; Langel U.; Wasterlain C.; Bartfai T.; Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus. Eur J Neurosci 2004,19(12),3235-3244","journal-title":"Eur J Neurosci"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S1474-4422(03)00482-4","volume":"2","author":"Hökfelt T.","year":"2003","unstructured":"Hökfelt T.; Bartfai T.; Bloom F.; Neuropeptides: opportunities for drug discovery. Lancet Neurol 2003,2(8),463-472","journal-title":"Lancet Neurol"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.npep.2004.07.006","volume":"38","author":"Mazarati A.M.","year":"2004","unstructured":"Mazarati A.M.; Galanin and galanin receptors in epilepsy. Neuropeptides 2004,38(6),331-343","journal-title":"Neuropeptides"},{"key":"ref=209","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.npep.2004.12.017","author":"Wiesenfeld-Hallin Z.","year":"2005","unstructured":"Wiesenfeld-Hallin Z.; Xu X.J.; Crawley J.N.; Hökfelt T.; Galanin and spinal nociceptive mechanisms: Recent results from transgenic and knock-out models. Neuropeptides 2005,207-210","journal-title":"Neuropeptides"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"E4726","DOI":"10.1073\/pnas.1609198113","volume":"113","author":"Wang P.","year":"2016","unstructured":"Wang P.; Li H.; Barde S.; Zhang M.D.; Sun J.; Wang T.; Zhang P.; Luo H.; Wang Y.; Yang Y.; Wang C.; Svenningsson P.; Theodorsson E.; Hökfelt T.G.; Xu Z.Q.; Depression-like behavior in rat: Involvement of galanin receptor subtype 1 in the ventral periaqueductal gray. Proc Natl Acad Sci USA 2016,113(32),E4726-E4735","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1385\/NMM:7:1-2:157","volume":"7","author":"Lundström L.","year":"2005","unstructured":"Lundström L.; Elmquist A.; Bartfai T.; Langel U.; Galanin and its receptors in neurological disorders. Neuromol Med 2005,7(1-2),157-180","journal-title":"Neuromol Med"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1124\/pr.114.010249","volume":"67","author":"Panula P.","year":"2015","unstructured":"Panula P.; Chazot P.L.; Cowart M.; Gutzmer R.; Leurs R.; Liu W.L.S.; Stark H.; Thurmond R.L.; Haas H.L.; International union of basic and clinical pharmacology. XCVIII. Histamine receptors. Pharmacol Rev 2015,67(3),601-655","journal-title":"Pharmacol Rev"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1124\/mol.116.104752","volume":"90","author":"Nieto-Alamilla G.","year":"2016","unstructured":"Nieto-Alamilla G.; Márquez-Gómez R.; García-Gálvez A-M.; Morales-Figueroa G-E.; Arias-Montaño J-A.; The histamine H3 receptor: Structure, pharmacology, and function. Mol Pharmacol 2016,90(5),649-673","journal-title":"Mol Pharmacol"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/aap.12037","volume":"35","author":"Keppel H.J.M.","year":"2015","unstructured":"Keppel H.J.M.; The terms \u2018autacoid\u2019, \u2018hormone\u2019 and \u2018chalone\u2019 and how they have shifted with time. Auton Autacoid Pharmacol 2015,35(4),51-58","journal-title":"Auton Autacoid Pharmacol"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1136\/gutjnl-2015-309151","volume":"65","author":"Wouters M.M.","year":"2016","unstructured":"Wouters M.M.; Vicario M.; Santos J.; The role of mast cells in functional GI disorders. Gut 2016,65(1),155-168","journal-title":"Gut"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fnsys.2012.00033","volume":"6","author":"Blandina P.","year":"2012","unstructured":"Blandina P.; Provensi G.; Munari L.; Passani M.B.; Histamine neurons in the tuberomamillary nucleus: A whole center or distinct subpopulations? Front Syst Neurosci 2012,6,33","journal-title":"Front Syst Neurosci"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1038\/s41598-019-40384-1","volume":"9","author":"Stromberga Z.","year":"2019","unstructured":"Stromberga Z.; Chess-Williams R.; Moro C.; \nHistamine modulation of urinary bladder urothelium, lamina propria and detrusor contractile activity\nvia \nH1 and H2 receptors.\n Sci Rep 2019,9(1),3899","journal-title":"Sci Rep"},{"key":"ref=218","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fnsys.2014.00064","volume":"8","author":"Passani M.B.","year":"2014","unstructured":"Passani M.B.; Panula P.; Lin J-S.; Histamine in the brain. Front Syst Neurosci 2014,8,64","journal-title":"Front Syst Neurosci"},{"key":"ref=219","first-page":"4","author":"Chazot P.","year":"2019","unstructured":"Chazot P.; Cowart M.; Fukui H.; Ganellin C.R.; Gutzmer R.; Haas H.L.; Histamine receptors (version 2019.4) in the IUPHAR\/ BPS guide to pharmacology database. IUPHAR\/BPS Guid to Pharmacol CITE 2019,4","journal-title":"IUPHAR\/BPS Guid to Pharmacol CITE"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.tips.2005.12.007","volume":"27","author":"Bond R.A.","year":"2006","unstructured":"Bond R.A.; Ijzerman A.P.; Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol Sci 2006,27(2),92-96","journal-title":"Trends Pharmacol Sci"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12991-014-0034-y","volume":"13","author":"Baronio D.","year":"2014","unstructured":"Baronio D.; Gonchoroski T.; Castro K.; Zanatta G.; Gottfried C.; Riesgo R.; Histaminergic system in brain disorders: lessons from the translational approach and future perspectives. Ann Gen Psychiatry 2014,13(1),34","journal-title":"Ann Gen Psychiatry"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.neuropharm.2010.05.005","volume":"59","author":"Jadidi-Niaragh F.","year":"2010","unstructured":"Jadidi-Niaragh F.; Mirshafiey A.; Histamine and histamine receptors in pathogenesis and treatment of multiple sclerosis. Neuropharmacology 2010,59(3),180-189","journal-title":"Neuropharmacology"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/1533317513488925","volume":"28","author":"Naddafi F.","year":"2013","unstructured":"Naddafi F.; Mirshafiey A.; The neglected role of histamine in Alzheimer\u2019s disease. Am J Alzheimers Dis Other Demen 2013,28(4),327-336","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1358\/dnp.2004.17.6.829029","volume":"17","author":"Ito C.","year":"2004","unstructured":"Ito C.; The role of the central histaminergic system on schizophrenia. Drug News Perspect 2004,17(6),383-387","journal-title":"Drug News Perspect"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"564","DOI":"10.12816\/0048906","volume":"10","author":"Mahmood D.","year":"2016","unstructured":"Mahmood D.; Histamine H receptors and its antagonism as a novel mechanism for antipsychotic effect: A current preclinical","journal-title":"Int J Health Sci (Qassim)"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/odi.13435","volume":"27","author":"Liu Q.","year":"2021","unstructured":"Liu Q.; Fan W.; He H.; Huang F.; The role of peripheral opioid receptors in orofacial pain. Oral Dis 2021,27(5),1106-1114","journal-title":"Oral Dis"},{"key":"ref=227","first-page":"CD012592","volume":"7","author":"Wiffen P.J.","year":"2017","unstructured":"Wiffen P.J.; Wee B.; Derry S.; Bell R.F.; Moore R.A.; Opioids for cancer pain - an overview of Cochrane reviews. Cochrane Database Syst Rev 2017,7(7),CD012592","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/0014-2999(93)90233-8","volume":"236","author":"Barber A.","year":"1993","unstructured":"Barber A.; μ- and κ-opioid receptor agonists produce peripheral inhibition of neurogenic plasma extravasation in rat skin. Eur J Pharmacol 1993,236(1),113-120","journal-title":"Eur J Pharmacol"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1159\/000211422","volume":"9","author":"Earl J.R.","year":"1996","unstructured":"Earl J.R.; Grootveld M.C.; Blake D.R.; Morris C.J.; Effect of μ, δ and κ opioid receptor agonists on a reactive oxygen species mediated model of skin inflammation. Skin Pharmacol 1996,9(4),250-258","journal-title":"Skin Pharmacol"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1124\/pr.110.003145","volume":"63","author":"Stein C.","year":"2011","unstructured":"Stein C.; Machelska H.; Modulation of peripheral sensory neurons by the immune system: implications for pain therapy. Pharmacol Rev 2011,63(4),860-881","journal-title":"Pharmacol Rev"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"S153","DOI":"10.1038\/sj.bjp.0706435","volume":"147","author":"Corbett A.D.","year":"2006","unstructured":"Corbett A.D.; Henderson G.; McKnight A.T.; Paterson S.J.; 75 years of opioid research: the exciting but vain quest for the Holy Grail. Br J Pharmacol 2006,147(Suppl. 1),S153-S162","journal-title":"Br J Pharmacol"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.peptides.2005.01.017","volume":"26","author":"Israel Y.","year":"2005","unstructured":"Israel Y.; Kandov Y.; Khaimova E.; Kest A.; Lewis S.R.; Pasternak G.W.; Pan Y.X.; Rossi G.C.; Bodnar R.J.; NPY-induced feeding: pharmacological characterization using selective opioid antagonists and antisense probes in rats. Peptides 2005,26(7),1167-1175","journal-title":"Peptides"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12017-012-8180-3","volume":"14","author":"Cai Z.","year":"2012","unstructured":"Cai Z.; Ratka A.; Opioid system and Alzheimer\u2019s disease. Neuromolecular Med 2012,14(2),91-111","journal-title":"Neuromolecular Med"},{"key":"ref=234","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1600-0625.1997.tb00166.x","volume":"6","author":"Nissen J.B.","year":"1997","unstructured":"Nissen J.B.; Kragballe K.; \nEnkephalins modulate differentiation of normal human keratinocytes \nin vitro\n.\n Exp Dermatol 1997,6(5),222-229","journal-title":"Exp Dermatol"},{"key":"ref=235","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.neuropharm.2010.11.010","volume":"60","author":"Hadjiconstantinou M.","year":"2011","unstructured":"Hadjiconstantinou M.; Neff N.H.; Nicotine and endogenous opioids: neurochemical and pharmacological evidence. Neuropharmacology 2011,60(7-8),1209-1220","journal-title":"Neuropharmacology"},{"key":"ref=236","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/0006-8993(88)90371-X","volume":"460","author":"Jeftinija S.","year":"1988","unstructured":"Jeftinija S.; Enkephalins modulate excitatory synaptic transmission in the superficial dorsal horn by acting at μ-opioid receptor sites. Brain Res 1988,460(2),260-268","journal-title":"Brain Res"},{"key":"ref=237","doi-asserted-by":"publisher","first-page":"8042","DOI":"10.1073\/pnas.91.17.8042","volume":"91","author":"Kong H.","year":"1994","unstructured":"Kong H.; Raynor K.; Yano H.; Takeda J.; Bell G.I.; Reisine T.; Agonists and antagonists bind to different domains of the cloned κ opioid receptor. Proc Natl Acad Sci USA 1994,91(17),8042-8046","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=238","doi-asserted-by":"publisher","first-page":"5177","DOI":"10.1210\/endo.136.11.7588256","volume":"136","author":"Maggi R.","year":"1995","unstructured":"Maggi R.; Pimpinelli F.; Martini L.; Piva F.; Inhibition of luteinizing hormone-releasing hormone secretion by delta-opioid agonists in GT1-1 neuronal cells. Endocrinology 1995,136(11),5177-5181","journal-title":"Endocrinology"},{"key":"ref=239","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0014-2999(89)90105-2","volume":"171","author":"Meucci E.","year":"1989","unstructured":"Meucci E.; Delay-Goyet P.; Roques B.P.; Zajac J.M.; \nBinding \nin vivo\nof selective μ and δ opioid receptor agonists: opioid receptor occupancy by endogenous enkephalins.\n Eur J Pharmacol 1989,171(2-3),167-178","journal-title":"Eur J Pharmacol"},{"key":"ref=240","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1146\/annurev-med-062613-093100","volume":"67","author":"Stein C.","year":"2016","unstructured":"Stein C.; Opioid Receptors. Annu Rev Med 2016,67,433-451","journal-title":"Annu Rev Med"},{"key":"ref=241","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.2741\/3474","author":"Alfaras-Melainis K.","year":"2009","unstructured":"Alfaras-Melainis K.; Modulation of opioid receptor function by protein-protein interactions. Front Biosci 2009(14),3594","journal-title":"Front Biosci"},{"key":"ref=242","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1210\/edrv-9-2-200","volume":"9","author":"Simonds W.F.","year":"1988","unstructured":"Simonds W.F.; The molecular basis of opioid receptor function. Endocr Rev 1988,9(2),200-212","journal-title":"Endocr Rev"},{"key":"ref=243","doi-asserted-by":"publisher","first-page":"812","DOI":"10.3389\/fmolb.2021.715215","author":"Barreto C.A.V.","unstructured":"Barreto C.A.V.; Baptista S.J.; Preto A.J.; Silvério D.; Melo R.; Moreira I.S.; Decoding partner specificity of opioid receptor family. Front Mol Biosci ,812","journal-title":"Front Mol Biosci"},{"key":"ref=244","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.pharmthera.2013.06.003","volume":"140","author":"Chu S.C.P.","year":"2013","unstructured":"Chu S.C.P.; Kieffer B.L.; Delta opioid receptors in brain function and diseases. Pharmacol Ther 2013,140(1),112-120","journal-title":"Pharmacol Ther"},{"key":"ref=245","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ejphar.2013.01.076","volume":"716","author":"Stein C.","year":"2013","unstructured":"Stein C.; Opioids, sensory systems and chronic pain. Eur J Pharmacol 2013,716(1-3),179-187","journal-title":"Eur J Pharmacol"},{"key":"ref=246","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/bja\/aen078","volume":"101","author":"Rittner H.L.","year":"2008","unstructured":"Rittner H.L.; Brack A.; Stein C.; Pain and the immune system. Br J Anaesth 2008,101(1),40-44","journal-title":"Br J Anaesth"},{"key":"ref=247","first-page":"25","volume":"8","author":"Epelbaum J.","year":"1994","unstructured":"Epelbaum J.; Dournaud P.; Fodor M.; Viollet C.; The neurobiology of somatostatin. Crit Rev Neurobiol 1994,8(1-2),25-44","journal-title":"Crit Rev Neurobiol"},{"key":"ref=248","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1006\/frne.1999.0183","volume":"20","author":"Patel Y.C.","year":"1999","unstructured":"Patel Y.C.; Somatostatin and its receptor family. Front Neuroendocrinol 1999,20(3),157-198","journal-title":"Front Neuroendocrinol"},{"key":"ref=249","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJM198312153092406","volume":"309","author":"Somatostatin R.S.","year":"1983","unstructured":"Somatostatin R.S.; N Engl J Med 1983,309(24),1495-1501","journal-title":"N Engl J Med"},{"key":"ref=250","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1210\/me.2002-0068","volume":"16","author":"Ramírez J.L.","year":"2002","unstructured":"Ramírez J.L.; Mouchantaf R.; Kumar U.; Otero Corchon V.; Rubinstein M.; Low M.J.; Patel Y.C.; Brain somatostatin receptors are up-regulated in somatostatin-deficient mice. Mol Endocrinol 2002,16(8),1951-1963","journal-title":"Mol Endocrinol"},{"key":"ref=251","first-page":"427","volume":"16","author":"Reisine T.","year":"1995","unstructured":"Reisine T.; Bell G.I.; Molecular biology of somatostatin receptors. Endocr Rev 1995,16(4),427-442","journal-title":"Endocr Rev"},{"key":"ref=252","doi-asserted-by":"publisher","first-page":"24550","DOI":"10.1074\/jbc.274.35.24550","volume":"274","author":"Hukovic N.","year":"1999","unstructured":"Hukovic N.; Rocheville M.; Kumar U.; Sasi R.; Khare S.; Patel Y.C.; Agonist-dependent up-regulation of human somatostatin receptor type 1 requires molecular signals in the cytoplasmic C-tail. J Biol Chem 1999,274(35),24550-24558","journal-title":"J Biol Chem"},{"key":"ref=253","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1210\/endo.137.9.8756582","volume":"137","author":"Hukovic N.","year":"1996","unstructured":"Hukovic N.; Panetta R.; Kumar U.; Patel Y.C.; Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. Endocrinology 1996,137(9),4046-4049","journal-title":"Endocrinology"},{"key":"ref=254","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s12276-021-00580-4","volume":"53","author":"Song Y-H.","year":"2021","unstructured":"Song Y-H.; Yoon J.; Lee S-H.; The role of neuropeptide somatostatin in the brain and its application in treating neurological disorders. Exp Mol Med 2021,53(3),328-338","journal-title":"Exp Mol Med"},{"key":"ref=255","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/0016-5085(90)91151-U","volume":"99","author":"Francis B.H.","year":"1990","unstructured":"Francis B.H.; Baskin D.G.; Saunders D.R.; Ensinck J.W.; Distribution of somatostatin-14 and somatostatin-28 gastrointestinal-pancreatic cells of rats and humans. Gastroenterology 1990,99(5),1283-1291","journal-title":"Gastroenterology"},{"key":"ref=256","doi-asserted-by":"publisher","first-page":"R485","DOI":"10.1530\/ERC-14-0389","volume":"21","author":"Abdel-Rahman O.","year":"2014","unstructured":"Abdel-Rahman O.; Lamarca A.; Valle J.W.; Hubner R.A.; Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations. Endocr Relat Cancer 2014,21(6),R485-R493","journal-title":"Endocr Relat Cancer"},{"key":"ref=257","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3389\/fncir.2016.00048","volume":"10","author":"Liguz-Lecznar M.","year":"2016","unstructured":"Liguz-Lecznar M.; Urban-Ciecko J.; Kossut M.; Somatostatin and somatostatin-containing neurons in shaping neuronal activity and plasticity. Front Neural Circuits 2016,10,48","journal-title":"Front Neural Circuits"},{"key":"ref=258","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.tins.2004.01.008","volume":"27","author":"Baraban S.C.","year":"2004","unstructured":"Baraban S.C.; Tallent M.K.; Interneuron Diversity series: Interneuronal neuropeptides--endogenous regulators of neuronal excitability. Trends Neurosci 2004,27(3),135-142","journal-title":"Trends Neurosci"},{"key":"ref=259","first-page":"4","author":"Bichet D.","year":"2019","unstructured":"Bichet D.; Bouvier M.; Chini B.; Gimpl G.; Guillon G.; Kimura T.; Vasopressin and oxytocin receptors (version 2019.4) in the IUPHAR\/ BPS Guide to Pharmacology Database. IUPHAR\/BPS Guid to Pharmacol CITE 2019,4","journal-title":"IUPHAR\/BPS Guid to Pharmacol CITE"},{"key":"ref=260","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/cc2337","volume":"7","author":"Holmes C.L.","year":"2003","unstructured":"Holmes C.L.; Landry D.W.; Granton J.T.; Science review: Vasopressin and the cardiovascular system part 1--receptor physiology. Crit Care 2003,7(6),427-434","journal-title":"Crit Care"},{"key":"ref=261","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.biopsych.2016.11.004","volume":"81","author":"Fineberg S.K.","year":"2017","unstructured":"Fineberg S.K.; Ross D.A.; Oxytocin and the Social Brain. Biol Psychiatry 2017,81(3),e19-e21","journal-title":"Biol Psychiatry"},{"key":"ref=262","first-page":"127","volume":"88","author":"Lee H.J.","year":"2009","unstructured":"Lee H.J.; Macbeth A.H.; Pagani J.H.; Young W.S.; Oxytocin: the great facilitator of life. Prog Neurobiol 2009,88(2),127-151","journal-title":"Prog Neurobiol"},{"key":"ref=263","doi-asserted-by":"publisher","first-page":"179272","DOI":"10.1155\/2013\/179272","volume":"2013","author":"Yang H-P.","year":"2013","unstructured":"Yang H-P.; Wang L.; Han L.; Wang S.C.; Nonsocial functions of hypothalamic oxytocin. ISRN Neurosci 2013,2013,179272","journal-title":"ISRN Neurosci"},{"key":"ref=264","first-page":"405","volume":"30","author":"Rousseau-Merck M.F.","year":"1995","unstructured":"Rousseau-Merck M.F.; René P.; Derré J.; Bienvenu T.; Berger R.; de Keyzer Y.; Chromosomal localization of the human V3 pituitary vasopressin receptor gene (AVPR3) to 1q32. Genomics 1995,30(2),405-406","journal-title":"Genomics"},{"key":"ref=265","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1210\/endo.138.10.5432","volume":"138","author":"Thibonnier M.","year":"1997","unstructured":"Thibonnier M.; Preston J.A.; Dulin N.; Wilkins P.L.; Berti-Mattera L.N.; Mattera R.; The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology 1997,138(10),4109-4122","journal-title":"Endocrinology"},{"key":"ref=266","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/978-1-4615-4871-3_34","volume":"449","author":"Thibonnier M.","year":"1998","unstructured":"Thibonnier M.; Conarty D.M.; Preston J.A.; Wilkins P.L.; Berti-Mattera L.N.; Mattera R.; Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol 1998,449,251-276","journal-title":"Adv Exp Med Biol"},{"key":"ref=267","doi-asserted-by":"publisher","first-page":"7807","DOI":"10.1073\/pnas.0600875103","volume":"103","author":"Koshimizu T.A.","year":"2006","unstructured":"Koshimizu T.A.; Nasa Y.; Tanoue A.; Oikawa R.; Kawahara Y.; Kiyono Y.; Adachi T.; Tanaka T.; Kuwaki T.; Mori T.; Takeo S.; Okamura H.; Tsujimoto G.; V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci USA 2006,103(20),7807-7812","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=268","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1210\/en.2006-1315","volume":"148","author":"Aoyagi T.","year":"2007","unstructured":"Aoyagi T.; Birumachi J.; Hiroyama M.; Fujiwara Y.; Sanbe A.; Yamauchi J.; Tanoue A.; Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology 2007,148(5),2075-2084","journal-title":"Endocrinology"},{"key":"ref=269","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ejphar.2007.03.022","volume":"566","author":"Birumachi J.","year":"2007","unstructured":"Birumachi J.; Hiroyama M.; Fujiwara Y.; Aoyagi T.; Sanbe A.; Tanoue A.; Impaired arginine-vasopressin-induced aldosterone release from adrenal gland cells in mice lacking the vasopressin V1A receptor. Eur J Pharmacol 2007,566(1-3),226-230","journal-title":"Eur J Pharmacol"},{"key":"ref=270","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0143-4179(94)90017-5","volume":"27","author":"Briley E.M.","year":"1994","unstructured":"Briley E.M.; Lolait S.J.; Axelrod J.; Felder C.C.; The cloned vasopressin V1a receptor stimulates phospholipase A2, phospholipase C, and phospholipase D through activation of receptor-operated calcium channels. Neuropeptides 1994,27(1),63-74","journal-title":"Neuropeptides"},{"key":"ref=271","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S0022-2828(03)00053-1","volume":"35","author":"Chandrashekhar Y.","year":"2003","unstructured":"Chandrashekhar Y.; Prahash A.J.; Sen S.; Gupta S.; Roy S.; Anand I.S.; The role of arginine vasopressin and its receptors in the normal and failing rat heart. J Mol Cell Cardiol 2003,35(5),495-504","journal-title":"J Mol Cell Cardiol"},{"key":"ref=272","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/sj.mp.4001812","volume":"11","author":"Yirmiya N.","year":"2006","unstructured":"Yirmiya N.; Rosenberg C.; Levi S.; Salomon S.; Shulman C.; Nemanov L.; Dina C.; Ebstein R.P.; Association between the arginine vasopressin 1a receptor (AVPR1a) gene and autism in a family-based study: mediation by socialization skills. Mol Psychiatry 2006,11(5),488-494","journal-title":"Mol Psychiatry"},{"key":"ref=273","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/23475","volume":"400","author":"Young L.J.","year":"1999","unstructured":"Young L.J.; Nilsen R.; Waymire K.G.; MacGregor G.R.; Insel T.R.; Increased affiliative response to vasopressin in mice expressing the V1a receptor from a monogamous vole. Nature 1999,400(6746),766-768","journal-title":"Nature"},{"key":"ref=274","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/sj.npp.1300360","volume":"29","author":"Bielsky I.F.","year":"2004","unstructured":"Bielsky I.F.; Hu S.B.; Szegda K.L.; Westphal H.; Young L.J.; Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology 2004,29(3),483-493","journal-title":"Neuropsychopharmacology"},{"key":"ref=275","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nature02539","volume":"429","author":"Lim M.M.","year":"2004","unstructured":"Lim M.M.; Wang Z.; Olazábal D.E.; Ren X.; Terwilliger E.F.; Young L.J.; Enhanced partner preference in a promiscuous species by manipulating the expression of a single gene. Nature 2004,429(6993),754-757","journal-title":"Nature"},{"key":"ref=276","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1073\/pnas.81.9.2907","volume":"81","author":"Gaillard R.C.","year":"1984","unstructured":"Gaillard R.C.; Schoenenberg P.; Favrod-Coune C.A.; Muller A.F.; Marie J.; Bockaert J.; Jard S.; Properties of rat anterior pituitary vasopressin receptors: relation to adenylate cyclase and the effect of corticotropin-releasing factor. Proc Natl Acad Sci USA 1984,81(9),2907-2911","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=277","doi-asserted-by":"publisher","first-page":"6783","DOI":"10.1073\/pnas.92.15.6783","volume":"92","author":"Lolait S.J.","year":"1995","unstructured":"Lolait S.J.; O\u2019Carroll A.M.; Mahan L.C.; Felder C.C.; Button D.C.; Young W.S.; Mezey E.; Brownstein M.J.; Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci USA 1995,92(15),6783-6787","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=278","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1210\/en.2006-1309","volume":"148","author":"Lolait S.J.","year":"2007","unstructured":"Lolait S.J.; Stewart L.Q.; Jessop D.S.; Young W.S.; O\u2019Carroll A.M.; The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology 2007,148(2),849-856","journal-title":"Endocrinology"},{"key":"ref=279","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0378-1119(99)00468-0","volume":"241","author":"René P.","year":"2000","unstructured":"René P.; Lenne F.; Ventura M.A.; Bertagna X.; de Keyzer Y.; Nucleotide sequence and structural organization of the human vasopressin pituitary receptor (V3) gene. Gene 2000,241(1),57-64","journal-title":"Gene"},{"key":"ref=280","doi-asserted-by":"publisher","first-page":"6370","DOI":"10.1073\/pnas.092012099","volume":"99","author":"Griebel G.","year":"2002","unstructured":"Griebel G.; Simiand J.; Serradeil-Le Gal C.; Wagnon J.; Pascal M.; Scatton B.; Maffrand J.P.; Soubrie P.; Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 2002,99(9),6370-6375","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=281","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.bbi.2019.11.024","volume":"87","author":"Nikkheslat N.","year":"2020","unstructured":"Nikkheslat N.; McLaughlin A.P.; Hastings C.; Zajkowska Z.; Nettis M.A.; Mariani N.; Enache D.; Lombardo G.; Pointon L.; Cowen P.J.; Cavanagh J.; Harrison N.A.; Bullmore E.T.; Pariante C.M.; Mondelli V.; Childhood trauma, HPA axis activity and antidepressant response in patients with depression. Brain Behav Immun 2020,87,229-237","journal-title":"Brain Behav Immun"},{"key":"ref=282","doi-asserted-by":"publisher","first-page":"636","DOI":"10.2174\/1570159X13666150630175044","volume":"13","author":"Rosenblat J.D.","year":"2015","unstructured":"Rosenblat J.D.; McIntyre R.S.; Alves G.S.; Fountoulakis K.N.; Carvalho A.F.; Beyond monoamines-novel targets for treatment-resistant depression: A comprehensive review. Curr Neuropharmacol 2015,13(5),636-655","journal-title":"Curr Neuropharmacol"},{"key":"ref=283","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1192\/bjp.bp.108.050278","volume":"194","author":"Juruena M.F.","year":"2009","unstructured":"Juruena M.F.; Pariante C.M.; Papadopoulos A.S.; Poon L.; Lightman S.; Cleare A.J.; Prednisolone suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment resistance. Br J Psychiatry 2009,194(4),342-349","journal-title":"Br J Psychiatry"},{"key":"ref=284","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/PSY.0b013e31820ad12b","volume":"73","author":"Stetler C.","year":"2011","unstructured":"Stetler C.; Miller G.E.; Depression and hypothalamic-pituitary-adrenal activation: A quantitative summary of four decades of research. Psychosom Med 2011,73(2),114-126","journal-title":"Psychosom Med"},{"key":"ref=285","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1469-7580.2005.00443.x","volume":"207","author":"Dinan T.G.","year":"2005","unstructured":"Dinan T.G.; Scott L.V.; Anatomy of melancholia: focus on hypothalamic-pituitary-adrenal axis overactivity and the role of vasopressin. J Anat 2005,207(3),259-264","journal-title":"J Anat"},{"key":"ref=286","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.biopsych.2005.12.010","volume":"60","author":"Meynen G.","year":"2006","unstructured":"Meynen G.; Unmehopa U.A.; van Heerikhuize J.J.; Hofman M.A.; Swaab D.F.; Hoogendijk W.J.G.; Increased arginine vasopressin mRNA expression in the human hypothalamus in depression: A preliminary report. Biol Psychiatry 2006,60(8),892-895","journal-title":"Biol Psychiatry"},{"key":"ref=287","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/archpsyc.58.7.655","volume":"58","author":"Zhou J-N.","year":"2001","unstructured":"Zhou J-N.; Riemersma R.F.; Unmehopa U.A.; Hoogendijk W.J.G.; van Heerikhuize J.J.; Hofman M.A.; Swaab D.F.; Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression. Arch Gen Psychiatry 2001,58(7),655-662","journal-title":"Arch Gen Psychiatry"},{"key":"ref=288","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S0893-133X(97)00054-7","volume":"17","author":"van Londen L.","year":"1997","unstructured":"van Londen L.; Goekoop J.G.; van Kempen G.M.J.; Frankhuijzen-Sierevogel A.C.; Wiegant V.M.; van der Velde E.A.; De Wied D.; Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 1997,17(4),284-292","journal-title":"Neuropsychopharmacology"},{"key":"ref=289","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1001\/archpsyc.1996.01830020055007","volume":"53","author":"Purba J.S.","year":"1996","unstructured":"Purba J.S.; Hoogendijk W.J.G.; Hofman M.A.; Swaab D.F.; Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry 1996,53(2),137-143","journal-title":"Arch Gen Psychiatry"},{"key":"ref=290","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1093\/ijnp\/pyab013","volume":"24","author":"Chaki S.","year":"2021","unstructured":"Chaki S.; Vasopressin V1B receptor antagonists as potential antidepressants. Int J Neuropsychopharmacol 2021,24(6),450-463","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=291","first-page":"169","volume":"35","author":"Fatima S.","year":"2011","unstructured":"Fatima S.; Muhammad H.; Arif A.; Nephrogenic diabetes insipidus. Pak Pediatr J 2011,35(3),169-170","journal-title":"Pak Pediatr J"},{"key":"ref=292","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1681\/ASN.V9101861","volume":"9","author":"Ala Y.","year":"1998","unstructured":"Ala Y.; Morin D.; Mouillac B.; Sabatier N.; Vargas R.; Cotte N.; Déchaux M.; Antignac C.; Arthus M.F.; Lonergan M.; Turner M.S.; Balestre M.N.; Alonso G.; Hibert M.; Barberis C.; Hendy G.N.; Bichet D.G.; Jard S.; Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype. J Am Soc Nephrol 1998,9(10),1861-1872","journal-title":"J Am Soc Nephrol"},{"key":"ref=293","doi-asserted-by":"publisher","first-page":"808","DOI":"10.2169\/internalmedicine.38.808","volume":"38","author":"Sato K.","year":"1999","unstructured":"Sato K.; Fukuno H.; Taniguchi T.; Sawada S.; Fukui T.; Kinoshita M.; A novel mutation in the vasopressin V2 receptor gene in a woman with congenital nephrogenic diabetes insipidus. Intern Med 1999,38(10),808-812","journal-title":"Intern Med"},{"key":"ref=294","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/978-1-4615-4871-3_44","volume":"449","author":"Schöneberg T.","year":"1998","unstructured":"Schöneberg T.; Kostenis E.; Liu J.; Gudermann T.; Wess J.; Molecular aspects of vasopressin receptor function. Adv Exp Med Biol 1998,449,347-358","journal-title":"Adv Exp Med Biol"},{"key":"ref=295","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1161\/01.CIR.101.13.1578","volume":"101","author":"Weig H.J.","year":"2000","unstructured":"Weig H.J.; Laugwitz K.L.; Moretti A.; Kronsbein K.; Städele C.; Brüning S.; Seyfarth M.; Brill T.; Schömig A.; Ungerer M.; \nEnhanced cardiac contractility after gene transfer of V2 vasopressin receptors \nin vivo\nby ultrasound-guided injection or transcoronary delivery.\n Circulation 2000,101(13),1578-1585","journal-title":"Circulation"},{"key":"ref=296","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/j.1471-0528.1999.tb08112.x","volume":"106","author":"Åkerlund M.","year":"1999","unstructured":"Åkerlund M.; Bossmar T.; Brouard R.; Kostrzewska A.; Laudanski T.; Lemancewicz A.; Serradeil-Le Gal C.; Steinwall M.; Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women. Br J Obstet Gynaecol 1999,106(10),1047-1053","journal-title":"Br J Obstet Gynaecol"},{"key":"ref=297","doi-asserted-by":"publisher","first-page":"931-940","DOI":"10.1152\/ajprenal.00604.2013","volume":"306","author":"Juul KV","year":"2014","unstructured":"Juul KV; Bichet DG; Nielsen S; Nørgaard JP; The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors 2014,306(9),931-940","journal-title":"The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors"},{"key":"ref=298","first-page":"062-75","volume":"2","author":"Yayla MA","year":"2021","unstructured":"Yayla MA; Arda B; Peptide hormones and neurodegenerative diseases. J Exp Basic Med Sci 2021,2(1),062-75","journal-title":"J Exp Basic Med Sci"},{"key":"ref=299","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.pbb.2013.09.005","volume":"119","author":"Buisman-Pijlman F.T.A.","year":"2014","unstructured":"Buisman-Pijlman F.T.A.; Sumracki N.M.; Gordon J.J.; Hull P.R.; Carter C.S.; Tops M.; Individual differences underlying susceptibility to addiction: Role for the endogenous oxytocin system. Pharmacol Biochem Behav 2014,119,22-38","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=300","doi-asserted-by":"publisher","first-page":"170, 207-218","DOI":"10.1016\/S0079-6123(08)00418-4","author":"Viviani D.","year":"2008","unstructured":"Viviani D.; Stoop R.; Opposite effects of oxytocin and vasopressin on the emotional expression of the fear response. Prog Brain Res 2008,170, 207-218","journal-title":"Prog Brain Res"},{"key":"ref=301","doi-asserted-by":"publisher","first-page":"11489","DOI":"10.1523\/JNEUROSCI.3984-05.2005","volume":"25","author":"Kirsch P.","year":"2005","unstructured":"Kirsch P.; Esslinger C.; Chen Q.; Mier D.; Lis S.; Siddhanti S.; Gruppe H.; Mattay V.S.; Gallhofer B.; Meyer-Lindenberg A.; Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci 2005,25(49),11489-11493","journal-title":"J Neurosci"},{"key":"ref=302","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/PL00005227","volume":"357","author":"Petersson M.","year":"1998","unstructured":"Petersson M.; Lundeberg T.; Sohlström A.; Wiberg U.; Uvnäs-Moberg K.; Oxytocin increases the survival of musculocutaneous flaps. Naunyn Schmiedebergs Arch Pharmacol 1998,357(6),701-704","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=303","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/13557850701837310","volume":"13","author":"Grewen K.M.","year":"2008","unstructured":"Grewen K.M.; Light K.C.; Mechlin B.; Girdler S.S.; Ethnicity is associated with alterations in oxytocin relationships to pain sensitivity in women. Ethn Health 2008,13(3),219-241","journal-title":"Ethn Health"},{"key":"ref=304","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.tins.2012.08.004","volume":"35","author":"Neumann I.D.","year":"2012","unstructured":"Neumann I.D.; Landgraf R.; Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. Trends Neurosci 2012,35(11),649-659","journal-title":"Trends Neurosci"},{"key":"ref=305","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.neubiorev.2014.07.005","volume":"45","author":"McQuaid R.J.","year":"2014","unstructured":"McQuaid R.J.; McInnis O.A.; Abizaid A.; Anisman H.; Making room for oxytocin in understanding depression. Neurosci Biobehav Rev 2014,45,305-322","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=306","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.psyneuen.2010.01.011","volume":"35","author":"Wulsin A.C.","year":"2010","unstructured":"Wulsin A.C.; Herman J.P.; Solomon M.B.; Mifepristone decreases depression-like behavior and modulates neuroendocrine and central hypothalamic-pituitary-adrenocortical axis responsiveness to stress. Psychoneuroendocrinology 2010,35(7),1100-1112","journal-title":"Psychoneuroendocrinology"},{"key":"ref=307","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15592294.2021.1943864","author":"Bey K.","year":"2021","unstructured":"Bey K.; Campos-Martin R.; Klawohn J.; Reuter B.; Grützmann R.; Riesel A.; Wagner M.; Ramirez A.; Kathmann N.; Hypermethylation of the oxytocin receptor gene (OXTR) in obsessive-compulsive disorder: further evidence for a biomarker of disease and treatment response. Epigenetics 2021,1-11","journal-title":"Epigenetics"},{"key":"ref=308","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/nan.12709","volume":"47","author":"Gabery S.","year":"2021","unstructured":"Gabery S.; Ahmed R.M.; Caga J.; Kiernan M.C.; Halliday G.M.; Petersén Å.; Loss of the metabolism and sleep regulating neuronal populations expressing orexin and oxytocin in the hypothalamus in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 2021,47(7),979-989","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref=309","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1124\/mol.60.6.1181","volume":"60","author":"Bunzow J.R.","year":"2001","unstructured":"Bunzow J.R.; Sonders M.S.; Arttamangkul S.; Harrison L.M.; Zhang G.; Quigley D.I.; Darland T.; Suchland K.L.; Pasumamula S.; Kennedy J.L.; Olson S.B.; Magenis R.E.; Amara S.G.; Grandy D.K.; Amphetamine, 3,4-methylenedioxymethamphe-tamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 2001,60(6),1181-1188","journal-title":"Mol Pharmacol"},{"key":"ref=310","doi-asserted-by":"publisher","first-page":"8966","DOI":"10.1073\/pnas.151105198","volume":"98","author":"Borowsky B.","year":"2001","unstructured":"Borowsky B.; Adham N.; Jones K.A.; Raddatz R.; Artymyshyn R.; Ogozalek K.L.; Durkin M.M.; Lakhlani P.P.; Bonini J.A.; Pathirana S.; Boyle N.; Pu X.; Kouranova E.; Lichtblau H.; Ochoa F.Y.; Branchek T.A.; Gerald C.; Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci USA 2001,98(16),8966-8971","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=311","doi-asserted-by":"publisher","first-page":"e0151023","DOI":"10.1371\/journal.pone.0151023","volume":"11","author":"Eyun S-I.","year":"2016","unstructured":"Eyun S-I.; Moriyama H.; Hoffmann F.G.; Moriyama E.N.; Molecular evolution and functional divergence of trace amine-associated receptors. PLoS One 2016,11(3),e0151023","journal-title":"PLoS One"},{"key":"ref=312","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ygeno.2004.11.010","volume":"85","author":"Lindemann L.","year":"2005","unstructured":"Lindemann L.; Ebeling M.; Kratochwil N.A.; Bunzow J.R.; Grandy D.K.; Hoener M.C.; Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors. Genomics 2005,85(3),372-385","journal-title":"Genomics"},{"key":"ref=313","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/mp.2012.57","volume":"18","author":"Revel F.G.","year":"2013","unstructured":"Revel F.G.; Moreau J.L.; Pouzet B.; Mory R.; Bradaia A.; Buchy D.; Metzler V.; Chaboz S.; Groebke Z.K.; Galley G.; Norcross R.D.; Tuerck D.; Bruns A.; Morairty S.R.; Kilduff T.S.; Wallace T.L.; Risterucci C.; Wettstein J.G.; Hoener M.C.; A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Mol Psychiatry 2013,18(5),543-556","journal-title":"Mol Psychiatry"},{"key":"ref=314","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3389\/fnins.2016.00148","volume":"10","author":"Pei Y.","year":"2016","unstructured":"Pei Y.; Asif-Malik A.; Canales J.J.; Trace amines and the trace amine-associated receptor 1: Pharmacology, neurochemistry, and clinical implications. Front Neurosci 2016,10,148","journal-title":"Front Neurosci"},{"key":"ref=315","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.molmet.2015.09.015","volume":"5","author":"Raab S.","year":"2015","unstructured":"Raab S.; Wang H.; Uhles S.; Cole N.; Alvarez-Sanchez R.; Künnecke B.; Ullmer C.; Matile H.; Bedoucha M.; Norcross R.D.; Ottaway-Parker N.; Perez-Tilve D.; Conde Knape K.; Tschöp M.H.; Hoener M.C.; Sewing S.; Incretin-like effects of small molecule trace amine-associated receptor 1 agonists. Mol Metab 2015,5(1),47-56","journal-title":"Mol Metab"},{"key":"ref=316","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/sj.bjp.0706948","volume":"149","author":"Zucchi R.","year":"2006","unstructured":"Zucchi R.; Chiellini G.; Scanlan T.S.; Grandy D.K.; Trace amine-associated receptors and their ligands. Br J Pharmacol 2006,149(8),967-978","journal-title":"Br J Pharmacol"},{"key":"ref=317","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1124\/pr.117.015305","volume":"70","author":"Gainetdinov R.R.","year":"2018","unstructured":"Gainetdinov R.R.; Hoener M.C.; Berry M.D.; Trace amines and their receptors. Pharmacol Rev 2018,70(3),549-620","journal-title":"Pharmacol Rev"},{"key":"ref=318","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0278-5846(91)90076-D","volume":"15","author":"Boulton A.A.","year":"1991","unstructured":"Boulton A.A.; Phenylethylaminergic modulation of catecholaminergic neurotransmission. Prog Neuropsychopharmacol Biol Psychiatry 1991,15(2),139-156","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=319","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3389\/fphar.2017.00987","volume":"8","author":"Rutigliano G.","year":"2018","unstructured":"Rutigliano G.; Accorroni A.; Zucchi R.; The case for TAAR1 as a modulator of central nervous system function. Front Pharmacol 2018,8(JAN),987","journal-title":"Front Pharmacol"},{"key":"ref=320","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0014-2999(82)90012-7","volume":"77","author":"Jones R.S.G.","year":"1982","unstructured":"Jones R.S.G.; Noradrenaline-octopamine interactions on cortical neurones in the rat. Eur J Pharmacol 1982,77(2-3),159-162","journal-title":"Eur J Pharmacol"},{"key":"ref=321","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.conb.2015.01.001","volume":"34","author":"Liberles S.D.","year":"2015","unstructured":"Liberles S.D.; Trace amine-associated receptors: ligands, neural circuits, and behaviors. Curr Opin Neurobiol 2015,34,1-7","journal-title":"Curr Opin Neurobiol"},{"key":"ref=322","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.neuropharm.2015.02.010","volume":"93","author":"Espinoza S.","year":"2015","unstructured":"Espinoza S.; Ghisi V.; Emanuele M.; Leo D.; Sukhanov I.; Sotnikova T.D.; Chieregatti E.; Gainetdinov R.R.; Postsynaptic D2 dopamine receptor supersensitivity in the striatum of mice lacking TAAR1. Neuropharmacology 2015,93,308-313","journal-title":"Neuropharmacology"},{"key":"ref=323","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.euroneuro.2015.08.011","volume":"25","author":"Harmeier A.","year":"2015","unstructured":"Harmeier A.; Obermueller S.; Meyer C.A.; Revel F.G.; Buchy D.; Chaboz S.; Dernick G.; Wettstein J.G.; Iglesias A.; Rolink A.; Bettler B.; Hoener M.C.; Trace amine-associated receptor 1 activation silences GSK3β signaling of TAAR1 and D2R heteromers. Eur Neuropsychopharmacol 2015,25(11),2049-2061","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=324","doi-asserted-by":"publisher","first-page":"20081","DOI":"10.1073\/pnas.0906522106","volume":"106","author":"Bradaia A.","year":"2009","unstructured":"Bradaia A.; Trube G.; Stalder H.; Norcross R.D.; Ozmen L.; Wettstein J.G.; Pinard A.; Buchy D.; Gassmann M.; Hoener M.C.; Bettler B.; The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc Natl Acad Sci USA 2009,106(47),20081-20086","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=325","doi-asserted-by":"publisher","first-page":"8485","DOI":"10.1073\/pnas.1103029108","volume":"108","author":"Revel F.G.","year":"2011","unstructured":"Revel F.G.; Moreau J-L.; Gainetdinov R.R.; Bradaia A.; Sotnikova T.D.; Mory R.; Durkin S.; Zbinden K.G.; Norcross R.; Meyer C.A.; Metzler V.; Chaboz S.; Ozmen L.; Trube G.; Pouzet B.; Bettler B.; Caron M.G.; Wettstein J.G.; Hoener M.C.; TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci USA 2011,108(20),8485-8490","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=326","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nature05066","volume":"442","author":"Liberles S.D.","year":"2006","unstructured":"Liberles S.D.; Buck L.B.; A second class of chemosensory receptors in the olfactory epithelium. Nature 2006,442(7103),645-650","journal-title":"Nature"},{"key":"ref=327","doi-asserted-by":"publisher","first-page":"e54950","DOI":"10.1371\/journal.pone.0054950","volume":"8","author":"Wallrabenstein I.","year":"2013","unstructured":"Wallrabenstein I.; Kuklan J.; Weber L.; Zborala S.; Werner M.; Altmüller J.; Becker C.; Schmidt A.; Hatt H.; Hummel T.; Gisselmann G.; Human trace amine-associated receptor TAAR5 can be activated by trimethylamine. PLoS One 2013,8(2),e54950","journal-title":"PLoS One"},{"key":"ref=328","doi-asserted-by":"publisher","first-page":"e0117774","DOI":"10.1371\/journal.pone.0117774","volume":"10","author":"Dinter J.","year":"2015","unstructured":"Dinter J.; Mühlhaus J.; Wienchol C.L.; Yi C.X.; Nürnberg D.; Morin S.; Grüters A.; Köhrle J.; Schöneberg T.; Tschöp M.; Krude H.; Kleinau G.; Biebermann H.; Inverse agonistic action of 3-iodothyronamine at the human trace amine-associated receptor 5. PLoS One 2015,10(2),e0117774","journal-title":"PLoS One"},{"key":"ref=329","doi-asserted-by":"publisher","first-page":"20638","DOI":"10.3390\/ijms151120638","volume":"15","author":"Mühlhaus J.","year":"2014","unstructured":"Mühlhaus J.; Dinter J.; Nürnberg D.; Rehders M.; Depke M.; Golchert J.; Homuth G.; Yi C.X.; Morin S.; Köhrle J.; Brix K.; Tschöp M.; Kleinau G.; Biebermann H.; Analysis of human TAAR8 and murine Taar8b mediated signaling pathways and expression profile. Int J Mol Sci 2014,15(11),20638-20655","journal-title":"Int J Mol Sci"},{"key":"ref=330","first-page":"4","author":"Mazella J.","year":"2019","unstructured":"Mazella J.; Sarret P.; Vincent J-P.; Neurotensin receptors (version 2019.4) in the IUPHAR\/BPS Guide to Pharmacology Database. IUPHAR\/BPS Guid to Pharmacol CITE 2019,4","journal-title":"IUPHAR\/BPS Guid to Pharmacol CITE"},{"key":"ref=331","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0014-5793(93)81509-X","volume":"317","author":"Vita N.","year":"1993","unstructured":"Vita N.; Laurent P.; Lefort S.; Chalon P.; Dumont X.; Kaghad M.; Gully D.; Le Fur G.; Ferrara P.; Caput D.; Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. FEBS Lett 1993,317(1-2),139-142","journal-title":"FEBS Lett"},{"key":"ref=332","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1523\/JNEUROSCI.15-04-02733.1995","volume":"15","author":"Zhang X.","year":"1995","unstructured":"Zhang X.; Xu Z.Q.; Bao L.; Dagerlind A.; Hökfelt T.; Complementary distribution of receptors for neurotensin and NPY in small neurons in rat lumbar DRGs and regulation of the receptors and peptides after peripheral axotomy. J Neurosci 1995,15(4),2733-2747","journal-title":"J Neurosci"},{"key":"ref=333","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/0304-3940(90)90187-E","volume":"120","author":"Elde R.","year":"1990","unstructured":"Elde R.; Schalling M.; Ceccatelli S.; Nakanishi S.; Hökfelt T.; Localization of neuropeptide receptor mRNA in rat brain: initial observations using probes for neurotensin and substance P receptors. Neurosci Lett 1990,120(1),134-138","journal-title":"Neurosci Lett"},{"key":"ref=334","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0014-5793(96)00397-3","volume":"386","author":"Chalon P.","year":"1996","unstructured":"Chalon P.; Vita N.; Kaghad M.; Guillemot M.; Bonnin J.; Delpech B.; Le Fur G.; Ferrara P.; Caput D.; Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett 1996,386(2-3),91-94","journal-title":"FEBS Lett"},{"key":"ref=335","doi-asserted-by":"publisher","first-page":"5613","DOI":"10.1523\/JNEUROSCI.16-18-05613.1996","volume":"16","author":"Mazella J.","year":"1996","unstructured":"Mazella J.; Botto J.M.; Guillemare E.; Coppola T.; Sarret P.; Vincent J.P.; Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin\/neuromedin N receptor from mouse brain. J Neurosci 1996,16(18),5613-5620","journal-title":"J Neurosci"},{"key":"ref=336","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0014-2999(98)00678-5","volume":"360","author":"Vita N.","year":"1998","unstructured":"Vita N.; Oury-Donat F.; Chalon P.; Guillemot M.; Kaghad M.; Bachy A.; Thurneyssen O.; Garcia S.; Poinot-Chazel C.; Casellas P.; Keane P.; Le Fur G.; Maffrand J.P.; Soubrie P.; Caput D.; Ferrara P.; Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells. Eur J Pharmacol 1998,360(2-3),265-272","journal-title":"Eur J Pharmacol"},{"key":"ref=337","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/(SICI)1096-9861(19980511)394:3<344:AID-CNE6>3.0.CO;2-1","volume":"394","author":"Sarret P.","year":"1998","unstructured":"Sarret P.; Beaudet A.; Vincent J.P.; Mazella J.; Regional and cellular distribution of low affinity neurotensin receptor mRNA in adult and developing mouse brain. J Comp Neurol 1998,394(3),344-356","journal-title":"J Comp Neurol"},{"key":"ref=338","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0169-328X(98)00074-6","volume":"57","author":"Walker N.","year":"1998","unstructured":"Walker N.; Lepee-Lorgeoux I.; Fournier J.; Betancur C.; Rostene W.; Ferrara P.; Caput D.; Tissue distribution and cellular localization of the levocabastine-sensitive neurotensin receptor mRNA in adult rat brain. Brain Res Mol Brain Res 1998,57(2),193-200","journal-title":"Brain Res Mol Brain Res"},{"key":"ref=339","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/0014-5793(86)80565-8","volume":"201","author":"Amar S.","year":"1986","unstructured":"Amar S.; Kitabgi P.; Vincent J.P.; Activation of phosphatidylinositol turnover by neurotensin receptors in the human colonic adenocarcinoma cell line HT29. FEBS Lett 1986,201(1),31-36","journal-title":"FEBS Lett"},{"key":"ref=340","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/j.1471-4159.1987.tb09986.x","volume":"49","author":"Amar S.","year":"1987","unstructured":"Amar S.; Kitabgi P.; Vincent J-P.; Stimulation of inositol phosphate production by neurotensin in neuroblastoma N1E115 cells: implication of GTP-binding proteins and relationship with the cyclic GMP response. J Neurochem 1987,49(4),999-1006","journal-title":"J Neurochem"},{"key":"ref=341","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0014-5793(00)02095-0","volume":"483","author":"Gailly P.","year":"2000","unstructured":"Gailly P.; Najimi M.; Hermans E.; Evidence for the dual coupling of the rat neurotensin receptor with pertussis toxin-sensitive and insensitive G-proteins. FEBS Lett 2000,483(2-3),109-113","journal-title":"FEBS Lett"},{"key":"ref=342","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0006-291X(85)91411-1","volume":"129","author":"Amar S.","year":"1985","unstructured":"Amar S.; Mazella J.; Checler F.; Kitabgi P.; Vincent J.P.; Regulation of cyclic GMP levels by neurotensin in neuroblastoma clone N1E115. Biochem Biophys Res Commun 1985,129(1),117-125","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=343","first-page":"489","volume":"29","author":"Bozou J.C.","year":"1986","unstructured":"Bozou J.C.; Amar S.; Vincent J.P.; Kitabgi P.; Neurotensinmediated inhibition of cyclic AMP formation in neuroblastoma N1E115 cells: involvement of the inhibitory GTP-binding component of adenylate cyclase. Mol Pharmacol 1986,29(5),489-496","journal-title":"Mol Pharmacol"},{"key":"ref=344","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/0014-2999(77)90236-9","volume":"46","author":"Clineschmidt B.V.","year":"1977","unstructured":"Clineschmidt B.V.; McGuffin J.C.; Neurotensin administered intracisternally inhibits responsiveness of mice to noxious stimuli. Eur J Pharmacol 1977,46(4),395-396","journal-title":"Eur J Pharmacol"},{"key":"ref=345","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1476-5381.1984.tb10117.x","volume":"83","author":"Furuta S.","year":"1984","unstructured":"Furuta S.; Kisara K.; Sakurada S.; Sakurada T.; Sasaki Y.; Suzuki K.; Structure-antinociceptive activity studies with neurotensin. Br J Pharmacol 1984,83(1),43-48","journal-title":"Br J Pharmacol"},{"key":"ref=346","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejphar.2013.03.004","volume":"716","author":"Kleczkowska P.","year":"2013","unstructured":"Kleczkowska P.; Lipkowski A.W.; Neurotensin and neurotensin receptors: characteristic, structure-activity relationship and pain modulation--a review. Eur J Pharmacol 2013,716(1-3),54-60","journal-title":"Eur J Pharmacol"},{"key":"ref=347","author":"Alexander W","unstructured":"Alexander W; Bernstein KE; Catt KJ; Gasparo M; de, ; Singh, KD; Eguchi, S Angiotensin receptors (version 2019.4) in the IUPHAR\/ BPS Guide to Pharmacology Database. IUPHAR\/BPS Guid to Pharmacol CITE, 2019, 4."},{"key":"ref=348","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1124\/pr.114.010454","volume":"67","author":"Karnik S.S.","year":"2015","unstructured":"Karnik S.S.; Unal H.; Kemp J.R.; Tirupula K.C.; Eguchi S.; Vanderheyden P.M.L.; Thomas W.G.; International union of basic and clinical pharmacology. XCIX. Angiotensin receptors: interpreters of pathophysiological angiotensinergic stimuli. [corrected]. Pharmacol Rev 2015,67(4),754-819","journal-title":"Pharmacol Rev"},{"key":"ref=349","first-page":"415","volume":"52","author":"de Gasparo M.","year":"2000","unstructured":"de Gasparo M.; Catt K.J.; Inagami T.; Wright J.W.; Unger T.; International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000,52(3),415-472","journal-title":"Pharmacol Rev"},{"key":"ref=350","doi-asserted-by":"publisher","first-page":"734917","DOI":"10.3389\/fphar.2021.734917","volume":"12","author":"Verma K.","year":"2021","unstructured":"Verma K.; Pant M.; Paliwal S.; Dwivedi J.; Sharma S.; An insight on multicentric signaling of angiotensin II in cardiovascular system: A recent update. Front Pharmacol 2021,12,734917","journal-title":"Front Pharmacol"},{"key":"ref=351","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.3390\/ijms22094762","volume":"22","author":"Adamcova M.","year":"2021","unstructured":"Adamcova M.; Kawano I.; Simko F.; The impact of microRNAs in renin-angiotensin-system-induced cardiac remodelling. Int J Mol Sci 2021,22(9),4762","journal-title":"Int J Mol Sci"},{"key":"ref=352","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1161\/01.RES.83.12.1182","volume":"83","author":"Matsubara H.","year":"1998","unstructured":"Matsubara H.; Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998,83(12),1182-1191","journal-title":"Circ Res"},{"key":"ref=353","doi-asserted-by":"publisher","first-page":"4-13","DOI":"10.1016\/j.phrs.2017.05.008","volume":"125","author":"Kawai T.","year":"2017","unstructured":"Kawai T.; Forrester S.J.; O\u2019Brien S.; Baggett A.; Rizzo V.; Eguchi S.; AT1 receptor signaling pathways in the cardiovascular system. Pharmacol Res 2017,125((Pt A)),4-13","journal-title":"Pharmacol Res"},{"key":"ref=354","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0167-0115(98)00138-4","volume":"79","author":"Allen A.M.","year":"1999","unstructured":"Allen A.M.; MacGregor D.P.; McKinley M.J.; Mendelsohn F.A.O.; Angiotensin II receptors in the human brain. Regul Pept 1999,79(1),1-7","journal-title":"Regul Pept"},{"key":"ref=355","first-page":"56","volume":"2","author":"Li Y.","year":"2012","unstructured":"Li Y.; Li X.H.; Yuan H.; Angiotensin II type-2 receptor-specific effects on the cardiovascular system. Cardiovasc Diagn Ther 2012,2(1),56-62","journal-title":"Cardiovasc Diagn Ther"},{"key":"ref=356","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1042\/CS20060342","volume":"112","author":"Higuchi S.","year":"2007","unstructured":"Higuchi S.; Ohtsu H.; Suzuki H.; Shirai H.; Frank G.D.; Eguchi S.; Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 2007,112(8),417-428","journal-title":"Clin Sci (Lond)"},{"key":"ref=357","doi-asserted-by":"publisher","first-page":"S575","DOI":"10.1097\/00005344-198406004-00004","volume":"6","author":"Catt K.J.","year":"1984","unstructured":"Catt K.J.; Mendelsohn F.A.; Millan M.A.; Aguilera G.; The role of angiotensin II receptors in vascular regulation. J Cardiovasc Pharmacol 1984,6(Suppl. 4),S575-S586","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=358","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/gbb.12235","volume":"14","author":"Hurt R.C.","year":"2015","unstructured":"Hurt R.C.; Garrett J.C.; Keifer O.P.; Linares A.; Couling L.; Speth R.C.; Ressler K.J.; Marvar P.J.; Angiotensin type 1a receptors on corticotropin-releasing factor neurons contribute to the expression of conditioned fear. Genes Brain Behav 2015,14(7),526-533","journal-title":"Genes Brain Behav"},{"key":"ref=359","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.biopsych.2013.08.024","volume":"75","author":"Marvar P.J.","year":"2014","unstructured":"Marvar P.J.; Goodman J.; Fuchs S.; Choi D.C.; Banerjee S.; Ressler K.J.; Angiotensin type 1 receptor inhibition enhances the extinction of fear memory. Biol Psychiatry 2014,75(11),864-872","journal-title":"Biol Psychiatry"},{"key":"ref=360","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1161\/01.HYP.33.2.719","volume":"33","author":"Nazzaro P.","year":"1999","unstructured":"Nazzaro P.; Manzari M.; Merlo M.; Triggiani R.; Scarano A.; Ciancio L.; Pirrelli A.; Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension 1999,33(2),719-725","journal-title":"Hypertension"},{"key":"ref=361","doi-asserted-by":"publisher","first-page":"10663","DOI":"10.1073\/pnas.92.23.10663","volume":"92","author":"Nakajima M.","year":"1995","unstructured":"Nakajima M.; Hutchinson H.G.; Fujinaga M.; Hayashida W.; Morishita R.; Zhang L.; Horiuchi M.; Pratt R.E.; Dzau V.J.; The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA 1995,92(23),10663-10667","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=362","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0167-0115(99)00027-0","volume":"81","author":"Millatt L.J.","year":"1999","unstructured":"Millatt L.J.; Abdel-Rahman E.M.; Siragy H.M.; Angiotensin II and nitric oxide: A question of balance. Regul Pept 1999,81(1-3),1-10","journal-title":"Regul Pept"},{"key":"ref=363","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurev.pa.36.040196.001433","volume":"36","author":"Griendling K.K.","year":"1996","unstructured":"Griendling K.K.; Lassègue B.; Alexander R.W.; Angiotensin receptors and their therapeutic implications. Annu Rev Pharmacol Toxicol 1996,36,281-306","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=364","first-page":"1695","author":"Laragh J.H.","year":"1995","unstructured":"Laragh J.H.; Brenner B.M.; Characteristics of angiotensin II receptors and their role in cell and organ physiologyHypertension : pathophysiology, diagnosis, and management 1995,1695-1720","journal-title":"Characteristics of angiotensin II receptors and their role in cell and organ physiologyHypertension : pathophysiology, diagnosis, and management"},{"key":"ref=365","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1161\/01.HYP.33.2.613","volume":"33","author":"Horiuchi M.","year":"1999","unstructured":"Horiuchi M.; Akishita M.; Dzau V.J.; Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999,33(2),613-621","journal-title":"Hypertension"},{"key":"ref=366","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0167-0115(99)00023-3","volume":"81","author":"de Gasparo M.","year":"1999","unstructured":"de Gasparo M.; Siragy H.M.; The AT2 receptor: fact, fancy and fantasy. Regul Pept 1999,81(1-3),11-24","journal-title":"Regul Pept"},{"key":"ref=367","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1161\/01.HYP.0000193504.51489.cf","volume":"46","author":"D\u2019Amore A.","year":"2005","unstructured":"D\u2019Amore A.; Black M.J.; Thomas W.G.; The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension 2005,46(6),1347-1354","journal-title":"Hypertension"},{"key":"ref=368","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1097\/00043764-198911000-00018","volume":"31","author":"Gold S.","year":"1989","unstructured":"Gold S.; Haran I.; Attias J.; Shapira I.; Shahar A.; Biochemical and cardiovascular measures in subjects with noise-induced hearing loss. J Occup Med 1989,31(11),933-937","journal-title":"J Occup Med"},{"key":"ref=369","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1161\/HYPERTENSIONAHA.107.103242","volume":"51","author":"Padia S.H.","year":"2008","unstructured":"Padia S.H.; Kemp B.A.; Howell N.L.; Fournie-Zaluski M-C.; Roques B.P.; Carey R.M.; Conversion of renal angiotensin II to angiotensin III is critical for AT2 receptor-mediated natriuresis in rats. Hypertension 2008,51(2),460-465","journal-title":"Hypertension"},{"key":"ref=370","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1161\/HYPERTENSIONAHA.112.191403","volume":"60","author":"Kemp B.A.","year":"2012","unstructured":"Kemp B.A.; Bell J.F.; Rottkamp D.M.; Howell N.L.; Shao W.; Navar L.G.; Padia S.H.; Carey R.M.; Intrarenal angiotensin III is the predominant agonist for proximal tubule angiotensin type 2 receptors. Hypertension 2012,60(2),387-395","journal-title":"Hypertension"},{"key":"ref=371","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1161\/01.HYP.34.5.1112","volume":"34","author":"Barber M.N.","year":"1999","unstructured":"Barber M.N.; Sampey D.B.; Widdop R.E.; AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. Hypertension 1999,34(5),1112-1116","journal-title":"Hypertension"},{"key":"ref=372","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1074\/jbc.270.4.1670","volume":"270","author":"Buisson B.","year":"1995","unstructured":"Buisson B.; Laflamme L.; Bottari S.P.; de Gasparo M.; Gallo-Payet N.; Payet M.D.A.A.; G protein is involved in the angiotensin AT2 receptor inhibition of the T-type calcium current in non-differentiated NG108-15 cells. J Biol Chem 1995,270(4),1670-1674","journal-title":"J Biol Chem"},{"key":"ref=373","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0169-328X(00)00093-0","volume":"78","author":"Stroth U.","year":"2000","unstructured":"Stroth U.; Blume A.; Mielke K.; Unger T.; Angiotensin AT(2) receptor stimulates ERK1 and ERK2 in quiescent but inhibits ERK in NGF-stimulated PC12W cells. Brain Res Mol Brain Res 2000,78(1-2),175-180","journal-title":"Brain Res Mol Brain Res"},{"key":"ref=374","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1172\/JCI7886","volume":"104","author":"Tsutsumi Y.","year":"1999","unstructured":"Tsutsumi Y.; Matsubara H.; Masaki H.; Kurihara H.; Murasawa S.; Takai S.; Miyazaki M.; Nozawa Y.; Ozono R.; Nakagawa K.; Miwa T.; Kawada N.; Mori Y.; Shibasaki Y.; Tanaka Y.; Fujiyama S.; Koyama Y.; Fujiyama A.; Takahashi H.; Iwasaka T.; Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999,104(7),925-935","journal-title":"J Clin Invest"},{"key":"ref=375","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1161\/hq0102.102277","volume":"22","author":"Wu L.","year":"2002","unstructured":"Wu L.; Iwai M.; Nakagami H.; Chen R.; Suzuki J.; Akishita M.; de Gasparo M.; Horiuchi M.; Effect of angiotensin II type 1 receptor blockade on cardiac remodeling in angiotensin II type 2 receptor null mice. Arterioscler Thromb Vasc Biol 2002,22(1),49-54","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=376","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1161\/hc4601.099404","volume":"104","author":"Wu L.","year":"2001","unstructured":"Wu L.; Iwai M.; Nakagami H.; Li Z.; Chen R.; Suzuki J.; Akishita M.; de Gasparo M.; Horiuchi M.; Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 2001,104(22),2716-2721","journal-title":"Circulation"},{"key":"ref=377","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1073\/pnas.93.1.156","volume":"93","author":"Yamada T.","year":"1996","unstructured":"Yamada T.; Horiuchi M.; Dzau V.J.; Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 1996,93(1),156-160","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=378","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1152\/ajprenal.2001.281.2.F300","volume":"281","author":"Zimpelmann J.","year":"2001","unstructured":"Zimpelmann J.; Burns K.D.; Angiotensin II AT2 receptors inhibit growth responses in proximal tubule cells. Am J Physiol Renal Physiol 2001,281(2),50-52","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=379","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1161\/01.RES.87.9.753","volume":"87","author":"Hansen J.L.","year":"2000","unstructured":"Hansen J.L.; Servant G.; Baranski T.J.; Fujita T.; Iiri T.; Sheikh S.P.; Functional reconstitution of the angiotensin II type 2 receptor and G(i) activation. Circ Res 2000,87(9),753-759","journal-title":"Circ Res"},{"key":"ref=380","doi-asserted-by":"publisher","first-page":"15026","DOI":"10.1074\/jbc.271.25.15026","volume":"271","author":"Zhang J.","year":"1996","unstructured":"Zhang J.; Pratt R.E.; The AT2 receptor selectively associates with Gialpha2 and Gialpha3 in the rat fetus. J Biol Chem 1996,271(25),15026-15033","journal-title":"J Biol Chem"},{"key":"ref=381","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S0008-6363(00)00299-6","volume":"49","author":"Cui T.","year":"2001","unstructured":"Cui T.; Nakagami H.; Iwai M.; Takeda Y.; Shiuchi T.; Daviet L.; Nahmias C.; Horiuchi M.; Pivotal role of tyrosine phosphatase SHP-1 in AT2 receptor-mediated apoptosis in rat fetal vascular smooth muscle cell. Cardiovasc Res 2001,49(4),863-871","journal-title":"Cardiovasc Res"},{"key":"ref=382","doi-asserted-by":"crossref","first-page":"301-307","DOI":"10.1161\/01.HYP.37.2.301","volume":"37","author":"Dimitropoulou C.","year":"2001","unstructured":"Dimitropoulou C.; White R.E.; Fuchs L.; Zhang H.; Catravas J.D.; Carrier G.O.; Angiotensin II relaxes microvessels via the AT2 receptor and Ca2+-activated K+ (BKCa) channels. Hypertension 2001,37(21),301-307","journal-title":"Hypertension"},{"key":"ref=383","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1152\/ajpheart.1998.275.3.H906","volume":"275","author":"Fischer T.A.","year":"1998","unstructured":"Fischer T.A.; Singh K.; O\u2019Hara D.S.; Kaye D.M.; Kelly R.A.; Role of AT1 and AT2 receptors in regulation of MAPKS and MKP-1 by ANG II in adult cardiac myocytes. Am J Physiol Heart Circ Physiol 1998,275(3),44-53","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=384","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1161\/01.HYP.31.1.349","volume":"31","author":"Gohlke P.","year":"1998","unstructured":"Gohlke P.; Pees C.; Unger T.; AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998,31(1 Pt 2),349-355","journal-title":"Hypertension"},{"key":"ref=385","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1152\/ajpcell.1995.268.1.C278","volume":"268","author":"Kang J.","year":"1995","unstructured":"Kang J.; Richards E.M.; Posner P.; Sumners C.; Modulation of the delayed rectifier K+ current in neurons by an angiotensin II type 2 receptor fragment. Am J Physiol Cell Physiol 1995,268(1),37","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=386","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1161\/01.ATV.0000035392.38687.65","volume":"22","author":"Rueckschloss U.","year":"2002","unstructured":"Rueckschloss U.; Quinn M.T.; Holtz J.; Morawietz H.; Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2002,22(11),1845-1851","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=387","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1161\/01.RES.0000019892.41157.24","volume":"90","author":"Silvestre J.S.","year":"2002","unstructured":"Silvestre J.S.; Tamarat R.; Senbonmatsu T.; Icchiki T.; Ebrahimian T.; Iglarz M.; Besnard S.; Duriez M.; Inagami T.; Lévy B.I.; Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb. Circ Res 2002,90(10),1072-1079","journal-title":"Circ Res"},{"key":"ref=388","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/sj.bjp.0703566","volume":"131","author":"Sohn H.Y.","year":"2000","unstructured":"Sohn H.Y.; Raff U.; Hoffmann A.; Gloe T.; Heermeier K.; Galle J.; Pohl U.; Differential role of angiotensin II receptor subtypes on endothelial superoxide formation. Br J Pharmacol 2000,131(4),667-672","journal-title":"Br J Pharmacol"},{"key":"ref=389","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1590\/S0100-879X2002000900001","volume":"35","author":"Touyz R.M.","year":"2002","unstructured":"Touyz R.M.; Berry C.; Recent advances in angiotensin II signaling. Braz J Med Biol Res 2002,35(9),1001-1015","journal-title":"Braz J Med Biol Res"},{"key":"ref=390","first-page":"226","volume":"43","author":"Inagami T.","year":"1993","unstructured":"Inagami T.; Iwai N.; Sasaki K.; Guo D.F.; Furuta H.; Yamano Y.; Bardhan S.; Chaki S.; Makito N.; Badr K.; Angiotensin II receptors: cloning and regulation. Arzneimittelforschung 1993,43(2A),226-228","journal-title":"Arzneimittelforschung"},{"key":"ref=391","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S1043-2760(02)00037-1","volume":"14","author":"Albiston A.L.","year":"2003","unstructured":"Albiston A.L.; Mustafa T.; McDowall S.G.; Mendelsohn F.A.; Lee J.; Chai S.Y.; AT4 receptor is insulin-regulated membrane aminopeptidase: potential mechanisms of memory enhancement. Trends Endocrinol Metab 2003,14(2),72-77","journal-title":"Trends Endocrinol Metab"},{"key":"ref=392","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/0922-4106(92)90111-8","volume":"225","author":"Chaki S.","year":"1992","unstructured":"Chaki S.; Inagami T.; A newly found angiotensin II receptor subtype mediates cyclic GMP formation in differentiated Neuro-2A cells. Eur J Pharmacol 1992,225(4),355-356","journal-title":"Eur J Pharmacol"},{"key":"ref=393","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1358\/dnp.2009.22.3.1325032","volume":"22","author":"Hallberg M.","year":"2009","unstructured":"Hallberg M.; Targeting the insulin-regulated aminopeptidase\/AT4 receptor for cognitive disorders. Drug News Perspect 2009,22(3),133-139","journal-title":"Drug News Perspect"},{"key":"ref=394","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/S0006-8993(10)80047-2","volume":"583","author":"Harding J.W.","year":"1992","unstructured":"Harding J.W.; Cook V.I.; Miller-Wing A.V.; Hanesworth J.M.; Sardinia M.F.; Hall K.L.; Stobb J.W.; Swanson G.N.; Coleman J.K.; Wright J.W.; Identification of an AII(3-8) [AIV] binding site in guinea pig hippocampus. Brain Res 1992,583(1-2),340-343","journal-title":"Brain Res"},{"key":"ref=395","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1124\/jpet.111.182220","volume":"339","author":"Benoist C.C.","year":"2011","unstructured":"Benoist C.C.; Wright J.W.; Zhu M.; Appleyard S.M.; Wayman G.A.; Harding J.W.; Facilitation of hippocampal synaptogenesis and spatial memory by C-terminal truncated Nle1-angiotensin IV analogs. J Pharmacol Exp Ther 2011,339(1),35-44","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=396","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.pneurobio.2011.07.001","volume":"95","author":"Wright J.W.","year":"2011","unstructured":"Wright J.W.; Harding J.W.; Brain renin-angiotensin--a new look at an old system. Prog Neurobiol 2011,95(1),49-67","journal-title":"Prog Neurobiol"},{"key":"ref=397","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00213-010-1791-1","volume":"209","author":"Beyer C.E.","year":"2010","unstructured":"Beyer C.E.; Dwyer J.M.; Platt B.J.; Neal S.; Luo B.; Ling H.P.; Lin Q.; Mark R.J.; Rosenzweig-Lipson S.; Schechter L.E.; Angiotensin IV elevates oxytocin levels in the rat amygdala and produces anxiolytic-like activity through subsequent oxytocin receptor activation. Psychopharmacology (Berl) 2010,209(4),303-311","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=398","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.neuroscience.2005.10.051","volume":"137","author":"Davis C.J.","year":"2006","unstructured":"Davis C.J.; Kramár E.A.; De A.; Meighan P.C.; Simasko S.M.; Wright J.W.; Harding J.W.; AT4 receptor activation increases intracellular calcium influx and induces a non-N-methyl-D-aspartate dependent form of long-term potentiation. Neuroscience 2006,137(4),1369-1379","journal-title":"Neuroscience"},{"key":"ref=399","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1007\/s00018-004-4246-1","volume":"61","author":"Chai S.Y.","year":"2004","unstructured":"Chai S.Y.; Fernando R.; Peck G.; Ye S-Y.; Mendelsohn F.A.O.; Jenkins T.A.; Albiston A.L.; The angiotensin IV\/AT4 receptor. Cell Mol Life Sci 2004,61(21),2728-2737","journal-title":"Cell Mol Life Sci"},{"key":"ref=400","doi-asserted-by":"publisher","first-page":"4749","DOI":"10.2174\/138161212803216906","volume":"18","author":"Laviano A.","year":"2012","unstructured":"Laviano A.; Molfino A.; Rianda S.; Rossi Fanelli F.; The growth hormone secretagogue receptor (Ghs-R). Curr Pharm Des 2012,18(31),4749-4754","journal-title":"Curr Pharm Des"},{"key":"ref=401","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1517\/14728222.12.9.1177","volume":"12","author":"Soares J-B.","year":"2008","unstructured":"Soares J-B.; Roncon-Albuquerque R.; Leite-Moreira A.; Ghrelin and ghrelin receptor inhibitors: Agents in the treatment of obesity. Expert Opin Ther Targets 2008,12(9),1177-1189","journal-title":"Expert Opin Ther Targets"},{"key":"ref=402","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/dmrr.830","volume":"24","author":"Pusztai P.","year":"2008","unstructured":"Pusztai P.; Sarman B.; Ruzicska E.; Toke J.; Racz K.; Somogyi A.; Tulassay Z.; Ghrelin: A new peptide regulating the neurohormonal system, energy homeostasis and glucose metabolism. Diabetes Metab Res Rev 2008,24(5),343-352","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=403","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0169-328X(97)00071-5","volume":"48","author":"Guan X.M.","year":"1997","unstructured":"Guan X.M.; Yu H.; Palyha O.C.; McKee K.K.; Feighner S.D.; Sirinathsinghji D.J.S.; Smith R.G.; Van der Ploeg L.H.; Howard A.D.; Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res Mol Brain Res 1997,48(1),23-29","journal-title":"Brain Res Mol Brain Res"},{"key":"ref=404","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.neuropharm.2009.06.024","volume":"58","author":"Schellekens H.","year":"2010","unstructured":"Schellekens H.; Dinan T.G.; Cryan J.F.; Lean mean fat reducing “ghrelin” machine: hypothalamic ghrelin and ghrelin receptors as therapeutic targets in obesity. Neuropharmacology 2010,58(1),2-16","journal-title":"Neuropharmacology"},{"key":"ref=405","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1210\/jcem.87.6.8739","volume":"87","author":"Gnanapavan S.","year":"2002","unstructured":"Gnanapavan S.; Kola B.; Bustin S.A.; Morris D.G.; McGee P.; Fairclough P.; Bhattacharya S.; Carpenter R.; Grossman A.B.; Korbonits M.; The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002,87(6),2988-2991","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=406","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1517\/14728220902914834","volume":"13","author":"Gómez R.","year":"2009","unstructured":"Gómez R.; Lago F.; Gómez-Reino J.J.; Gualillo O.; Novel factors as therapeutic targets to treat diabetes. Focus on leptin and ghrelin. Expert Opin Ther Targets 2009,13(5),583-591","journal-title":"Expert Opin Ther Targets"},{"key":"ref=407","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/j.1365-2265.2004.02011.x","volume":"60","author":"Broglio F.","year":"2004","unstructured":"Broglio F.; Gianotti L.; Destefanis S.; Fassino S.; Abbate D.G.; Mondelli V.; Lanfranco F.; Gottero C.; Gauna C.; Hofland L.; Van der Lely A.J.; Ghigo E.; The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state. Clin Endocrinol (Oxf) 2004,60(5),592-599","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref=408","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jpsychires.2010.10.001","volume":"45","author":"Müller T.D.","year":"2011","unstructured":"Müller T.D.; Tschöp M.H.; Jarick I.; Ehrlich S.; Scherag S.; Herpertz-Dahlmann B.; Zipfel S.; Herzog W.; de Zwaan M.; Burghardt R.; Fleischhaker C.; Klampfl K.; Wewetzer C.; Herpertz S.; Zeeck A.; Tagay S.; Burgmer M.; Pfluger P.T.; Scherag A.; Hebebrand J.; Hinney A.; Genetic variation of the ghrelin activator gene ghrelin O-acyltransferase (GOAT) is associated with anorexia nervosa. J Psychiatr Res 2011,45(5),706-711","journal-title":"J Psychiatr Res"},{"key":"ref=409","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/ncponc0112","volume":"2","author":"Laviano A.","year":"2005","unstructured":"Laviano A.; Meguid M.M.; Inui A.; Muscaritoli M.; Rossi-Fanelli F.; Therapy insight: Cancer anorexia-cachexia syndrome--when all you can eat is yourself. Nat Clin Pract Oncol 2005,2(3),158-165","journal-title":"Nat Clin Pract Oncol"},{"key":"ref=410","doi-asserted-by":"publisher","first-page":"e16391","DOI":"10.1371\/journal.pone.0016391","volume":"6","author":"Ma X.","year":"2011","unstructured":"Ma X.; Lin L.; Qin G.; Lu X.; Fiorotto M.; Dixit V.D.; Sun Y.; Ablations of ghrelin and ghrelin receptor exhibit differential metabolic phenotypes and thermogenic capacity during aging. PLoS One 2011,6(1),e16391","journal-title":"PLoS One"},{"key":"ref=411","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0167-0115(03)00117-4","volume":"114","author":"Nagaya N.","year":"2003","unstructured":"Nagaya N.; Kangawa K.; Ghrelin, a novel growth hormone-releasing peptide, in the treatment of chronic heart failure. Regul Pept 2003,114(2-3),71-77","journal-title":"Regul Pept"},{"key":"ref=412","doi-asserted-by":"publisher","first-page":"e10084","DOI":"10.1371\/journal.pone.0010084","volume":"5","author":"Gjesing A.P.","year":"2010","unstructured":"Gjesing A.P.; Larsen L.H.; Torekov S.S.; Hainerová I.A.; Kapur R.; Johansen A.; Albrechtsen A.; Boj S.; Holst B.; Harper A.; Urhammer S.A.; Borch-Johnsen K.; Pisinger C.; Echwald S.M.; Eiberg H.; Astrup A.; Lebl J.; Ferrer J.; Schwartz T.W.; Hansen T.; Pedersen O.; Family and population-based studies of variation within the ghrelin receptor locus in relation to measures of obesity. PLoS One 2010,5(4),e10084","journal-title":"PLoS One"},{"key":"ref=413","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.regpep.2004.12.001","volume":"127","author":"Kamegai J.","year":"2005","unstructured":"Kamegai J.; Tamura H.; Shimizu T.; Ishii S.; Sugihara H.; Oikawa S.; Insulin-like growth factor-I down-regulates ghrelin receptor (growth hormone secretagogue receptor) expression in the rat pituitary. Regul Pept 2005,127(1-3),203-206","journal-title":"Regul Pept"},{"key":"ref=414","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2174\/157339908783502352","volume":"4","author":"Yada T.","year":"2008","unstructured":"Yada T.; Dezaki K.; Sone H.; Koizumi M.; Damdindorj B.; Nakata M.; Kakei M.; Ghrelin regulates insulin release and glycemia: physiological role and therapeutic potential. Curr Diabetes Rev 2008,4(1),18-23","journal-title":"Curr Diabetes Rev"},{"key":"ref=415","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.pharmthera.2008.02.008","volume":"118","author":"Dezaki K.","year":"2008","unstructured":"Dezaki K.; Sone H.; Yada T.; Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. Pharmacol Ther 2008,118(2),239-249","journal-title":"Pharmacol Ther"},{"key":"ref=416","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1021\/jm401343c","volume":"57","author":"Zlotos D.P.","year":"2014","unstructured":"Zlotos D.P.; Jockers R.; Cecon E.; Rivara S.; Witt-Enderby P.A.; MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem 2014,57(8),3161-3185","journal-title":"J Med Chem"},{"key":"ref=417","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/0896-6273(94)90055-8","volume":"13","author":"Reppert S.M.","year":"1994","unstructured":"Reppert S.M.; Weaver D.R.; Ebisawa T.; Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994,13(5),1177-1185","journal-title":"Neuron"},{"key":"ref=418","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1124\/pr.110.002832","volume":"62","author":"Dubocovich M.L.","year":"2010","unstructured":"Dubocovich M.L.; Delagrange P.; Krause D.N.; Sugden D.; Cardinali D.P.; Olcese J.; International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev 2010,62(3),343-380","journal-title":"Pharmacol Rev"},{"key":"ref=419","author":"Cardinali D.P.","year":"2019","unstructured":"Cardinali D.P.; Delagrange P.; Dubocovich M.L.; Jockers R.; Krause D.N.; Markus R.P.; Melatonin receptors (version 20194) in the IUPHAR\/BPS guide to pharmacology database 2019(4)","journal-title":"Melatonin receptors (version 20194) in the IUPHAR\/BPS guide to pharmacology database"},{"key":"ref=420","doi-asserted-by":"publisher","first-page":"135","DOI":"10.5152\/eurasianjmed.2015.0267","volume":"48","author":"Emet M.","year":"2016","unstructured":"Emet M.; Ozcan H.; Ozel L.; Yayla M.; Halici Z.; Hacimuftuoglu A.; A Review of Melatonin, Its Receptors and Drugs. Eurasian J Med 2016,48(2),135-141","journal-title":"Eurasian J Med"},{"key":"ref=421","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1124\/jpet.118.253260","volume":"368","author":"Boutin J.A.","year":"2019","unstructured":"Boutin J.A.; Ferry G.; \nIs There Sufficient Evidence that the Melatonin Binding Site \nMT\nIs Quinone Reductase 2?\n J Pharmacol Exp Ther 2019,368(1),59-65","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=422","doi-asserted-by":"publisher","first-page":"31311","DOI":"10.1074\/jbc.M005141200","volume":"275","author":"Nosjean O.","year":"2000","unstructured":"Nosjean O.; Ferro M.; Cogé F.; Beauverger P.; Henlin J.M.; Lefoulon F.; Fauchere J.L.; Delagrange P.; Canet E.; Boutin J.A.; Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 2000,275(40),31311-31317","journal-title":"J Biol Chem"},{"key":"ref=423","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/bies.201400017","volume":"36","author":"Tosini G.","year":"2014","unstructured":"Tosini G.; Owino S.; Guillaume J.L.; Jockers R.; Understanding melatonin receptor pharmacology: latest insights from mouse models, and their relevance to human disease. BioEssays 2014,36(8),778-787","journal-title":"BioEssays"},{"key":"ref=424","doi-asserted-by":"publisher","first-page":"10979","DOI":"10.3390\/ijms140610979","volume":"14","author":"Markus R.P.","year":"2013","unstructured":"Markus R.P.; Cecon E.; Pires-Lapa M.A.; Immune-pineal axis: nuclear factor κB (NF-kB) mediates the shift in the melatonin source from pinealocytes to immune competent cells. Int J Mol Sci 2013,14(6),10979-10997","journal-title":"Int J Mol Sci"},{"key":"ref=425","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1038\/bjp.2008.184","volume":"154","author":"Jockers R.","year":"2008","unstructured":"Jockers R.; Maurice P.; Boutin J.A.; Delagrange P.; Melatonin receptors, heterodimerization, signal transduction and binding sites: what\u2019s new? Br J Pharmacol 2008,154(6),1182-1195","journal-title":"Br J Pharmacol"},{"key":"ref=426","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.5664\/jcsm.26932","volume":"3","author":"Doghramji K.","year":"2007","unstructured":"Doghramji K.; Melatonin and its receptors: A new class of sleep-promoting agents. J Clin Sleep Med 2007,3(5)(Suppl.),S17-S23","journal-title":"J Clin Sleep Med"},{"key":"ref=427","doi-asserted-by":"publisher","first-page":"150","DOI":"10.2174\/1874467213666200421160835","volume":"14","author":"Wongprayoon P.","year":"2021","unstructured":"Wongprayoon P.; Govitrapong P.; Melatonin Receptor as a Drug Target for Neuroprotection. Curr Mol Pharmacol 2021,14(2),150-164","journal-title":"Curr Mol Pharmacol"},{"key":"ref=428","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.sleep.2007.10.007","volume":"8","author":"Dubocovich M.L.","year":"2007","unstructured":"Dubocovich M.L.; Melatonin receptors: role on sleep and circadian rhythm regulation. Sleep Med 2007,8(Suppl. 3),34-42","journal-title":"Sleep Med"},{"key":"ref=429","doi-asserted-by":"crossref","first-page":"e0255249","DOI":"10.1371\/journal.pone.0255249","volume":"16","author":"Lépinay J.","year":"2021","unstructured":"Lépinay J.; Taragnat C.; Dubois J.P.; Chesneau D.; Jockers R.; Delagrange, P Negative regulation of melatonin secretion by melatonin receptors in ovine pinealocytes. PLoS One 2021,16,e0255249","journal-title":"PLoS One"},{"key":"ref=430","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1111\/bph.13536","volume":"173","author":"Jockers R.","year":"2016","unstructured":"Jockers R.; Delagrange P.; Dubocovich M.L.; Markus R.P.; Renault N.; Tosini G.; Cecon E.; Zlotos D.P.; Update on melatonin receptors: IUPHAR Review 20. Br J Pharmacol 2016,173(18),2702-2725","journal-title":"Br J Pharmacol"},{"key":"ref=431","doi-asserted-by":"publisher","first-page":"8734","DOI":"10.1073\/pnas.92.19.8734","volume":"92","author":"Reppert S.M.","year":"1995","unstructured":"Reppert S.M.; Godson C.; Mahle C.D.; Weaver D.R.; Slaugenhaupt S.A.; Gusella J.F.; Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci USA 1995,92(19),8734-8738","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=432","first-page":"1341-1343","volume":"219","author":"Besharse JC","year":"1983","unstructured":"Besharse JC; Dunis DA; Methoxyindoles and photoreceptor metabolism: Activation of rod shedding. Science (80) 1983,219((4590)),1341-1343","journal-title":"Science (80)"},{"key":"ref=433","doi-asserted-by":"publisher","first-page":"e12423","DOI":"10.1111\/jpi.12423","volume":"63","author":"Sharan K.","year":"2017","unstructured":"Sharan K.; Lewis K.; Furukawa T.; Yadav V.K.; Regulation of bone mass through pineal-derived melatonin-MT2 receptor pathway. J Pineal Res 2017,63(2),e12423","journal-title":"J Pineal Res"},{"key":"ref=434","doi-asserted-by":"publisher","first-page":"e12704","DOI":"10.1111\/jpi.12704","volume":"70","author":"Rui T.","year":"2021","unstructured":"Rui T.; Wang H.; Li Q.; Cheng Y.; Gao Y.; Fang X.; Ma X.; Chen G.; Gao C.; Gu Z.; Song S.; Zhang J.; Wang C.; Wang Z.; Wang T.; Zhang M.; Min J.; Chen X.; Tao L.; Wang F.; Luo C.; Deletion of ferritin H in neurons counteracts the protective effect of melatonin against traumatic brain injury-induced ferroptosis. J Pineal Res 2021,70(2),e12704","journal-title":"J Pineal Res"},{"key":"ref=435","doi-asserted-by":"publisher","first-page":"173722","DOI":"10.1016\/j.ejphar.2020.173722","volume":"891","author":"Noseda A.C.D.","year":"2021","unstructured":"Noseda A.C.D.; Rodrigues L.S.; Targa A.D.S.; Ilkiw J.L.; Fagotti J.; Dos Santos P.D.; Cecon E.; Markus R.P.; Solimena M.; Jockers R.; Lima M.M.S.; MT melatonin receptors expressed in the olfactory bulb modulate depressive-like behavior and olfaction in the 6-OHDA model of Parkinson\u2019s disease. Eur J Pharmacol 2021,891,173722","journal-title":"Eur J Pharmacol"},{"key":"ref=436","doi-asserted-by":"publisher","first-page":"21522","DOI":"10.1074\/jbc.M200729200","volume":"277","author":"Ayoub M.A.","year":"2002","unstructured":"Ayoub M.A.; Couturier C.; Lucas-Meunier E.; Angers S.; Fossier P.; Bouvier M.; Jockers R.; Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J Biol Chem 2002,277(24),21522-21528","journal-title":"J Biol Chem"},{"key":"ref=437","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1124\/mol.104.000398","volume":"66","author":"Ayoub M.A.","year":"2004","unstructured":"Ayoub M.A.; Levoye A.; Delagrange P.; Jockers R.; Preferential formation of MT1\/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared with MT2 homodimers. Mol Pharmacol 2004,66(2),312-321","journal-title":"Mol Pharmacol"},{"key":"ref=438","doi-asserted-by":"publisher","first-page":"ra89","DOI":"10.1126\/scisignal.2004302","volume":"6","author":"Baba K.","year":"2013","unstructured":"Baba K.; Benleulmi-Chaachoua A.; Journé A.S.; Kamal M.; Guillaume J.L.; Dussaud S.; Gbahou F.; Yettou K.; Liu C.; Contreras-Alcantara S.; Jockers R.; Tosini G.; Heteromeric MT1\/MT2 melatonin receptors modulate photoreceptor function. Sci Signal 2013,6(296),ra89","journal-title":"Sci Signal"},{"key":"ref=439","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0014-5793(02)02775-8","volume":"520","author":"Takeda S.","year":"2002","unstructured":"Takeda S.; Kadowaki S.; Haga T.; Takaesu H.; Mitaku S.; Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett 2002,520(1-3),97-101","journal-title":"FEBS Lett"},{"key":"ref=440","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1111\/bph.13878","volume":"174","author":"Alexander S.P.","year":"2017","unstructured":"Alexander S.P.; Christopoulos A.; Davenport A.P.; Kelly E.; Marrion N.V.; Peters J.A.; Faccenda E.; Harding S.D.; Pawson A.J.; Sharman J.L.; Southan C.; Davies J.A.; The concise guide to pharmacology 2017\/18: G protein-coupled receptors. Br J Pharmacol 2017,174(Suppl. 1),S17-S129","journal-title":"Br J Pharmacol"},{"key":"ref=441","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1124\/pr.112.007179","volume":"65","author":"Davenport A.P.","year":"2013","unstructured":"Davenport A.P.; Alexander S.P.H.; Sharman J.L.; Pawson A.J.; Benson H.E.; Monaghan A.E.; Liew W.C.; Mpamhanga C.P.; Bonner T.I.; Neubig R.R.; Pin J.P.; Spedding M.; Harmar A.J.; International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev 2013,65(3),967-986","journal-title":"Pharmacol Rev"},{"key":"ref=442","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.bbagen.2004.12.001","volume":"1722","author":"Gloriam D.E.I.","year":"2005","unstructured":"Gloriam D.E.I.; Schiöth H.B.; Fredriksson R.; Nine new human Rhodopsin family G-protein coupled receptors: identification, sequence characterisation and evolutionary relationship. Biochim Biophys Acta 2005,1722(3),235-246","journal-title":"Biochim Biophys Acta"},{"key":"ref=443","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/bcpt.13263","volume":"126","author":"Vedel L.","year":"2020","unstructured":"Vedel L.; Nøhr A.C.; Gloriam D.E.; Bräuner-Osborne H.; Pharmacology and function of the orphan GPR139 G protein-coupled receptor. Basic Clin Pharmacol Toxicol 2020,126(S6)(Suppl. 6),35-46","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=444","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1523\/ENEURO.0153-18.2018","volume":"5","author":"Kononoff J.","year":"2018","unstructured":"Kononoff J.; Kallupi M.; Kimbrough A.; Conlisk D.; de Guglielmo G.; George O.; Systemic and intra-habenular activation of the orphan G protein-coupled receptor GPR139 decreases compulsive-like alcohol drinking and hyperalgesia in alcohol-dependent rats. eNeuro 2018,5(3),153-171","journal-title":"eNeuro"},{"key":"ref=445","author":"Hitchcock S","year":"2015","unstructured":"Hitchcock S; Lam B; Monenschein H; Reichard H.; 4-oxo-3,4- dihydro-1,2,3-benzotriazine modulators of GPR139 2015","journal-title":"4-oxo-3,4- dihydro-1,2,3-benzotriazine modulators of GPR139"},{"key":"ref=446","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1017\/thg.2013.12","volume":"16","author":"Ebejer J.L.","year":"2013","unstructured":"Ebejer J.L.; Duffy D.L.; van der Werf J.; Wright M.J.; Montgomery G.; Gillespie N.A.; Hickie I.B.; Martin N.G.; Medland S.E.; Genome-wide association study of inattention and hyperactivity-impulsivity measured as quantitative traits. Twin Res Hum Genet 2013,16(2),560-574","journal-title":"Twin Res Hum Genet"},{"key":"ref=447","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1017\/thg.2014.6","volume":"17","author":"Castellani C.A.","year":"2014","unstructured":"Castellani C.A.; Awamleh Z.; Melka M.G.; O\u2019Reilly R.L.; Singh S.M.; Copy number variation distribution in six monozygotic twin pairs discordant for schizophrenia. Twin Res Hum Genet 2014,17(2),108-120","journal-title":"Twin Res Hum Genet"},{"key":"ref=448","first-page":"304","volume":"4","author":"Al Hafid N.","year":"2015","unstructured":"Al Hafid N.; Christodoulou J.; Phenylketonuria: A review of current and future treatments. Transl Pediatr 2015,4(4),304-317","journal-title":"Transl Pediatr"},{"key":"ref=449","doi-asserted-by":"publisher","first-page":"15482","DOI":"10.1074\/jbc.M201539200","volume":"277","author":"Salim K.","year":"2002","unstructured":"Salim K.; Fenton T.; Bacha J.; Urien-Rodriguez H.; Bonnert T.; Skynner H.A.; Watts E.; Kerby J.; Heald A.; Beer M.; McAllister G.; Guest P.C.; Oligomerization of G-protein-coupled receptors shown by selective co-immunoprecipitation. J Biol Chem 2002,277(18),15482-15485","journal-title":"J Biol Chem"},{"key":"ref=450","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.neubiorev.2018.09.026","volume":"106","author":"Derouiche L.","year":"2019","unstructured":"Derouiche L.; Massotte D.; G protein-coupled receptor heteromers are key players in substance use disorder. Neurosci Biobehav Rev 2019,106,73-90","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=451","doi-asserted-by":"publisher","first-page":"9985","DOI":"10.1074\/jbc.M110.201939","volume":"286","author":"Pellissier L.P.","year":"2011","unstructured":"Pellissier L.P.; Barthet G.; Gaven F.; Cassier E.; Trinquet E.; Pin J.P.; Marin P.; Dumuis A.; Bockaert J.; Banères J.L.; Claeysen S.; G protein activation by serotonin type 4 receptor dimers: evidence that turning on two protomers is more efficient. J Biol Chem 2011,286(12),9985-9997","journal-title":"J Biol Chem"},{"key":"ref=452","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nchembio.199","volume":"5","author":"Han Y.","year":"2009","unstructured":"Han Y.; Moreira I.S.; Urizar E.; Weinstein H.; Javitch J.A.; Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat Chem Biol 2009,5(9),688-695","journal-title":"Nat Chem Biol"},{"key":"ref=453","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/B978-0-12-391862-8.00016-8","volume":"521","author":"Maggio R.","year":"2013","unstructured":"Maggio R.; Rocchi C.; Scarselli M.; Experimental strategies for studying G protein-coupled receptor homo- and heteromerization with radioligand binding and signal transduction methods. Methods Enzymol 2013,521,295-310","journal-title":"Methods Enzymol"},{"key":"ref=454","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-1-4939-3064-7_9","volume":"110","author":"Borroto-Escuela D.O.","year":"2016","unstructured":"Borroto-Escuela D.O.; Hagman B.; Woolfenden M.; Pinton L.; Jiménez-Beristain A.; Oflijan J.; \nIn situ\nproximity ligation assay to study and understand the distribution and balance of GPCR homo- and heteroreceptor complexes in the brain.\n Neuromethods 2016,110,109-124","journal-title":"Neuromethods"},{"key":"ref=455","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1124\/mol.115.099440","volume":"88","author":"Vischer H.F.","year":"2015","unstructured":"Vischer H.F.; Castro M.; Pin J.P.; G protein-coupled receptor multimers: A question still open despite the use of novel approaches. Mol Pharmacol 2015,88(3),561-571","journal-title":"Mol Pharmacol"},{"key":"ref=456","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1476-5381.2009.00181.x","volume":"158","author":"Franco R.","year":"2009","unstructured":"Franco R.; G-protein-coupled receptor heteromers or how neurons can display differently flavoured patterns in response to the same neurotransmitter. Br J Pharmacol 2009,158(1),23-31","journal-title":"Br J Pharmacol"},{"key":"ref=457","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3389\/fphar.2016.00076","volume":"7","author":"Franco R.","year":"2016","unstructured":"Franco R.; Martínez-Pinilla E.; Lanciego J.L.; Navarro G.; Basic pharmacological and structural evidence for class A G-protein-coupled receptor heteromerization. Front Pharmacol 2016,7(MAR),76","journal-title":"Front Pharmacol"},{"key":"ref=458","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1523\/JNEUROSCI.3574-05.2006","volume":"26","author":"Ciruela F.","year":"2006","unstructured":"Ciruela F.; Casadó V.; Rodrigues R.J.; Luján R.; Burgueño J.; Canals M.; Borycz J.; Rebola N.; Goldberg S.R.; Mallol J.; Cortés A.; Canela E.I.; López-Giménez J.F.; Milligan G.; Lluis C.; Cunha R.A.; Ferré S.; Franco R.; Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci 2006,26(7),2080-2087","journal-title":"J Neurosci"},{"key":"ref=459","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1100\/tsw.2007.211","volume":"7","author":"Ferré S.","year":"2007","unstructured":"Ferré S.; Ciruela F.; Quiroz C.; Luján R.; Popoli P.; Cunha R.A.; Agnati L.F.; Fuxe K.; Woods A.S.; Lluis C.; Franco R.; Adenosine receptor heteromers and their integrative role in striatal function. Sci World J 2007,7(Suppl. 2),74-85","journal-title":"Sci World J"},{"key":"ref=460","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s11302-013-9364-5","volume":"9","author":"Cristóvão-Ferreira S.","year":"2013","unstructured":"Cristóvão-Ferreira S.; Navarro G.; Brugarolas M.; Pérez-Capote K.; Vaz S.H.; Fattorini G.; Conti F.; Lluis C.; Ribeiro J.A.; McCormick P.J.; Casadó V.; Franco R.; Sebastião A.M.; A1R-A2AR heteromers coupled to Gs and G i\/0 proteins modulate GABA transport into astrocytes. Purinergic Signal 2013,9(3),433-449","journal-title":"Purinergic Signal"},{"key":"ref=461","doi-asserted-by":"publisher","first-page":"211, 183-200","DOI":"10.1016\/B978-0-444-63425-2.00008-8","author":"George S.R.","year":"2014","unstructured":"George S.R.; Kern A.; Smith R.G.; Franco R.; Dopamine receptor heteromeric complexes and their emerging functions. Prog Brain Res 2014,211, 183-200","journal-title":"Prog Brain Res"},{"key":"ref=462","doi-asserted-by":"publisher","first-page":"21377","DOI":"10.1073\/pnas.0903676106","volume":"106","author":"Hasbi A.","year":"2009","unstructured":"Hasbi A.; Fan T.; Alijaniaram M.; Nguyen T.; Perreault M.L.; O\u2019Dowd B.F.; George S.R.; Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. Proc Natl Acad Sci USA 2009,106(50),21377-21382","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=463","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1124\/mol.107.034884","volume":"72","author":"So C.H.","year":"2007","unstructured":"So C.H.; Verma V.; O\u2019Dowd B.F.; George S.R.; Desensitization of the dopamine D1 and D2 receptor hetero-oligomer mediated calcium signal by agonist occupancy of either receptor. Mol Pharmacol 2007,72(2),450-462","journal-title":"Mol Pharmacol"},{"key":"ref=464","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1073\/pnas.0604049104","volume":"104","author":"Rashid A.J.","year":"2007","unstructured":"Rashid A.J.; So C.H.; Kong M.M.C.; Furtak T.; El-Ghundi M.; Cheng R.; O\u2019Dowd B.F.; George S.R.; D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq\/11 in the striatum. Proc Natl Acad Sci USA 2007,104(2),654-659","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=465","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0014-2999(03)01599-1","volume":"467","author":"Portoghese P.S.","year":"2003","unstructured":"Portoghese P.S.; Lunzer M.M.; Identity of the putative δ1-opioid receptor as a δ-κ heteromer in the mouse spinal cord. Eur J Pharmacol 2003,467(1-3),233-234","journal-title":"Eur J Pharmacol"},{"key":"ref=466","doi-asserted-by":"publisher","first-page":"RC110","DOI":"10.1523\/JNEUROSCI.20-22-j0007.2000","volume":"20","author":"Gomes I.","year":"2000","unstructured":"Gomes I.; Jordan B.A.; Gupta A.; Trapaidze N.; Nagy V.; Devi L.A.; Heterodimerization of μ and δ opioid receptors: A role in opiate synergy. J Neurosci 2000,20(22),RC110-RC110","journal-title":"J Neurosci"},{"key":"ref=467","doi-asserted-by":"publisher","first-page":"ra54","DOI":"10.1126\/scisignal.2000807","volume":"3","author":"Gupta A.","year":"2010","unstructured":"Gupta A.; Mulder J.; Gomes I.; Rozenfeld R.; Bushlin I.; Ong E.; Lim M.; Maillet E.; Junek M.; Cahill C.M.; Harkany T.; Devi L.A.; Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci Signal 2010,3(131),ra54","journal-title":"Sci Signal"},{"key":"ref=468","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1021\/cn9000236","volume":"1","author":"Yekkirala A.S.","year":"2010","unstructured":"Yekkirala A.S.; Kalyuzhny A.E.; Portoghese P.S.; Standard opioid agonists activate heteromeric opioid receptors: evidence for morphine and [d-Ala(2)-MePhe(4)-Glyol(5)]enkephalin as selective μ-δ agonists. ACS Chem Neurosci 2010,1(2),146-154","journal-title":"ACS Chem Neurosci"},{"key":"ref=469","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.coph.2009.09.007","volume":"10","author":"van Rijn R.M.","year":"2010","unstructured":"van Rijn R.M.; Whistler J.L.; Waldhoer M.; Opioid-receptor-heteromer-specific trafficking and pharmacology. Curr Opin Pharmacol 2010,10(1),73-79","journal-title":"Curr Opin Pharmacol"},{"key":"ref=470","doi-asserted-by":"publisher","first-page":"9050","DOI":"10.1073\/pnas.0501112102","volume":"102","author":"Waldhoer M.","year":"2005","unstructured":"Waldhoer M.; Fong J.; Jones R.M.; Lunzer M.M.; Sharma S.K.; Kostenis E.; Portoghese P.S.; Whistler J.L.; \nA heterodimer-selective agonist shows \nin vivo\nrelevance of G protein-coupled receptor dimers.\n Proc Natl Acad Sci USA 2005,102(25),9050-9055","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=471","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1021\/jm034234f","volume":"48","author":"Daniels D.J.","year":"2005","unstructured":"Daniels D.J.; Kulkarni A.; Xie Z.; Bhushan R.G.; Portoghese P.S.; A bivalent ligand (KDAN-18) containing δ-antagonist and κ-agonist pharmacophores bridges δ2 and κ1 opioid receptor phenotypes. J Med Chem 2005,48(6),1713-1716","journal-title":"J Med Chem"},{"key":"ref=472","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1021\/jm0342358","volume":"47","author":"Bhushan R.G.","year":"2004","unstructured":"Bhushan R.G.; Sharma S.K.; Xie Z.; Daniels D.J.; Portoghese P.S.; A bivalent ligand (KDN-21) reveals spinal δ and κ opioid receptors are organized as heterodimers that give rise to δ(1) and κ(2) phenotypes. Selective targeting of δ-κ heterodimers. J Med Chem 2004,47(12),2969-2972","journal-title":"J Med Chem"},{"key":"ref=473","first-page":"10(Suppl. 12)","author":"Fuxe K.","year":"1987","unstructured":"Fuxe K.; Harfstrand A.; Agnati L.F.; Kalia M.; Fredholm B.; Svensson T.; Central catecholamine-neuropeptide Y interactions at the pre- and postsynaptic level in cardiovascular centers. J Cardiovasc Pharmacol 1987,10(Suppl. 12)","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=474","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/med.2610050404","volume":"5","author":"Fuxe K.","year":"1985","unstructured":"Fuxe K.; Agnati L.F.; Receptor-receptor interactions in the central nervous system. A new integrative mechanism in synapses. Med Res Rev 1985,5(4),441-482","journal-title":"Med Res Rev"},{"key":"ref=475","first-page":"165","volume":"18","author":"Fuxe K.","year":"1983","unstructured":"Fuxe K.; Agnati L.F.; Benfenati F.; Celani M.; Zini I.; Zoli M.; Mutt V.; Evidence for the existence of receptor--receptor interactions in the central nervous system. Studies on the regulation of monoamine receptors by neuropeptides. J Neural Transm Suppl 1983,18,165-179","journal-title":"J Neural Transm Suppl"},{"key":"ref=476","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.bbrc.2010.12.083","volume":"404","author":"Borroto-Escuela D.O.","year":"2011","unstructured":"Borroto-Escuela D.O.; Van Craenenbroeck K.; Romero-Fernandez W.; Guidolin D.; Woods A.S.; Rivera A.; Haegeman G.; Agnati L.F.; Tarakanov A.O.; Fuxe K.; Dopamine D2 and D4 receptor heteromerization and its allosteric receptor-receptor interactions. Biochem Biophys Res Commun 2011,404(4),928-934","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=477","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.coph.2009.09.008","volume":"10","author":"Fiorentini C.","year":"2010","unstructured":"Fiorentini C.; Busi C.; Spano P.; Missale C.; Dimerization of dopamine D1 and D3 receptors in the regulation of striatal function. Curr Opin Pharmacol 2010,10(1),87-92","journal-title":"Curr Opin Pharmacol"},{"key":"ref=478","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.pharep.2016.10.016","volume":"69","author":"B\u0142asiak E.","year":"2017","unstructured":"B\u0142asiak E.; \u0141ukasiewicz S.; Szafran-Pilch K.; Dziedzicka-Wasylewska M.; Genetic variants of dopamine D2 receptor impact heterodimerization with dopamine D1 receptor. Pharmacol Rep 2017,69(2),235-241","journal-title":"Pharmacol Rep"},{"key":"ref=479","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3389\/fphar.2020.01003","volume":"11","author":"Martel J.C.","year":"2020","unstructured":"Martel J.C.; Gatti, McArthur, S. Dopamine receptor subtypes, physiology and pharmacology: New ligands and concepts in schizophrenia. Front Pharmacol 2020,11,1003","journal-title":"Front Pharmacol"},{"key":"ref=480","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2174\/1389203715666140901110256","volume":"15","author":"Van Craenenbroeck K.","year":"2014","unstructured":"Van Craenenbroeck K.; Borroto-Escuela D.O.; Skieterska K.; Duchou J.; Romero-Fernandez W.; Fuxe K.; Role of dimerization in dopamine D(4) receptor biogenesis. Curr Protein Pept Sci 2014,15(7),659-665","journal-title":"Curr Protein Pept Sci"},{"key":"ref=481","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1006\/bbrc.1996.1489","volume":"227","author":"Ng G.Y.K.","year":"1996","unstructured":"Ng G.Y.K.; O\u2019Dowd B.F.; Lee S.P.; Chung H.T.; Brann M.R.; Seeman P.; George S.R.; Dopamine D2 receptor dimers and receptor-blocking peptides. Biochem Biophys Res Commun 1996,227(1),200-204","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=482","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1124\/mol.58.4.677","volume":"58","author":"Karpa K.D.","year":"2000","unstructured":"Karpa K.D.; Lin R.; Kabbani N.; Levenson R.; The dopamine D3 receptor interacts with itself and the truncated D3 splice variant d3nf: D3-D3nf interaction causes mislocalization of D3 receptors. Mol Pharmacol 2000,58(4),677-683","journal-title":"Mol Pharmacol"},{"key":"ref=483","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.bbrc.2012.12.139","volume":"431","author":"O\u2019Dowd B.F.","year":"2013","unstructured":"O\u2019Dowd B.F.; Nguyen T.; Ji X.; George S.R.; D5 dopamine receptor carboxyl tail involved in D5-D2 heteromer formation. Biochem Biophys Res Commun 2013,431(3),586-589","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=484","doi-asserted-by":"publisher","first-page":"30308","DOI":"10.1074\/jbc.M102297200","volume":"276","author":"Scarselli M.","year":"2001","unstructured":"Scarselli M.; Novi F.; Schallmach E.; Lin R.; Baragli A.; Colzi A.; Griffon N.; Corsini G.U.; Sokoloff P.; Levenson R.; Vogel Z.; Maggio R.; D2\/D3 dopamine receptor heterodimers exhibit unique functional properties. J Biol Chem 2001,276(32),30308-30314","journal-title":"J Biol Chem"},{"key":"ref=485","doi-asserted-by":"publisher","first-page":"17495","DOI":"10.1073\/pnas.0508950102","volume":"102","author":"Guo W.","year":"2005","unstructured":"Guo W.; Shi L.; Filizola M.; Weinstein H.; Javitch J.A.; Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. Proc Natl Acad Sci USA 2005,102(48),17495-17500","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=486","doi-asserted-by":"publisher","first-page":"36625","DOI":"10.1074\/jbc.M110.159954","volume":"285","author":"Perreault M.L.","year":"2010","unstructured":"Perreault M.L.; Hasbi A.; Alijaniaram M.; Fan T.; Varghese G.; Fletcher P.J.; Seeman P.; O\u2019Dowd B.F.; George S.R.; The dopamine D1-D2 receptor heteromer localizes in dynorphin\/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia. J Biol Chem 2010,285(47),36625-36634","journal-title":"J Biol Chem"},{"key":"ref=487","doi-asserted-by":"publisher","first-page":"35671","DOI":"10.1074\/jbc.M401923200","volume":"279","author":"Lee S.P.","year":"2004","unstructured":"Lee S.P.; So C.H.; Rashid A.J.; Varghese G.; Cheng R.; Lança A.J.; O\u2019Dowd B.F.; George S.R.; Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal. J Biol Chem 2004,279(34),35671-35678","journal-title":"J Biol Chem"},{"key":"ref=488","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nchembio.623","volume":"7","author":"Urizar E.","year":"2011","unstructured":"Urizar E.; Yano H.; Kolster R.; Galés C.; Lambert N.; Javitch J.A.; CODA-RET reveals functional selectivity as a result of GPCR heteromerization. Nat Chem Biol 2011,7(9),624-630","journal-title":"Nat Chem Biol"},{"key":"ref=489","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.euroneuro.2016.07.008","volume":"26","author":"Perreault M.L.","year":"2016","unstructured":"Perreault M.L.; Hasbi A.; Shen M.Y.F.; Fan T.; Navarro G.; Fletcher P.J.; Franco R.; Lanciego J.L.; George S.R.; Disruption of a dopamine receptor complex amplifies the actions of cocaine. Eur Neuropsychopharmacol 2016,26(9),1366-1377","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=490","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1007\/s00429-016-1306-x","volume":"222","author":"Rico A.J.","year":"2017","unstructured":"Rico A.J.; Dopeso-Reyes I.G.; Martínez-Pinilla E.; Sucunza D.; Pignataro D.; Roda E.; Marín-Ramos D.; Labandeira-García J.L.; George S.R.; Franco R.; Lanciego J.L.; Neurochemical evidence supporting dopamine D1-D2 receptor heteromers in the striatum of the long-tailed macaque: changes following dopaminergic manipulation. Brain Struct Funct 2017,222(4),1767-1784","journal-title":"Brain Struct Funct"},{"key":"ref=491","doi-asserted-by":"publisher","first-page":"100794","DOI":"10.1016\/j.isci.2019.100794","volume":"23","author":"Hasbi A.","year":"2020","unstructured":"Hasbi A.; Madras B.K.; Bergman J.; Kohut S.; Lin Z.; Withey S.L.; George S.R.; \u0394-tetrahydrocannabinol increases dopamine D1-D2 receptor heteromer and elicits phenotypic reprogramming in adult primate striatal neurons. iScience 2020,23(1),100794","journal-title":"iScience"},{"key":"ref=492","doi-asserted-by":"publisher","first-page":"105017","DOI":"10.1016\/j.nbd.2020.105017","volume":"143","author":"Hasbi A.","year":"2020","unstructured":"Hasbi A.; Sivasubramanian M.; Milenkovic M.; Komarek K.; Madras B.K.; George S.R.; Dopamine D1-D2 receptor heteromer expression in key brain regions of rat and higher species: Upregulation in rat striatum after cocaine administration. Neurobiol Dis 2020,143,105017","journal-title":"Neurobiol Dis"},{"key":"ref=493","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1124\/mol.108.051805","volume":"75","author":"So C.H.","year":"2009","unstructured":"So C.H.; Verma V.; Alijaniaram M.; Cheng R.; Rashid A.J.; O\u2019Dowd B.F.; George S.R.; Calcium signaling by dopamine D5 receptor and D5-D2 receptor hetero-oligomers occurs by a mechanism distinct from that for dopamine D1-D2 receptor hetero-oligomers. Mol Pharmacol 2009,75(4),843-854","journal-title":"Mol Pharmacol"},{"key":"ref=494","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.neuroscience.2009.10.017","volume":"165","author":"Ng J.","year":"2010","unstructured":"Ng J.; Rashid A.J.; So C.H.; O\u2019Dowd B.F.; George S.R.; Activation of calcium\/calmodulin-dependent protein kinase IIalpha in the striatum by the heteromeric D1-D2 dopamine receptor complex. Neuroscience 2010,165(2),535-541","journal-title":"Neuroscience"},{"key":"ref=495","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.biopsych.2005.09.018","volume":"59","author":"Nestler E.J.","year":"2006","unstructured":"Nestler E.J.; Carlezon W.A.; The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006,59(12),1151-1159","journal-title":"Biol Psychiatry"},{"key":"ref=496","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature11740","volume":"493","author":"Tye K.M.","year":"2013","unstructured":"Tye K.M.; Mirzabekov J.J.; Warden M.R.; Ferenczi E.A.; Tsai H.C.; Finkelstein J.; Kim S.Y.; Adhikari A.; Thompson K.R.; Andalman A.S.; Gunaydin L.A.; Witten I.B.; Deisseroth K.; Dopamine neurons modulate neural encoding and expression of depression-related behaviour. Nature 2013,493(7433),537-541","journal-title":"Nature"},{"key":"ref=497","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/0165-6147(94)90323-9","volume":"15","author":"Seeman P.","year":"1994","unstructured":"Seeman P.; Van Tol H.H.M.; Dopamine receptor pharmacology. Trends Pharmacol Sci 1994,15(7),264-270","journal-title":"Trends Pharmacol Sci"},{"key":"ref=498","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.bbrc.2011.11.027","volume":"417","author":"O\u2019Dowd B.F.","year":"2012","unstructured":"O\u2019Dowd B.F.; Ji X.; Nguyen T.; George S.R.; Two amino acids in each of D1 and D2 dopamine receptor cytoplasmic regions are involved in D1-D2 heteromer formation. Biochem Biophys Res Commun 2012,417(1),23-28","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=499","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/mp.2008.30","volume":"14","author":"Glatt S.J.","year":"2009","unstructured":"Glatt S.J.; Faraone S.V.; Lasky-Su J.A.; Kanazawa T.; Hwu H.G.; Tsuang M.T.; Family-based association testing strongly implicates DRD2 as a risk gene for schizophrenia in Han Chinese from Taiwan. Mol Psychiatry 2009,14(9),885-893","journal-title":"Mol Psychiatry"},{"key":"ref=500","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1017\/S1461145704004389","volume":"7","author":"Lane H.Y.","year":"2004","unstructured":"Lane H.Y.; Lee C.C.; Chang Y.C.; Lu C.T.; Huang C.H.; Chang W.H.; Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Int J Neuropsychopharmacol 2004,7(4),461-470","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=501","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3389\/fphar.2017.00924","volume":"8","author":"Hasbi A.","year":"2018","unstructured":"Hasbi A.; Perreault M.L.; Shen M.Y.F.; Fan T.; Nguyen T.; Alijaniaram M.; Banasikowski T.J.; Grace A.A.; O\u2019Dowd B.F.; Fletcher P.J.; George S.R.; Activation of dopamine D1-D2 receptor complex attenuates cocaine reward and reinstatement of cocaine-seeking through inhibition of DARPP-32, ERK, and \u0394FosB. Front Pharmacol 2018,8,924","journal-title":"Front Pharmacol"},{"key":"ref=502","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1038\/nm.2263","volume":"16","author":"Pei L.","year":"2010","unstructured":"Pei L.; Li S.; Wang M.; Diwan M.; Anisman H.; Fletcher P.J.; Nobrega J.N.; Liu F.; Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects. Nat Med 2010,16(12),1393-1395","journal-title":"Nat Med"},{"key":"ref=503","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.1096\/fj.14-254037","volume":"28","author":"Hasbi A.","year":"2014","unstructured":"Hasbi A.; Perreault M.L.; Shen M.Y.F.; Zhang L.; To R.; Fan T.; Nguyen T.; Ji X.; O\u2019Dowd B.F.; George S.R.; \nA peptide targeting an interaction interface disrupts the dopamine D1-D2 receptor heteromer to block signaling and function \nin vitro\nand \nin vivo\n: effective selective antagonism.\n FASEB J 2014,28(11),4806-4820","journal-title":"FASEB J"},{"key":"ref=504","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1124\/mol.114.093096","volume":"86","author":"Guitart X.","year":"2014","unstructured":"Guitart X.; Navarro G.; Moreno E.; Yano H.; Cai N.S.; Sánchez-Soto M.; Kumar-Barodia S.; Naidu Y.T.; Mallol J.; Cortés A.; Lluís C.; Canela E.I.; Casadó V.; McCormick P.J.; Ferré S.; Functional selectivity of allosteric interactions within G protein-coupled receptor oligomers: the dopamine D1-D3 receptor heterotetramer. Mol Pharmacol 2014,86(4),417-429","journal-title":"Mol Pharmacol"},{"key":"ref=505","doi-asserted-by":"publisher","first-page":"6756","DOI":"10.1007\/s12035-019-1564-8","volume":"56","author":"Guitart X.","year":"2019","unstructured":"Guitart X.; Moreno E.; Rea W.; Sánchez-Soto M.; Cai N.S.; Quiroz C.; Kumar V.; Bourque L.; Cortés A.; Canela E.I.; Bishop C.; Newman A.H.; Casadó V.; Ferré S.; Biased G.; Protein-independent signaling of dopamine D-D receptor heteromers in the nucleus accumbens. Mol Neurobiol 2019,56(10),6756-6769","journal-title":"Mol Neurobiol"},{"key":"ref=506","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1124\/mol.107.043885","volume":"74","author":"Fiorentini C.","year":"2008","unstructured":"Fiorentini C.; Busi C.; Gorruso E.; Gotti C.; Spano P.; Missale C.; Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol Pharmacol 2008,74(1),59-69","journal-title":"Mol Pharmacol"},{"key":"ref=507","doi-asserted-by":"publisher","first-page":"26016","DOI":"10.1074\/jbc.M710349200","volume":"283","author":"Marcellino D.","year":"2008","unstructured":"Marcellino D.; Ferré S.; Casadó V.; Cortés A.; Le Foll B.; Mazzola C.; Drago F.; Saur O.; Stark H.; Soriano A.; Barnes C.; Goldberg S.R.; Lluis C.; Fuxe K.; Franco R.; Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J Biol Chem 2008,283(38),26016-26025","journal-title":"J Biol Chem"},{"key":"ref=508","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1007\/s12035-014-8936-x","volume":"52","author":"Farré D.","year":"2015","unstructured":"Farré D.; Muñoz A.; Moreno E.; Reyes-Resina I.; Canet-Pons J.; Dopeso-Reyes I.G.; Rico A.J.; Lluís C.; Mallol J.; Navarro G.; Canela E.I.; Cortés A.; Labandeira-García J.L.; Casadó V.; Lanciego J.L.; Franco R.; Stronger dopamine D1 receptor-mediated neurotransmission in dyskinesia. Mol Neurobiol 2015,52(3),1408-1420","journal-title":"Mol Neurobiol"},{"key":"ref=509","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.neuropharm.2018.06.024","volume":"138","author":"Lanza K.","year":"2018","unstructured":"Lanza K.; Meadows S.M.; Chambers N.E.; Nuss E.; Deak M.M.; Ferré S.; Bishop C.; Behavioral and cellular dopamine D and D receptor-mediated synergy: Implications for L-DOPA-induced dyskinesia. Neuropharmacology 2018,138,304-314","journal-title":"Neuropharmacology"},{"key":"ref=510","first-page":"435","volume":"27","author":"Solís O.","year":"2017","unstructured":"Solís O.; Garcia-Montes J.R.; González-Granillo A.; Xu M.; Moratalla R.; Dopamine D3 receptor modulates l-DOPA-induced dyskinesia by targeting D1 receptor-mediated striatal signaling. Cereb Cortex 2017,27(1),435-446","journal-title":"Cereb Cortex"},{"key":"ref=511","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bbr.2014.01.011","volume":"263","author":"Cote S.R.","year":"2014","unstructured":"Cote S.R.; Chitravanshi V.C.; Bleickardt C.; Sapru H.N.; Kuzhikandathil E.V.; Overexpression of the dopamine D3 receptor in the rat dorsal striatum induces dyskinetic behaviors. Behav Brain Res 2014,263,46-50","journal-title":"Behav Brain Res"},{"key":"ref=512","doi-asserted-by":"publisher","first-page":"6579","DOI":"10.1523\/JNEUROSCI.16-20-06579.1996","volume":"16","author":"Surmeier D.J.","year":"1996","unstructured":"Surmeier D.J.; Song W.J.; Yan Z.; Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J Neurosci 1996,16(20),6579-6591","journal-title":"J Neurosci"},{"key":"ref=513","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0163-7258(01)00139-5","volume":"90","author":"Joyce J.N.","year":"2001","unstructured":"Joyce J.N.; Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther 2001,90(2-3),231-259","journal-title":"Pharmacol Ther"},{"key":"ref=514","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.coph.2009.10.001","volume":"10","author":"Maggio R.","year":"2010","unstructured":"Maggio R.; Millan M.J.; Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance. Curr Opin Pharmacol 2010,10(1),100-107","journal-title":"Curr Opin Pharmacol"},{"key":"ref=515","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1046\/j.1471-4159.2003.02038.x","volume":"87","author":"Maggio R.","year":"2003","unstructured":"Maggio R.; Scarselli M.; Novi F.; Millan M.J.; Corsini G.U.; Potent activation of dopamine D3\/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J Neurochem 2003,87(3),631-641","journal-title":"J Neurochem"},{"key":"ref=516","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1111\/j.1471-4159.2007.04660.x","volume":"102","author":"Novi F.","year":"2007","unstructured":"Novi F.; Millan M.J.; Corsini G.U.; Maggio R.; Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation. J Neurochem 2007,102(4),1410-1424","journal-title":"J Neurochem"},{"key":"ref=517","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.euroneuro.2014.09.016","volume":"25","author":"Maggio R.","year":"2015","unstructured":"Maggio R.; Scarselli M.; Capannolo M.; Millan M.J.; Novel dimensions of D3 receptor function: Focus on heterodimerisation, transactivation and allosteric modulation. Eur Neuropsychopharmacol 2015,25(9),1470-1479","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=518","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","volume":"78","author":"Missale C.","year":"1998","unstructured":"Missale C.; Nash S.R.; Robinson S.W.; Jaber M.; Caron M.G.; Dopamine receptors: from structure to function. Physiol Rev 1998,78(1),189-225","journal-title":"Physiol Rev"},{"key":"ref=519","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00018-010-0293-y","volume":"67","author":"Rondou P.","year":"2010","unstructured":"Rondou P.; Haegeman G.; Van Craenenbroeck K.; The dopamine D4 receptor: biochemical and signalling properties. Cell Mol Life Sci 2010,67(12),1971-1986","journal-title":"Cell Mol Life Sci"},{"key":"ref=520","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/350610a0","volume":"350","author":"Van Tol H.H.M.","year":"1991","unstructured":"Van Tol H.H.M.; Bunzow J.R.; Guan H.C.; Sunahara R.K.; Seeman P.; Niznik H.B.; Civelli O.; Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991,350(6319),610-614","journal-title":"Nature"},{"key":"ref=521","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/mp.2011.93","volume":"17","author":"González S.","year":"2012","unstructured":"González S.; Rangel-Barajas C.; Peper M.; Lorenzo R.; Moreno E.; Ciruela F.; Borycz J.; Ortiz J.; Lluís C.; Franco R.; McCormick P.J.; Volkow N.D.; Rubinstein M.; Floran B.; Ferré S.; Dopamine D4 receptor, but not the ADHD-associated D4.7 variant, forms functional heteromers with the dopamine D2S receptor in the brain. Mol Psychiatry 2012,17(6),650-662","journal-title":"Mol Psychiatry"},{"key":"ref=522","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1517\/14728222.2014.981529","volume":"19","author":"Fuxe K.","year":"2015","unstructured":"Fuxe K.; Guidolin D.; Agnati L.F.; Borroto-Escuela D.O.; Dopamine heteroreceptor complexes as therapeutic targets in Parkinson\u2019s disease. Expert Opin Ther Targets 2015,19(3),377-398","journal-title":"Expert Opin Ther Targets"},{"key":"ref=523","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1523\/JNEUROSCI.23-15-06245.2003","volume":"23","author":"Centonze D.","year":"2003","unstructured":"Centonze D.; Grande C.; Usiello A.; Gubellini P.; Erbs E.; Martín A.B.; Pisani A.; Tognazzi N.; Bernardi G.; Moratalla R.; Borrelli E.; Calabresi P.; Receptor subtypes involved in the presynaptic and postsynaptic actions of dopamine on striatal interneurons. J Neurosci 2003,23(15),6245-6254","journal-title":"J Neurosci"},{"key":"ref=524","doi-asserted-by":"publisher","first-page":"8606","DOI":"10.1073\/pnas.150241097","volume":"97","author":"Ginés S.","year":"2000","unstructured":"Ginés S.; Hillion J.; Torvinen M.; Le Crom S.; Casadó V.; Canela E.I.; Rondin S.; Lew J.Y.; Watson S.; Zoli M.; Agnati L.F.; Verniera P.; Lluis C.; Ferré S.; Fuxe K.; Franco R.; Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc Natl Acad Sci USA 2000,97(15),8606-8611","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=525","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00702-006-0566-7","volume":"114","author":"Franco R.","year":"2007","unstructured":"Franco R.; Lluis C.; Canela E.I.; Mallol J.; Agnati L.; Casadó V.; Ciruela F.; Ferré S.; Fuxe K.; Receptor-receptor interactions involving adenosine A1 or dopamine D1 receptors and accessory proteins. J Neural Transm (Vienna) 2007,114(1),93-104","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=526","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0006-8993(96)00424-6","volume":"730","author":"Caillé I.","year":"1996","unstructured":"Caillé I.; Dumartin B.; Bloch B.; Ultrastructural localization of D1 dopamine receptor immunoreactivity in rat striatonigral neurons and its relation with dopaminergic innervation. Brain Res 1996,730(1-2),17-31","journal-title":"Brain Res"},{"key":"ref=527","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0006-8993(95)00062-U","volume":"677","author":"Rivkees S.A.","year":"1995","unstructured":"Rivkees S.A.; Price S.L.; Zhou F.C.; Immunohistochemical detection of A1 adenosine receptors in rat brain with emphasis on localization in the hippocampal formation, cerebral cortex, cerebellum, and basal ganglia. Brain Res 1995,677(2),193-203","journal-title":"Brain Res"},{"key":"ref=528","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/00001756-199412300-00020","volume":"6","author":"Ferré S.","year":"1994","unstructured":"Ferré S.; Popoli P.; Giménez-Llort L.; Finnman U.B.; Martínez E.; Scotti de Carolis A.; Fuxe K.; Postsynaptic antagonistic interaction between adenosine A1 and dopamine D1 receptors. Neuroreport 1994,6(1),73-76","journal-title":"Neuroreport"},{"key":"ref=529","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/S0166-2236(97)01096-5","volume":"20","author":"Ferré S.","year":"1997","unstructured":"Ferré S.; Fredholm B.B.; Morelli M.; Popoli P.; Fuxe K.; Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 1997,20(10),482-487","journal-title":"Trends Neurosci"},{"key":"ref=530","doi-asserted-by":"publisher","first-page":"4718","DOI":"10.1074\/jbc.273.8.4718","volume":"273","author":"Ferré S.","year":"1998","unstructured":"Ferré S.; Torvinen M.; Antoniou K.; Irenius E.; Civelli O.; Arenas E.; Fredholm B.B.; Fuxe K.; Adenosine A1 receptor-mediated modulation of dopamine D1 receptors in stably cotransfected fibroblast cells. J Biol Chem 1998,273(8),4718-4724","journal-title":"J Biol Chem"},{"key":"ref=531","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1046\/j.1471-4159.2003.02121.x","volume":"87","author":"Toda S.","year":"2003","unstructured":"Toda S.; Alguacil L.F.; Kalivas P.W.; Repeated cocaine administration changes the function and subcellular distribution of adenosine A1 receptor in the rat nucleus accumbens. J Neurochem 2003,87(6),1478-1484","journal-title":"J Neurochem"},{"key":"ref=532","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s12035-018-1120-y","volume":"56","author":"Rivera-Oliver M.","year":"2019","unstructured":"Rivera-Oliver M.; Moreno E.; Álvarez-Bagnarol Y.; Ayala-Santiago C.; Cruz-Reyes N.; Molina-Castro G.C.; Clemens S.; Canela E.I.; Ferré S.; Casadó V.; Díaz-Ríos M.; Adenosine A-dopamine D receptor heteromers control the excitability of the spinal motoneuron. Mol Neurobiol 2019,56(2),797-811","journal-title":"Mol Neurobiol"},{"key":"ref=533","doi-asserted-by":"publisher","first-page":"46741","DOI":"10.1074\/jbc.M306451200","volume":"278","author":"Canals M.","year":"2003","unstructured":"Canals M.; Marcellino D.; Fanelli F.; Ciruela F.; de Benedetti P.; Goldberg S.R.; Neve K.; Fuxe K.; Agnati L.F.; Woods A.S.; Ferré S.; Lluis C.; Bouvier M.; Franco R.; Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem 2003,278(47),46741-46749","journal-title":"J Biol Chem"},{"key":"ref=534","doi-asserted-by":"publisher","first-page":"18091","DOI":"10.1074\/jbc.M107731200","volume":"277","author":"Hillion J.","year":"2002","unstructured":"Hillion J.; Canals M.; Torvinen M.; Casadó V.; Scott R.; Terasmaa A.; Hansson A.; Watson S.; Olah M.E.; Mallol J.; Canela E.I.; Zoli M.; Agnati L.F.; Ibanez C.F.; Lluis C.; Franco R.; Ferre S.; Fuxe K.; Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 2002,277(20),18091-18097","journal-title":"J Biol Chem"},{"key":"ref=535","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1212\/01.WNL.0000095206.44418.5C","volume":"61","author":"Fuxe K.","year":"2003","unstructured":"Fuxe K.; Agnati L.F.; Jacobsen K.; Hillion J.; Canals M.; Torvinen M.; Tinner-Staines B.; Staines W.; Rosin D.; Terasmaa A.; Popoli P.; Leo G.; Vergoni V.; Lluis C.; Ciruela F.; Franco R.; Ferré S.; Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson\u2019s disease. Neurology 2003,61(11)(Suppl. 6),S19-S23","journal-title":"Neurology"},{"key":"ref=536","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/S0006-291X(03)00991-4","volume":"306","author":"Kamiya T.","year":"2003","unstructured":"Kamiya T.; Saitoh O.; Yoshioka K.; Nakata H.; Oligomerization of adenosine A2A and dopamine D2 receptors in living cells. Biochem Biophys Res Commun 2003,306(2),544-549","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=537","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2144\/000113719","volume":"51","author":"Trifilieff P.","year":"2011","unstructured":"Trifilieff P.; Rives M.L.; Urizar E.; Piskorowski R.A.; Vishwasrao H.D.; Castrillon J.; Schmauss C.; Slättman M.; Gullberg M.; Javitch J.A.; Detection of antigen interactions ex vivo by proximity ligation assay: endogenous dopamine D2-adenosine A2A receptor complexes in the striatum. Biotechniques 2011,51(2),111-118","journal-title":"Biotechniques"},{"key":"ref=538","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/B978-0-12-391862-8.00015-6","volume":"521","author":"Borroto-Escuela D.O.","year":"2013","unstructured":"Borroto-Escuela D.O.; Romero-Fernandez W.; Garriga P.; Ciruela F.; Narvaez M.; Tarakanov A.O.; Palkovits M.; Agnati L.F.; Fuxe K.; G protein-coupled receptor heterodimerization in the brain. Methods Enzymol 2013,521,281-294","journal-title":"Methods Enzymol"},{"key":"ref=539","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1002\/mds.21440","volume":"22","author":"Fuxe K.","year":"2007","unstructured":"Fuxe K.; Marcellino D.; Genedani S.; Agnati L.; Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson\u2019s disease. Mov Disord 2007,22(14),1990-2017","journal-title":"Mov Disord"},{"key":"ref=540","doi-asserted-by":"publisher","first-page":"7238","DOI":"10.1073\/pnas.88.16.7238","volume":"88","author":"Ferre S.","year":"1991","unstructured":"Ferre S.; von Euler G.; Johansson B.; Fredholm B.B.; Fuxe K.; Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc Natl Acad Sci USA 1991,88(16),7238-7241","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=541","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/0006-8993(92)91036-E","volume":"594","author":"Ferré S.","year":"1992","unstructured":"Ferré S.; Fuxe K.; Dopamine denervation leads to an increase in the intramembrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum. Brain Res 1992,594(1),124-130","journal-title":"Brain Res"},{"key":"ref=542","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.2174\/138161208784480108","volume":"14","author":"Ferré S.","year":"2008","unstructured":"Ferré S.; Quiroz C.; Woods A.S.; Cunha R.; Popoli P.; Ciruela F.; Lluis C.; Franco R.; Azdad K.; Schiffmann S.N.; An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. Curr Pharm Des 2008,14(15),1468-1474","journal-title":"Curr Pharm Des"},{"key":"ref=543","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3389\/fphar.2017.00985","volume":"8","author":"Ballesteros-Yáñez I.","year":"2018","unstructured":"Ballesteros-Yáñez I.; Castillo C.A.; Merighi S.; Gessi S.; The Role of Adenosine Receptors in Psychostimulant Addiction. Front Pharmacol 2018,8(JAN),985","journal-title":"Front Pharmacol"},{"key":"ref=544","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.pharmthera.2008.03.004","volume":"118","author":"Dalrymple M.B.","year":"2008","unstructured":"Dalrymple M.B.; Pfleger K.D.G.; Eidne K.A.; G protein-coupled receptor dimers: functional consequences, disease states and drug targets. Pharmacol Ther 2008,118(3),359-371","journal-title":"Pharmacol Ther"},{"key":"ref=545","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1212\/01.WNL.0000095205.33940.99","volume":"61","author":"Rosin D.L.","year":"2003","unstructured":"Rosin D.L.; Hettinger B.D.; Lee A.; Linden J.; Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function. Neurology 2003,61(11)(Suppl. 6),S12-S18","journal-title":"Neurology"},{"key":"ref=546","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.physbeh.2007.05.034","volume":"92","author":"Fuxe K.","year":"2007","unstructured":"Fuxe K.; Ferré S.; Genedani S.; Franco R.; Agnati L.F.; Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiol Behav 2007,92(1-2),210-217","journal-title":"Physiol Behav"},{"key":"ref=547","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00702-004-0107-1","volume":"111","author":"Gluck M.R.","year":"2004","unstructured":"Gluck M.R.; Santana L.A.; Granson H.; Yahr M.D.; Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson\u2019s activity. J Neural Transm (Vienna) 2004,111(6),713-724","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=548","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.pneurobio.2007.05.001","volume":"83","author":"Schiffmann S.N.","year":"2007","unstructured":"Schiffmann S.N.; Fisone G.; Moresco R.; Cunha R.A.; Ferré S.; Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol 2007,83(5),277-292","journal-title":"Prog Neurobiol"},{"key":"ref=549","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1523\/JNEUROSCI.5255-07.2008","volume":"28","author":"Shen H.Y.","year":"2008","unstructured":"Shen H.Y.; Coelho J.E.; Ohtsuka N.; Canas P.M.; Day Y.J.; Huang Q.Y.; Rebola N.; Yu L.; Boison D.; Cunha R.A.; Linden J.; Tsien J.Z.; Chen J.F.; A critical role of the adenosine A2A receptor in extrastriatal neurons in modulating psychomotor activity as revealed by opposite phenotypes of striatum and forebrain A2A receptor knock-outs. J Neurosci 2008,28(12),2970-2975","journal-title":"J Neurosci"},{"key":"ref=550","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1073\/pnas.252753799","volume":"100","author":"Kim D.S.","year":"2003","unstructured":"Kim D.S.; Palmiter R.D.; Adenosine receptor blockade reverses hypophagia and enhances locomotor activity of dopamine-deficient mice. Proc Natl Acad Sci USA 2003,100(3),1346-1351","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=551","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1212\/01.WNL.0000095223.08711.48","volume":"61","author":"Chase T.N.","year":"2003","unstructured":"Chase T.N.; Bibbiani F.; Bara-Jimenez W.; Dimitrova T.; Oh-Lee J.D.; Translating A2A antagonist KW6002 from animal models to parkinsonian patients. Neurology 2003,61(11)(Suppl. 6),S107-S111","journal-title":"Neurology"},{"key":"ref=552","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1124\/mol.104.003376","volume":"67","author":"Torvinen M.","year":"2005","unstructured":"Torvinen M.; Marcellino D.; Canals M.; Agnati L.F.; Lluis C.; Franco R.; Fuxe K.; Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A\/D3 heteromeric complexes. Mol Pharmacol 2005,67(2),400-407","journal-title":"Mol Pharmacol"},{"key":"ref=553","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/0006-8993(86)90992-3","volume":"364","author":"Takagi H.","year":"1986","unstructured":"Takagi H.; Morishima Y.; Matsuyama T.; Hayashi H.; Watanabe T.; Wada H.; Histaminergic axons in the neostriatum and cerebral cortex of the rat: A correlated light and electron microscopic immunocytochemical study using histidine decarboxylase as a marker. Brain Res 1986,364(1),114-123","journal-title":"Brain Res"},{"key":"ref=554","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1476-5381.2009.00152.x","volume":"157","author":"Ferrada C.","year":"2009","unstructured":"Ferrada C.; Moreno E.; Casadó V.; Bongers G.; Cortés A.; Mallol J.; Canela E.I.; Leurs R.; Ferré S.; Lluís C.; Franco R.; Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors. Br J Pharmacol 2009,157(1),64-75","journal-title":"Br J Pharmacol"},{"key":"ref=555","doi-asserted-by":"publisher","first-page":"5846","DOI":"10.1074\/jbc.M110.161489","volume":"286","author":"Moreno E.","year":"2011","unstructured":"Moreno E.; Hoffmann H.; Gonzalez-Sepúlveda M.; Navarro G.; Casadó V.; Cortés A.; Mallol J.; Vignes M.; McCormick P.J.; Canela E.I.; Lluís C.; Moratalla R.; Ferré S.; Ortiz J.; Franco R.; Dopamine D1-histamine H3 receptor heteromers provide a selective link to MAPK signaling in GABAergic neurons of the direct striatal pathway. J Biol Chem 2011,286(7),5846-5854","journal-title":"J Biol Chem"},{"key":"ref=556","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1523\/JNEUROSCI.4147-13.2014","volume":"34","author":"Moreno E.","year":"2014","unstructured":"Moreno E.; Moreno-Delgado D.; Navarro G.; Hoffmann H.M.; Fuentes S.; Rosell-Vilar S.; Gasperini P.; Rodríguez-Ruiz M.; Medrano M.; Mallol J.; Cortés A.; Casadó V.; Lluís C.; Ferré S.; Ortiz J.; Canela E.; McCormick P.J.; Cocaine disrupts histamine H3 receptor modulation of dopamine D1 receptor signaling: σ1-D1-H3 receptor complexes as key targets for reducing cocaine\u2019s effects. J Neurosci 2014,34(10),3545-3558","journal-title":"J Neurosci"},{"key":"ref=557","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/jpet.115.230771","volume":"357","author":"Kononoff Vanhanen J.","year":"2016","unstructured":"Kononoff Vanhanen J.; Nuutinen S.; Tuominen M.; Panula P.; Histamine H3 receptor regulates sensorimotor gating and dopaminergic signaling in the striatum. J Pharmacol Exp Ther 2016,357(2),264-272","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=558","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.neuropharm.2008.05.008","volume":"55","author":"Ferrada C.","year":"2008","unstructured":"Ferrada C.; Ferré S.; Casadó V.; Cortés A.; Justinova Z.; Barnes C.; Canela E.I.; Goldberg S.R.; Leurs R.; Lluis C.; Franco R.; Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology 2008,55(2),190-197","journal-title":"Neuropharmacology"},{"key":"ref=559","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0306-4522(02)00135-5","volume":"114","author":"Pillot C.","year":"2002","unstructured":"Pillot C.; Heron A.; Cochois V.; Tardivel-Lacombe J.; Ligneau X.; Schwartz J.C.; Arrang J.M.; A detailed mapping of the histamine H(3) receptor and its gene transcripts in rat brain. Neuroscience 2002,114(1),173-193","journal-title":"Neuroscience"},{"key":"ref=560","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.tins.2007.07.001","volume":"30","author":"Ferré S.","year":"2007","unstructured":"Ferré S.; Ciruela F.; Woods A.S.; Lluis C.; Franco R.; Functional relevance of neurotransmitter receptor heteromers in the central nervous system. Trends Neurosci 2007,30(9),440-446","journal-title":"Trends Neurosci"},{"key":"ref=561","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S1734-1140(12)70921-0","volume":"64","author":"Szafran K.","year":"2012","unstructured":"Szafran K.; \u0141ukasiewicz S.; Faron-Górecka A.; Kolasa M.; Kuśmider M.; Solich J.; Dziedzicka-Wasylewska M.; \nAntidepressant drugs promote the heterodimerization of the dopamine D2 and somatostatin Sst5 receptors--fluorescence \nin vitro\nstudies.\n Pharmacol Rep 2012,64(5),1253-1258","journal-title":"Pharmacol Rep"},{"key":"ref=562","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.brainresbull.2017.10.003","volume":"135","author":"Szafran-Pilch K.","year":"2017","unstructured":"Szafran-Pilch K.; Faron-Górecka A.; Kolasa M.; Żurawek D.; Szlachta M.; Solich J.; Kuśmider M.; Dziedzicka-Wasylewska M.; Antidepressants promote formation of heterocomplexes of dopamine D2 and somatostatin subtype 5 receptors in the mouse striatum. Brain Res Bull 2017,135,92-97","journal-title":"Brain Res Bull"},{"key":"ref=563","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/S1734-1140(13)71525-1","volume":"65","author":"Faron-Górecka A.","year":"2013","unstructured":"Faron-Górecka A.; Kuśmider M.; Solich J.; Kolasa M.; Szafran K.; Zurawek D.; Pabian P.; Dziedzicka-Wasylewska M.; Involvement of prolactin and somatostatin in depression and the mechanism of action of antidepressant drugs. Pharmacol Rep 2013,65(6),1640-1646","journal-title":"Pharmacol Rep"},{"key":"ref=564","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bbrc.2013.04.058","volume":"435","author":"Borroto-Escuela D.O.","year":"2013","unstructured":"Borroto-Escuela D.O.; Ravani A.; Tarakanov A.O.; Brito I.; Narvaez M.; Romero-Fernandez W.; Corrales F.; Agnati L.F.; Tanganelli S.; Ferraro L.; Fuxe K.; Dopamine D2 receptor signaling dynamics of dopamine D2-neurotensin 1 receptor heteromers. Biochem Biophys Res Commun 2013,435(1),140-146","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=565","doi-asserted-by":"publisher","first-page":"16312","DOI":"10.1038\/s41598-019-52540-8","volume":"9","author":"Plach M.","year":"2019","unstructured":"Plach M.; Schäfer T.; Borroto-Escuela D.O.; Weikert D.; Gmeiner P.; Fuxe K.; Friedland K.; Differential allosteric modulation within dopamine DR - neurotensin NTS1R and DR - serotonin 5-HTR receptor complexes gives bias to intracellular calcium signalling. Sci Rep 2019,9(1),16312","journal-title":"Sci Rep"},{"key":"ref=566","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.brainresrev.2007.11.001","volume":"58","author":"Ferraro L.","year":"2008","unstructured":"Ferraro L.; Tomasini M.C.; Mazza R.; Fuxe K.; Fournier J.; Tanganelli S.; Antonelli T.; Neurotensin receptors as modulators of glutamatergic transmission. Brain Res Brain Res Rev 2008,58(2),365-373","journal-title":"Brain Res Brain Res Rev"},{"key":"ref=567","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1021\/cn200020y","volume":"2","author":"Koschatzky S.","year":"2011","unstructured":"Koschatzky S.; Tschammer N.; Gmeiner P.; Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics. ACS Chem Neurosci 2011,2(6),308-316","journal-title":"ACS Chem Neurosci"},{"key":"ref=568","doi-asserted-by":"publisher","first-page":"105-113","DOI":"10.1007\/s00702-006-0558-7","author":"Antonelli T.","year":"2007","unstructured":"Antonelli T.; Tomasini M.C.; Fuxe K.; Agnati L.F.; Tanganelli S.; Ferraro L.; Focus on NTR\/D2 interactions in the basal ganglia. J Neural Trans 2007,105-113","journal-title":"J Neural Trans"},{"key":"ref=569","doi-asserted-by":"publisher","first-page":"304","DOI":"10.2174\/092986712803414268","volume":"19","author":"Tanganelli S.","year":"2012","unstructured":"Tanganelli S.; Antonelli T.; Tomasini M.C.; Beggiato S.; Fuxe K.; Ferraro L.; Relevance of dopamine D(2)\/neurotensin NTS1 and NMDA\/neurotensin NTS1 receptor interaction in psychiatric and neurodegenerative disorders. Curr Med Chem 2012,19(3),304-316","journal-title":"Curr Med Chem"},{"key":"ref=570","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1124\/mol.111.073304","volume":"80","author":"Espinoza S.","year":"2011","unstructured":"Espinoza S.; Salahpour A.; Masri B.; Sotnikova T.D.; Messa M.; Barak L.S.; Caron M.G.; Gainetdinov R.R.; Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. Mol Pharmacol 2011,80(3),416-425","journal-title":"Mol Pharmacol"},{"key":"ref=571","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-1-62703-251-3_8","volume":"964","author":"Espinoza S.","year":"2013","unstructured":"Espinoza S.; Masri B.; Salahpour A.; Gainetdinov R.R.; BRET approaches to characterize dopamine and TAAR1 receptor pharmacology and signaling. Methods Mol Biol 2013,964,107-122","journal-title":"Methods Mol Biol"},{"key":"ref=572","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1124\/jpet.107.132647","volume":"324","author":"Lindemann L.","year":"2008","unstructured":"Lindemann L.; Meyer C.A.; Jeanneau K.; Bradaia A.; Ozmen L.; Bluethmann H.; Bettler B.; Wettstein J.G.; Borroni E.; Moreau J.L.; Hoener M.C.; Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharmacol Exp Ther 2008,324(3),948-956","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=573","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/mp.2012.103","volume":"18","author":"Romero-Fernandez W.","year":"2013","unstructured":"Romero-Fernandez W.; Borroto-Escuela D.O.; Agnati L.F.; Fuxe K.; Evidence for the existence of dopamine D2-oxytocin receptor heteromers in the ventral and dorsal striatum with facilitatory receptor-receptor interactions. Mol Psychiatry 2013,18(8),849-850","journal-title":"Mol Psychiatry"},{"key":"ref=574","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.bbadis.2016.07.004","volume":"1862","author":"de la Mora M.P.","year":"2016","unstructured":"de la Mora M.P.; Pérez-Carrera D.; Crespo-Ramírez M.; Tarakanov A.; Fuxe K.; Borroto-Escuela D.O.; Signaling in dopamine D2 receptor-oxytocin receptor heterocomplexes and its relevance for the anxiolytic effects of dopamine and oxytocin interactions in the amygdala of the rat. Biochim Biophys Acta 2016,1862(11),2075-2085","journal-title":"Biochim Biophys Acta"},{"key":"ref=575","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/MCO.0b013e328365b9be","volume":"16","author":"Pradhan G.","year":"2013","unstructured":"Pradhan G.; Samson S.L.; Sun Y.; Ghrelin: much more than a hunger hormone. Curr Opin Clin Nutr Metab Care 2013,16(6),619-624","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"ref=576","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1124\/pr.57.4.1","volume":"57","author":"Davenport A.P.","year":"2005","unstructured":"Davenport A.P.; Bonner T.I.; Foord S.M.; Harmar A.J.; Neubig R.R.; Pin J-P.; Spedding M.; Kojima M.; Kangawa K.; International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. Pharmacol Rev 2005,57(4),541-546","journal-title":"Pharmacol Rev"},{"key":"ref=577","year":"2005","unstructured":"GHSR growth hormone secretagogue receptor [Homo sapiens (human)] Gene - NCBI 2005"},{"key":"ref=578","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1210\/edrv.18.5.0316","volume":"18","author":"Smith R.G.","year":"1997","unstructured":"Smith R.G.; Van der Ploeg L.H.T.; Howard A.D.; Feighner S.D.; Cheng K.; Hickey G.J.; Wyvratt M.J.; Fisher M.H.; Nargund R.P.; Patchett A.A.; Peptidomimetic regulation of growth hormone secretion. Endocr Rev 1997,18(5),621-645","journal-title":"Endocr Rev"},{"key":"ref=579","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1007\/s00125-016-4033-1","volume":"59","author":"Adriaenssens A.E.","year":"2016","unstructured":"Adriaenssens A.E.; Svendsen B.; Lam B.Y.H.; Yeo G.S.H.; Holst J.J.; Reimann F.; Gribble F.M.; Transcriptomic profiling of pancreatic alpha, beta and delta cell populations identifies delta cells as a principal target for ghrelin in mouse islets. Diabetologia 2016,59(10),2156-2165","journal-title":"Diabetologia"},{"key":"ref=580","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0899-9007(00)00449-4","volume":"16","author":"Meguid M.M.","year":"2000","unstructured":"Meguid M.M.; Fetissov S.O.; Varma M.; Sato T.; Zhang L.; Laviano A.; Rossi-Fanelli F.; Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition 2000,16(10),843-857","journal-title":"Nutrition"},{"key":"ref=581","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/wsbm.77","volume":"2","author":"Vucetic Z.","year":"2010","unstructured":"Vucetic Z.; Reyes T.M.; Central dopaminergic circuitry controlling food intake and reward: implications for the regulation of obesity. Wiley Interdiscip Rev Syst Biol Med 2010,2(5),577-593","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"key":"ref=582","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.neuron.2011.10.038","volume":"73","author":"Kern A.","year":"2012","unstructured":"Kern A.; Albarran-Zeckler R.; Walsh H.E.; Smith R.G.; Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism. Neuron 2012,73(2),317-332","journal-title":"Neuron"},{"key":"ref=583","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1007\/s00018-021-03761-6","volume":"78","author":"Franco R.","year":"2021","unstructured":"Franco R.; Cordomí A.; Llinas Del Torrent C.; Lillo A.; Serrano-Marín J.; Navarro G.; Pardo L.; Structure and function of adenosine receptor heteromers. Cell Mol Life Sci 2021,78(8),3957-3968","journal-title":"Cell Mol Life Sci"},{"key":"ref=584","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1517\/14728214.12.3.479","volume":"12","author":"Gao Z.G.","year":"2007","unstructured":"Gao Z.G.; Jacobson K.A.; Emerging adenosine receptor agonists. Expert Opin Emerg Drugs 2007,12(3),479-492","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref=585","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0006-2952(00)00570-0","volume":"61","author":"Fredholm B.B.","year":"2001","unstructured":"Fredholm B.B.; Irenius E.; Kull B.; Schulte G.; Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 2001,61(4),443-448","journal-title":"Biochem Pharmacol"},{"key":"ref=586","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12915-018-0491-x","volume":"16","author":"Navarro G.","year":"2018","unstructured":"Navarro G.; Cordomí A.; Brugarolas M.; Moreno E.; Aguinaga D.; Pérez-Benito L.; Ferre S.; Cortés A.; Casadó V.; Mallol J.; Canela E.I.; Lluís C.; Pardo L.; McCormick P.J.; Franco R.; Cross-communication between G and G in a G-protein-coupled receptor heterotetramer guided by a receptor C-terminal domain. BMC Biol 2018,16(1),24","journal-title":"BMC Biol"},{"key":"ref=587","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00702-019-01969-2","volume":"126","author":"Borroto-Escuela D.O.","year":"2019","unstructured":"Borroto-Escuela D.O.; Fuxe K.; Adenosine heteroreceptor complexes in the basal ganglia are implicated in Parkinson\u2019s disease and its treatment. J Neural Transm (Vienna) 2019,126(4),455-471","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=588","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.2741\/2852","volume":"13","author":"Ferre S.","year":"2008","unstructured":"Ferre S.; Ciruela F.; Borycz J.; Solinas M.; Quarta D.; Antoniou K.; Quiroz C.; Justinova Z.; Lluis C.; Franco R.; Goldberg S.R.; Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brain. Front Biosci 2008,13(6),2391-2399","journal-title":"Front Biosci"},{"key":"ref=589","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S0028-3908(97)00051-8","volume":"36","author":"Aghajanian G.K.","year":"1997","unstructured":"Aghajanian G.K.; Marek G.J.; Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 1997,36(4-5),589-599","journal-title":"Neuropharmacology"},{"key":"ref=590","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1016\/S0893-133X(99)00106-2","volume":"21","author":"Aghajanian G.K.","year":"1999","unstructured":"Aghajanian G.K.; Marek G.J.; Serotonin-glutamate interactions:A new target for antipsychotic drugs. Neuropsychopharmacology 1999,21(6),S122-S133","journal-title":"Neuropsychopharmacology"},{"key":"ref=591","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0306-4522(01)00170-1","volume":"105","author":"Stutzmann G.E.","year":"2001","unstructured":"Stutzmann G.E.; Marek G.J.; Aghajanian G.K.; Adenosine preferentially suppresses serotonin2A receptor-enhanced excitatory postsynaptic currents in layer V neurons of the rat medial prefrontal cortex. Neuroscience 2001,105(1),55-69","journal-title":"Neuroscience"},{"key":"ref=592","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.neuropharm.2009.03.005","volume":"56","author":"Marek G.J.","year":"2009","unstructured":"Marek G.J.; Activation of adenosine(1) (A(1)) receptors suppresses head shakes induced by a serotonergic hallucinogen in rats. Neuropharmacology 2009,56(8),1082-1087","journal-title":"Neuropharmacology"},{"key":"ref=593","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.phrs.2017.11.036","volume":"129","author":"Márquez-Gómez R.","year":"2018","unstructured":"Márquez-Gómez R.; Robins M.T.; Gutiérrez-Rodelo C.; Arias J.M.; Olivares-Reyes J.A.; van Rijn R.M.; Arias-Montaño J.A.; Functional histamine H and adenosine A receptor heteromers in recombinant cells and rat striatum. Pharmacol Res 2018,129,515-525","journal-title":"Pharmacol Res"},{"key":"ref=594","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1056\/NEJMra025411","volume":"349","author":"Ballantyne J.C.","year":"2003","unstructured":"Ballantyne J.C.; Mao J.; Opioid therapy for chronic pain. N Engl J Med 2003,349(20),1943-1953","journal-title":"N Engl J Med"},{"key":"ref=595","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1146\/annurev-pharmtox-010617-052534","volume":"58","author":"Skolnick P.","year":"2018","unstructured":"Skolnick P.; The Opioid Epidemic: Crisis and Solutions. Annu Rev Pharmacol Toxicol 2018,58,143-159","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=596","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMsa1406143","volume":"372","author":"Dart R.C.","year":"2015","unstructured":"Dart R.C.; Surratt H.L.; Cicero T.J.; Parrino M.W.; Severtson S.G.; Bucher-Bartelson B.; Green J.L.; Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015,372(3),241-248","journal-title":"N Engl J Med"},{"key":"ref=597","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3389\/fphar.2018.01388","volume":"9","author":"Machelska H.","year":"2018","unstructured":"Machelska H.; Celik M.Ö.; Advances in Achieving Opioid Analgesia Without Side Effects. Front Pharmacol 2018,9(NOV),1388","journal-title":"Front Pharmacol"},{"key":"ref=598","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2174\/0929866023408850","volume":"9","author":"Li-Wei C.","year":"2002","unstructured":"Li-Wei C.; Can G.; De-He Z.; Qiang W.; Xue-Jun X.; Jie C.; Zhi-Qiang C.; Homodimerization of human mu-opioid receptor overexpressed in Sf9 insect cells. Protein Pept Lett 2002,9(2),145-152","journal-title":"Protein Pept Lett"},{"key":"ref=599","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1021\/cn300049m","volume":"3","author":"Yekkirala A.S.","year":"2012","unstructured":"Yekkirala A.S.; Banks M.L.; Lunzer M.M.; Negus S.S.; Rice K.C.; Portoghese P.S.; \nClinically employed opioid analgesics produce antinociception\nvia \nμ-δ opioid receptor heteromers in Rhesus monkeys.\n ACS Chem Neurosci 2012,3(9),720-727","journal-title":"ACS Chem Neurosci"},{"key":"ref=600","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1017\/erm.2012.5","volume":"14","author":"Costantino C.M.","year":"2012","unstructured":"Costantino C.M.; Gomes I.; Stockton S.D.; Lim M.P.; Devi L.A.; Opioid receptor heteromers in analgesia. Expert Rev Mol Med 2012,14,e9","journal-title":"Expert Rev Mol Med"},{"key":"ref=601","doi-asserted-by":"publisher","first-page":"5135","DOI":"10.1073\/pnas.0307601101","volume":"101","author":"Gomes I.","year":"2004","unstructured":"Gomes I.; Gupta A.; Filipovska J.; Szeto H.H.; Pintar J.E.; Devi L.A.; A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci USA 2004,101(14),5135-5139","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=602","doi-asserted-by":"publisher","first-page":"20115","DOI":"10.1073\/pnas.1009923107","volume":"107","author":"Chakrabarti S.","year":"2010","unstructured":"Chakrabarti S.; Liu N-J.; Gintzler A.R.; Formation of mu-\/kappa-opioid receptor heterodimer is sex-dependent and mediates female-specific opioid analgesia. Proc Natl Acad Sci USA 2010,107(46),20115-20119","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=603","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/21441","volume":"399","author":"Jordan B.A.","year":"1999","unstructured":"Jordan B.A.; Devi L.A.; G-protein-coupled receptor heterodimerization modulates receptor function. Nature 1999,399(6737),697-700","journal-title":"Nature"},{"key":"ref=604","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3389\/fphar.2020.01078","volume":"11","author":"Zhang L.","year":"2020","unstructured":"Zhang L.; Zhang J-T.; Hang L.; Liu T.; Mu opioid receptor heterodimers emerge as novel therapeutic targets: Recent progress and future perspective. Front Pharmacol 2020,11,1078","journal-title":"Front Pharmacol"},{"key":"ref=605","doi-asserted-by":"publisher","first-page":"6075","DOI":"10.1021\/acs.jmedchem.8b00403","volume":"61","author":"Olson K.M.","year":"2018","unstructured":"Olson K.M.; Keresztes A.; Tashiro J.K.; Daconta L.V.; Hruby V.J.; Streicher J.M.; Synthesis and evaluation of a novel bivalent selective antagonist for the mu-delta opioid receptor heterodimer that reduces morphine withdrawal in mice. J Med Chem 2018,61(14),6075-6086","journal-title":"J Med Chem"},{"key":"ref=606","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1096\/fj.06-7793com","volume":"21","author":"Rozenfeld R.","year":"2007","unstructured":"Rozenfeld R.; Devi L.A.; Receptor heterodimerization leads to a switch in signaling: β-arrestin2-mediated ERK activation by μ-δ opioid receptor heterodimers. FASEB J 2007,21(10),2455-2465","journal-title":"FASEB J"},{"key":"ref=607","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1021\/cn3000394","volume":"3","author":"Metcalf M.D.","year":"2012","unstructured":"Metcalf M.D.; Yekkirala A.S.; Powers M.D.; Kitto K.F.; Fairbanks C.A.; Wilcox G.L.; Portoghese P.S.; The δ opioid receptor agonist SNC80 selectively activates heteromeric μ-δ opioid receptors. ACS Chem Neurosci 2012,3(7),505-509","journal-title":"ACS Chem Neurosci"},{"key":"ref=608","doi-asserted-by":"publisher","first-page":"12072","DOI":"10.1073\/pnas.1222044110","volume":"110","author":"Gomes I.","year":"2013","unstructured":"Gomes I.; Fujita W.; Gupta A.; Saldanha S.A.; Negri A.; Pinello C.E.; Eberhart C.; Roberts E.; Filizola M.; Hodder P.; Devi L.A.; Identification of a μ-δ opioid receptor heteromer-biased agonist with antinociceptive activity. Proc Natl Acad Sci USA 2013,110(29),12072-12077","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=609","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1124\/jpet.111.179093","volume":"337","author":"Milan-Lobo L.","year":"2011","unstructured":"Milan-Lobo L.; Whistler J.L.; Heteromerization of the μ- and δ-opioid receptors produces ligand-biased antagonism and alters μ-receptor trafficking. J Pharmacol Exp Ther 2011,337(3),868-875","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=610","doi-asserted-by":"publisher","first-page":"12997","DOI":"10.1021\/bi701436w","volume":"46","author":"Hasbi A.","year":"2007","unstructured":"Hasbi A.; Nguyen T.; Fan T.; Cheng R.; Rashid A.; Alijaniaram M.; Rasenick M.M.; O\u2019Dowd B.F.; George S.R.; Trafficking of preassembled opioid μ-δ heterooligomer-Gz signaling complexes to the plasma membrane: coregulation by agonists. Biochemistry 2007,46(45),12997-13009","journal-title":"Biochemistry"},{"key":"ref=611","doi-asserted-by":"publisher","first-page":"16045","DOI":"10.1073\/pnas.0804106105","volume":"105","author":"Décaillot F.M.","year":"2008","unstructured":"Décaillot F.M.; Rozenfeld R.; Gupta A.; Devi L.A.; Cell surface targeting of μ-δ opioid receptor heterodimers by RTP4. Proc Natl Acad Sci USA 2008,105(41),16045-16050","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=612","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.neuron.2010.12.001","volume":"69","author":"He S.Q.","year":"2011","unstructured":"He S.Q.; Zhang Z.N.; Guan J.S.; Liu H.R.; Zhao B.; Wang H.B.; Li Q.; Yang H.; Luo J.; Li Z.Y.; Wang Q.; Lu Y.J.; Bao L.; Zhang X.; Facilitation of μ-opioid receptor activity by preventing δ-opioid receptor-mediated codegradation. Neuron 2011,69(1),120-131","journal-title":"Neuron"},{"key":"ref=613","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00429-014-0717-9","volume":"220","author":"Erbs E.","year":"2015","unstructured":"Erbs E.; Faget L.; Scherrer G.; Matifas A.; Filliol D.; Vonesch J.L.; Koch M.; Kessler P.; Hentsch D.; Birling M.C.; Koutsourakis M.; Vasseur L.; Veinante P.; Kieffer B.L.; Massotte D.; A mu-delta opioid receptor brain atlas reveals neuronal co-occurrence in subcortical networks. Brain Struct Funct 2015,220(2),677-702","journal-title":"Brain Struct Funct"},{"key":"ref=614","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.neuron.2018.03.002","volume":"98","author":"Wang D.","year":"2018","unstructured":"Wang D.; Tawfik V.L.; Corder G.; Low S.A.; François A.; Basbaum A.I.; Scherrer G.; Functional divergence of delta and mu opioid receptor organization in CNS pain circuits. Neuron 2018,98(1),90-108.e5","journal-title":"Neuron"},{"key":"ref=615","doi-asserted-by":"publisher","first-page":"11836","DOI":"10.1523\/JNEUROSCI.1901-11.2011","volume":"31","author":"Liu N.J.","year":"2011","unstructured":"Liu N.J.; Chakrabarti S.; Schnell S.; Wessendorf M.; Gintzler A.R.; Spinal synthesis of estrogen and concomitant signaling by membrane estrogen receptors regulate spinal κ- and μ-opioid receptor heterodimerization and female-specific spinal morphine antinociception. J Neurosci 2011,31(33),11836-11845","journal-title":"J Neurosci"},{"key":"ref=616","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0090-5","volume":"50","author":"Yang Y.","year":"2018","unstructured":"Yang Y.; Li Q.; He Q.H.; Han J.S.; Su L.; Wan Y.; Heteromerization of μ-opioid receptor and cholecystokinin B receptor through the third transmembrane domain of the μ-opioid receptor contributes to the anti-opioid effects of cholecystokinin octapeptide. Exp Mol Med 2018,50(5),1-16","journal-title":"Exp Mol Med"},{"key":"ref=617","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/nchembio.64","volume":"4","author":"Vilardaga J.P.","year":"2008","unstructured":"Vilardaga J.P.; Nikolaev V.O.; Lorenz K.; Ferrandon S.; Zhuang Z.; Lohse M.J.; Conformational cross-talk between α2A-adrenergic and μ-opioid receptors controls cell signaling. Nat Chem Biol 2008,4(2),126-131","journal-title":"Nat Chem Biol"},{"key":"ref=618","doi-asserted-by":"publisher","first-page":"7157","DOI":"10.1523\/JNEUROSCI.17-18-07157.1997","volume":"17","author":"Stone L.S.","year":"1997","unstructured":"Stone L.S.; MacMillan L.B.; Kitto K.F.; Limbird L.E.; Wilcox G.L.; The α2a adrenergic receptor subtype mediates spinal analgesia evoked by α2 agonists and is necessary for spinal adrenergic-opioid synergy. J Neurosci 1997,17(18),7157-7165","journal-title":"J Neurosci"},{"key":"ref=619","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/0028-3908(93)90076-F","volume":"32","author":"Bourgoin S.","year":"1993","unstructured":"Bourgoin S.; Pohl M.; Mauborgne A.; Benoliel J.J.; Collin E.; Hamon M.; Cesselin F.; Monoaminergic control of the release of calcitonin gene-related peptide- and substance P-like materials from rat spinal cord slices. Neuropharmacology 1993,32(7),633-640","journal-title":"Neuropharmacology"},{"key":"ref=620","first-page":"522","author":"Kamisaki Y.","year":"1993","unstructured":"Kamisaki Y.; Hamada T.; Maeda K.; Ishimura M.; Itoh T.; Presynaptic α2 Adrenoceptors Inhibit Glutamate Release from Rat Spinal Cord Synaptosomes 1993,522-526","journal-title":"Presynaptic α2 Adrenoceptors Inhibit Glutamate Release from Rat Spinal Cord Synaptosomes"},{"key":"ref=621","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/bja\/81.1.12","volume":"81","author":"Jordan B.","year":"1998","unstructured":"Jordan B.; Devi L.A.; Molecular mechanisms of opioid receptor signal transduction. Br J Anaesth 1998,81(1),12-19","journal-title":"Br J Anaesth"},{"key":"ref=622","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1152\/ajpcell.1998.274.3.C654","volume":"274","author":"Richman J.G.","year":"1998","unstructured":"Richman J.G.; Regan J.W.; α2-adrenergic receptors increase cell migration and decrease F-actin labeling in rat aortic smooth muscle cells. Am J Physiol Cell Physiol 1998,274(3),43","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=623","doi-asserted-by":"publisher","first-page":"1267-1273","DOI":"10.1126\/science.aau2078","volume":"365","author":"Wang D.","year":"2019","unstructured":"Wang D.; Stoveken H.M.; Zucca S.; Dao M.; Orlandi C.; Song C.; Genetic behavioral screen identifies an orphan anti-opioid system Science (80-) 2019,365((6459)),1267-1273","journal-title":"Science (80-)"},{"key":"ref=624","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41593-018-0144-y","volume":"21","author":"Koshimizu T.A.","year":"2018","unstructured":"Koshimizu T.A.; Honda K.; Nagaoka-Uozumi S.; Ichimura A.; Kimura I.; Nakaya M.; Sakai N.; Shibata K.; Ushijima K.; Fujimura A.; Hirasawa A.; Kurose H.; Tsujimoto G.; Tanoue A.; Takano Y.; Complex formation between the vasopressin 1b receptor, β-arrestin-2, and the μ-opioid receptor underlies morphine tolerance. Nat Neurosci 2018,21(6),820-833","journal-title":"Nat Neurosci"},{"key":"ref=625","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1523\/JNEUROSCI.2442-16.2016","volume":"37","author":"Moreno E.","year":"2017","unstructured":"Moreno E.; Quiroz C.; Rea W.; Cai N.S.; Mallol J.; Cortés A.; Lluís C.; Canela E.I.; Casadó V.; Ferré S.; Functional µ-Opioid-galanin receptor heteromers in the ventral tegmental area. J Neurosci 2017,37(5),1176-1186","journal-title":"J Neurosci"},{"key":"ref=626","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1172\/JCI126912","volume":"129","author":"Cai N.S.","year":"2019","unstructured":"Cai N.S.; Quiroz C.; Bonaventura J.; Bonifazi A.; Cole T.O.; Purks J.; Billing A.S.; Massey E.; Wagner M.; Wish E.D.; Guitart X.; Rea W.; Lam S.; Moreno E.; Casadó-Anguera V.; Greenblatt A.D.; Jacobson A.E.; Rice K.C.; Casadó V.; Newman A.H.; Winkelman J.W.; Michaelides M.; Weintraub E.; Volkow N.D.; Belcher A.M.; Ferré S.; Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids. J Clin Invest 2019,129(7),2730-2744","journal-title":"J Clin Invest"},{"key":"ref=627","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1097\/00001756-200112040-00017","volume":"12","author":"Salio C.","year":"2001","unstructured":"Salio C.; Fischer J.; Franzoni M.F.; Mackie K.; Kaneko T.; Conrath M.; CB1-cannabinoid and μ-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. Neuroreport 2001,12(17),3689-3692","journal-title":"Neuroreport"},{"key":"ref=628","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/978-3-642-41199-1_22","volume":"219","author":"Raehal K.M.","year":"2014","unstructured":"Raehal K.M.; Bohn L.M.; β-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia. Handb Exp Pharmacol 2014,219,427-443","journal-title":"Handb Exp Pharmacol"},{"key":"ref=629","doi-asserted-by":"publisher","first-page":"107495","DOI":"10.1016\/j.pharmthera.2020.107495","volume":"209","author":"Bouchet C.A.","year":"2020","unstructured":"Bouchet C.A.; Ingram S.L.; Cannabinoids in the descending pain modulatory circuit: Role in inflammation. Pharmacol Ther 2020,209,107495","journal-title":"Pharmacol Ther"},{"key":"ref=630","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/sj.bjp.0706756","volume":"148","author":"Christie M.J.","year":"2006","unstructured":"Christie M.J.; Opioid and cannabinoid receptors: friends with benefits or just close friends? Br J Pharmacol 2006,148(4),385-386","journal-title":"Br J Pharmacol"},{"key":"ref=631","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3389\/fnbeh.2016.00211","volume":"10","author":"Manduca A.","year":"2016","unstructured":"Manduca A.; Lassalle O.; Sepers M.; Campolongo P.; Cuomo V.; Marsicano G.; Kieffer B.; Vanderschuren L.J.; Trezza V.; Manzoni O.J.; Interacting cannabinoid and opioid receptors in the nucleus accumbens core control adolescent social play. Front Behav Neurosci 2016,10(NOV),211","journal-title":"Front Behav Neurosci"},{"key":"ref=632","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.euroneuro.2015.04.005","volume":"25","author":"Manduca A.","year":"2015","unstructured":"Manduca A.; Morena M.; Campolongo P.; Servadio M.; Palmery M.; Trabace L.; Hill M.N.; Vanderschuren L.J.; Cuomo V.; Trezza V.; Distinct roles of the endocannabinoids anandamide and 2-arachidonoylglycerol in social behavior and emotionality at different developmental ages in rats. Eur Neuropsychopharmacol 2015,25(8),1362-1374","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=633","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1007\/s00213-016-4222-0","volume":"233","author":"Wei D.","year":"2016","unstructured":"Wei D.; Lee D.; Li D.; Daglian J.; Jung K.M.; Piomelli D.; A role for the endocannabinoid 2-arachidonoyl-sn-glycerol for social and high-fat food reward in male mice. Psychopharmacology (Berl) 2016,233(10),1911-1919","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=634","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0006-8993(94)90963-6","volume":"657","author":"Pu S.F.","year":"1994","unstructured":"Pu S.F.; Zhuang H.X.; Han J.S.; \nCholecystokinin octapeptide (CCK-8) antagonizes morphine analgesia in nucleus accumbens of the rat\nvia \nthe CCK-B receptor.\n Brain Res 1994,657(1-2),159-164","journal-title":"Brain Res"},{"key":"ref=635","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0014-2999(90)90129-T","volume":"176","author":"Dourish C.T.","year":"1990","unstructured":"Dourish C.T.; O\u2019Neill M.F.; Coughlan J.; Kitchener S.J.; Hawley D.; Iversen S.D.; The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur J Pharmacol 1990,176(1),35-44","journal-title":"Eur J Pharmacol"},{"key":"ref=636","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1006\/excr.2002.5638","volume":"280","author":"Suzuki S.","year":"2002","unstructured":"Suzuki S.; Chuang L.F.; Yau P.; Doi R.H.; Chuang R.Y.; Interactions of opioid and chemokine receptors: oligomerization of mu, kappa, and delta with CCR5 on immune cells. Exp Cell Res 2002,280(2),192-200","journal-title":"Exp Cell Res"},{"key":"ref=637","doi-asserted-by":"publisher","first-page":"10276","DOI":"10.1073\/pnas.102327699","volume":"99","author":"Szabo I.","year":"2002","unstructured":"Szabo I.; Chen X-H.; Xin L.; Adler M.W.; Howard O.M.Z.; Oppenheim J.J.; Rogers T.J.; Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain. Proc Natl Acad Sci USA 2002,99(16),10276-10281","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=638","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ejphar.2007.11.060","volume":"581","author":"Juhasz J.R.","year":"2008","unstructured":"Juhasz J.R.; Hasbi A.; Rashid A.J.; So C.H.; George S.R.; O\u2019Dowd B.F.; Mu-opioid receptor heterooligomer formation with the dopamine D1 receptor as directly visualized in living cells. Eur J Pharmacol 2008,581(3),235-243","journal-title":"Eur J Pharmacol"},{"key":"ref=639","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1111\/bph.13908","volume":"174","author":"Tao Y.M.","year":"2017","unstructured":"Tao Y.M.; Yu C.; Wang W.S.; Hou Y.Y.; Xu X.J.; Chi Z.Q.; Ding Y.Q.; Wang Y.J.; Liu J.G.; Heteromers of μ opioid and dopamine D receptors modulate opioid-induced locomotor sensitization in a dopamine-independent manner. Br J Pharmacol 2017,174(17),2842-2861","journal-title":"Br J Pharmacol"},{"key":"ref=640","doi-asserted-by":"publisher","first-page":"38746","DOI":"10.1038\/srep38746","volume":"6","author":"Dai W.L.","year":"2016","unstructured":"Dai W.L.; Xiong F.; Yan B.; Cao Z.Y.; Liu W.T.; Liu J.H.; Yu B.Y.; Blockade of neuronal dopamine D2 receptor attenuates morphine tolerance in mice spinal cord. Sci Rep 2016,6(1),38746","journal-title":"Sci Rep"},{"key":"ref=641","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3390\/biom9080368","volume":"9","author":"Vasudevan L.","year":"2019","unstructured":"Vasudevan L.; Borroto-Escuela D.O.; Huysentruyt J.; Fuxe K.; Saini D.K.; Stove C.; Heterodimerization of MU opioid receptor protomer with dopamine D2 receptor modulates agonist- induced internalization of MU opioid receptor. Biomolecules 2019,9(8),368","journal-title":"Biomolecules"},{"key":"ref=642","doi-asserted-by":"publisher","first-page":"13890","DOI":"10.1523\/JNEUROSCI.2304-11.2011","volume":"31","author":"Grecksch G.","year":"2011","unstructured":"Grecksch G.; Just S.; Pierstorff C.; Imhof A.K.; Glück L.; Doll C.; Lupp A.; Becker A.; Koch T.; Stumm R.; Höllt V.; Schulz S.; Analgesic tolerance to high-efficacy agonists but not to morphine is diminished in phosphorylation-deficient S375A μ-opioid receptor knock-in mice. J Neurosci 2011,31(39),13890-13896","journal-title":"J Neurosci"},{"key":"ref=643","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1124\/mol.110.066613","volume":"78","author":"McPherson J.","year":"2010","unstructured":"McPherson J.; Rivero G.; Baptist M.; Llorente J.; Al-Sabah S.; Krasel C.; Dewey W.L.; Bailey C.P.; Rosethorne E.M.; Charlton S.J.; Henderson G.; Kelly E.; μ-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol 2010,78(4),756-766","journal-title":"Mol Pharmacol"},{"key":"ref=644","doi-asserted-by":"publisher","first-page":"9914","DOI":"10.1073\/pnas.95.17.9914","volume":"95","author":"Whistler J.L.","year":"1998","unstructured":"Whistler J.L.; von Zastrow M.; Morphine-activated opioid receptors elude desensitization by beta-arrestin. Proc Natl Acad Sci USA 1998,95(17),9914-9919","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=645","first-page":"5(1), 041-50","author":"Bohn LM","year":"2004","unstructured":"Bohn LM; Gainetdinov RR; Caron MG. G; Protein-coupled receptor kinase\/β-arrestin systems and drugs of abuse: Psychostimulant and opiate studies in knockout mice. Neuro. Mol Med 2004,5(1), 041-50","journal-title":"Mol Med"},{"key":"ref=646","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.pharmthera.2012.09.006","volume":"137","author":"Artigas F.","year":"2013","unstructured":"Artigas F.; Serotonin receptors involved in antidepressant effects. Pharmacol Ther 2013,137(1),119-131","journal-title":"Pharmacol Ther"},{"key":"ref=647","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.1021\/acsomega.7b00629","volume":"2","author":"Borroto-Escuela D.O.","year":"2017","unstructured":"Borroto-Escuela D.O.; Li X.; Tarakanov A.O.; Savelli D.; Narváez M.; Shumilov K.; Andrade-Talavera Y.; Jimenez-Beristain A.; Pomierny B.; Díaz-Cabiale Z.; Cuppini R.; Ambrogini P.; Lindskog M.; Fuxe K.; Existence of brain 5-HT1A-5-HT2A isoreceptor complexes with antagonistic allosteric receptor-receptor interactions regulating 5-HT1A receptor recognition. ACS Omega 2017,2(8),4779-4789","journal-title":"ACS Omega"},{"key":"ref=648","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fnmol.2018.00040","volume":"11","author":"Szlachta M.","year":"2018","unstructured":"Szlachta M.; Kuśmider M.; Pabian P.; Solich J.; Kolasa M.; Żurawek D.; Dziedzicka-Wasylewska M.; Faron-Górecka A.; Repeated clozapine increases the level of serotonin 5-HT1A R heterodimerization with 5-HT2A or dopamine D2 receptors in the mouse cortex. Front Mol Neurosci 2018,11,40","journal-title":"Front Mol Neurosci"},{"key":"ref=649","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40263-013-0071-0","volume":"27","author":"Celada P.","year":"2013","unstructured":"Celada P.; Bortolozzi A.; Artigas F.; Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs 2013,27(9),703-716","journal-title":"CNS Drugs"},{"key":"ref=650","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.tips.2008.06.007","volume":"29","author":"Millan M.J.","year":"2008","unstructured":"Millan M.J.; Marin P.; Bockaert J.; Mannoury la Cour C.; Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol Sci 2008,29(9),454-464","journal-title":"Trends Pharmacol Sci"},{"key":"ref=651","doi-asserted-by":"publisher","first-page":"6846","DOI":"10.1523\/JNEUROSCI.22-16-06846.2002","volume":"22","author":"Carr D.B.","year":"2002","unstructured":"Carr D.B.; Cooper D.C.; Ulrich S.L.; Spruston N.; Surmeier D.J.; \nSerotonin receptor activation inhibits sodium current and dendritic excitability in prefrontal cortex\nvia \na protein kinase C-dependent mechanism.\n J Neurosci 2002,22(16),6846-6855","journal-title":"J Neurosci"},{"key":"ref=652","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1021\/acschemneuro.5b00094","volume":"6","author":"Anastasio N.C.","year":"2015","unstructured":"Anastasio N.C.; Stutz S.J.; Fink L.H.L.; Swinford-Jackson S.E.; Sears R.M.; DiLeone R.J.; Rice K.C.; Moeller F.G.; Cunningham K.A.; Serotonin (5-HT) 5-HT2A Receptor (5-HT2AR):5-HT2CR Imbalance in Medial Prefrontal Cortex Associates with Motor Impulsivity. ACS Chem Neurosci 2015,6(7),1248-1258","journal-title":"ACS Chem Neurosci"},{"key":"ref=653","doi-asserted-by":"publisher","first-page":"e20508","DOI":"10.1371\/journal.pone.0020508","volume":"6","author":"Bubar M.J.","year":"2011","unstructured":"Bubar M.J.; Stutz S.J.; Cunningham K.A.; 5-HT(2C) receptors localize to dopamine and GABA neurons in the rat mesoaccumbens pathway. PLoS One 2011,6(6),e20508","journal-title":"PLoS One"},{"key":"ref=654","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2174\/138945006775515455","volume":"7","author":"Esposito E.","year":"2006","unstructured":"Esposito E.; Serotonin-dopamine interaction as a focus of novel antidepressant drugs. Curr Drug Targets 2006,7(2),177-185","journal-title":"Curr Drug Targets"},{"key":"ref=655","doi-asserted-by":"publisher","first-page":"6352","DOI":"10.1074\/jbc.M117.779041","volume":"292","author":"Moutkine I.","year":"2017","unstructured":"Moutkine I.; Quentin E.; Guiard B.P.; Maroteaux L.; Doly S.; Heterodimers of serotonin receptor subtypes 2 are driven by 5-HT protomers. J Biol Chem 2017,292(15),6352-6368","journal-title":"J Biol Chem"},{"key":"ref=656","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1242\/jcs.101337","volume":"125","author":"Renner U.","year":"2012","unstructured":"Renner U.; Zeug A.; Woehler A.; Niebert M.; Dityatev A.; Dityateva G.; Gorinski N.; Guseva D.; Abdel-Galil D.; Fröhlich M.; Döring F.; Wischmeyer E.; Richter D.W.; Neher E.; Ponimaskin E.G.; Heterodimerization of serotonin receptors 5-HT1A and 5-HT7 differentially regulates receptor signalling and trafficking. J Cell Sci 2012,125(Pt 10),2486-2499","journal-title":"J Cell Sci"},{"key":"ref=657","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","volume":"38","author":"Barnes N.M.","year":"1999","unstructured":"Barnes N.M.; Sharp T.; A review of central 5-HT receptors and their function. Neuropharmacology 1999,38(8),1083-1152","journal-title":"Neuropharmacology"},{"key":"ref=658","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/sj.bjp.0702723","volume":"127","author":"Raymond J.R.","year":"1999","unstructured":"Raymond J.R.; Mukhin Y.V.; Gettys T.W.; Garnovskaya M.N.; The recombinant 5-HT1A receptor: G protein coupling and signalling pathways. Br J Pharmacol 1999,127(8),1751-1764","journal-title":"Br J Pharmacol"},{"key":"ref=659","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.neulet.2018.09.013","volume":"686","author":"Li Y.H.","year":"2018","unstructured":"Li Y.H.; Xiang K.; Xu X.; Zhao X.; Li Y.; Zheng L.; Wang J.; Co-activation of both 5-HT and 5-HT receptors induced attenuation of glutamatergic synaptic transmission in the rat visual cortex. Neurosci Lett 2018,686,122-126","journal-title":"Neurosci Lett"},{"key":"ref=660","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/cns.12247","volume":"20","author":"Naumenko V.S.","year":"2014","unstructured":"Naumenko V.S.; Popova N.K.; Lacivita E.; Leopoldo M.; Ponimaskin E.G.; Interplay between serotonin 5-HT1A and 5-HT7 receptors in depressive disorders. CNS Neurosci Ther 2014,20(7),582-590","journal-title":"CNS Neurosci Ther"},{"key":"ref=661","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/jnc.13582","volume":"137","author":"\u0141ukasiewicz S.","year":"2016","unstructured":"\u0141ukasiewicz S.; B\u0142asiak E.; Szafran-Pilch K.; Dziedzicka-Wasylewska M.; Dopamine D2 and serotonin 5-HT1A receptor interaction in the context of the effects of antipsychotics - in vitro studies. J Neurochem 2016,137(4),549-560","journal-title":"J Neurochem"},{"key":"ref=662","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.bbamcr.2010.08.010","volume":"1803","author":"\u0141ukasiewicz S.","year":"2010","unstructured":"\u0141ukasiewicz S.; Polit A.; K\u0119dracka-Krok S.; W\u0119dzony K.; Ma\u0107kowiak M.; Dziedzicka-Wasylewska M.; Hetero-dimerization of serotonin 5-HT(2A) and dopamine D(2) receptors. Biochim Biophys Acta 2010,1803(12),1347-1358","journal-title":"Biochim Biophys Acta"},{"key":"ref=663","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.neuropharm.2011.05.023","volume":"61","author":"Albizu L.","year":"2011","unstructured":"Albizu L.; Holloway T.; González-Maeso J.; Sealfon S.C.; Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors. Neuropharmacology 2011,61(4),770-777","journal-title":"Neuropharmacology"},{"key":"ref=664","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.bbrc.2010.09.110","volume":"401","author":"Borroto-Escuela D.O.","year":"2010","unstructured":"Borroto-Escuela D.O.; Romero-Fernandez W.; Tarakanov A.O.; Marcellino D.; Ciruela F.; Agnati L.F.; Fuxe K.; Dopamine D2 and 5-hydroxytryptamine 5-HT(A) receptors assemble into functionally interacting heteromers. Biochem Biophys Res Commun 2010,401(4),605-610","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=665","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/187152706784111614","volume":"5","author":"Glennon J.","year":"2008","unstructured":"Glennon J.; Wadman W.; McCreary A.; Werkman T.; Dopamine Receptor Pharmacology: Interactions with Serotonin Receptors and Significance for the Aetiology and Treatment of Schizophrenia. CNS Neurol Disord Drug Targets 2008,5(1),3-23","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=666","first-page":"237","volume":"22","author":"Reimherr F.W.","year":"1986","unstructured":"Reimherr F.W.; Wood D.R.; Wender P.H.; The use of MK-801, a novel sympathomimetic, in adults with attention deficit disorder, residual type. Psychopharmacol Bull 1986,22(1),237-242","journal-title":"Psychopharmacol Bull"},{"key":"ref=667","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/BF01294789","volume":"96","author":"Gattaz W.F.","year":"1994","unstructured":"Gattaz W.F.; Schummer B.; Behrens S.; Effects of zotepine, haloperidol and clozapine on MK-801-induced stereotypy and locomotion in rats. J Neural Transm (Vienna) 1994,96(3),227-232","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=668","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.bbrc.2010.02.078","volume":"393","author":"Borroto-Escuela D.O.","year":"2010","unstructured":"Borroto-Escuela D.O.; Narvaez M.; Marcellino D.; Parrado C.; Narvaez J.A.; Tarakanov A.O.; Agnati L.F.; Díaz-Cabiale Z.; Fuxe K.; \nGalanin receptor-1 modulates 5-hydroxtryptamine-1A signaling\nvia \nheterodimerization.\n Biochem Biophys Res Commun 2010,393(4),767-772","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=669","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1749-6632.1998.tb10687.x","volume":"863","author":"Branchek T.","year":"1998","unstructured":"Branchek T.; Smith K.E.; Walker M.W.; Molecular biology and pharmacology of galanin receptors. Ann N Y Acad Sci 1998,863(1),94-107","journal-title":"Ann N Y Acad Sci"},{"key":"ref=670","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/978-1-349-12664-4_16","author":"Fuxe K.","year":"1991","unstructured":"Fuxe K.; Hedlund P.; von Euler G.; Lundgren K.; Martire M.; Ögren S.O.; Galanin\/5-HT interactions in the rat central nervous system Relevance for depression 1991,221-235","journal-title":"Galanin\/5-HT interactions in the rat central nervous system Relevance for depression"},{"key":"ref=671","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0304-3940(00)01788-2","volume":"299","author":"Razani H.","year":"2001","unstructured":"Razani H.; Díaz-Cabiale Z.; Misane I.; Wang F.H.; Fuxe K.; Ögren S.O.; Prolonged effects of intraventricular galanin on a 5-hydroxytryptamine(1A) receptor mediated function in the rat. Neurosci Lett 2001,299(1-2),145-149","journal-title":"Neurosci Lett"},{"key":"ref=672","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0304-3940(88)90448-X","volume":"85","author":"Fuxe K.","year":"1988","unstructured":"Fuxe K.; von Euler G.; Agnati L.F.; Ögren S.O.; Galanin selectively modulates 5-hydroxytryptamine 1A receptors in the rat ventral limbic cortex. Neurosci Lett 1988,85(1),163-167","journal-title":"Neurosci Lett"},{"key":"ref=673","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1097\/00001756-200012180-00008","volume":"11","author":"Razani H.","year":"2000","unstructured":"Razani H.; Diaz-Cabiale Z.; Fuxe K.; Ögren S.O.; Intraventricular galanin produces a time-dependent modulation of 5-HT1A receptors in the dorsal raphe of the rat. Neuroreport 2000,11(18),3943-3948","journal-title":"Neuroreport"},{"key":"ref=674","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1748-1716.1988.tb08444.x","volume":"133","author":"Fuxe K.","year":"1988","unstructured":"Fuxe K.; Ögren S.O.; Jansson A.; Cintra A.; Härfstrand A.; Agnati L.F.; Intraventricular injections of galanin reduces 5-HT metabolism in the ventral limbic cortex, the hippocampal formation and the fronto-parietal cortex of the male rat. Acta Physiol Scand 1988,133(4),579-581","journal-title":"Acta Physiol Scand"},{"key":"ref=675","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0893-133X(02)00309-3","volume":"27","author":"Kehr J.","year":"2002","unstructured":"Kehr J.; Yoshitake T.; Wang F.H.; Razani H.; Gimenez-Llort L.; Jansson A.; Yamaguchi M.; Ogren S.O.; \nGalanin is a potent \nin vivo\nmodulator of mesencephalic serotonergic neurotransmission.\n Neuropsychopharmacology 2002,27(3),341-356","journal-title":"Neuropsychopharmacology"},{"key":"ref=676","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1021\/acschemneuro.8b00665","volume":"10","author":"Chruścicka B.","year":"2019","unstructured":"Chruścicka B.; Wallace Fitzsimons S.E.; Borroto-Escuela D.O.; Druelle C.; Stamou P.; Nally K.; Dinan T.G.; Cryan J.F.; Fuxe K.; Schellekens H.; Attenuation of oxytocin and serotonin 2A receptor signaling through novel heteroreceptor formation. ACS Chem Neurosci 2019,10(7),3225-3240","journal-title":"ACS Chem Neurosci"},{"key":"ref=677","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/dev.20566","volume":"54","author":"Eaton J.L.","year":"2012","unstructured":"Eaton J.L.; Roache L.; Nguyen K.N.; Cushing B.S.; Troyer E.; Papademetriou E.; Raghanti M.A.; Organizational effects of oxytocin on serotonin innervation. Dev Psychobiol 2012,54(1),92-97","journal-title":"Dev Psychobiol"},{"key":"ref=678","doi-asserted-by":"publisher","first-page":"6741","DOI":"10.1523\/JNEUROSCI.0659-17.2017","volume":"37","author":"Lefevre A.","year":"2017","unstructured":"Lefevre A.; Richard N.; Jazayeri M.; Beuriat P.A.; Fieux S.; Zimmer L.; Duhamel J.R.; Sirigu A.; Oxytocin and serotonin brain mechanisms in the nonhuman primate. J Neurosci 2017,37(28),6741-6750","journal-title":"J Neurosci"},{"key":"ref=679","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature12518","volume":"501","author":"Dölen G.","year":"2013","unstructured":"Dölen G.; Darvishzadeh A.; Huang K.W.; Malenka R.C.; Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin. Nature 2013,501(7466),179-184","journal-title":"Nature"},{"key":"ref=680","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1523\/JNEUROSCI.5593-08.2009","volume":"29","author":"Yoshida M.","year":"2009","unstructured":"Yoshida M.; Takayanagi Y.; Inoue K.; Kimura T.; Young L.J.; Onaka T.; Nishimori K.; \nEvidence that oxytocin exerts anxiolytic effects\nvia \noxytocin receptor expressed in serotonergic neurons in mice.\n J Neurosci 2009,29(7),2259-2271","journal-title":"J Neurosci"},{"key":"ref=681","doi-asserted-by":"publisher","first-page":"108394","DOI":"10.1016\/j.neuropharm.2020.108394","volume":"183","author":"Chruścicka B.","year":"2021","unstructured":"Chruścicka B.; Cowan C.S.M.; Wallace Fitzsimons S.E.; Borroto-Escuela D.O.; Druelle C.M.; Stamou P.; Bergmann C.A.; Dinan T.G.; Slattery D.A.; Fuxe K.; Cryan J.F.; Schellekens H.; Molecular, biochemical and behavioural evidence for a novel oxytocin receptor and serotonin 2C receptor heterocomplex. Neuropharmacology 2021,183,108394","journal-title":"Neuropharmacology"},{"key":"ref=682","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/S0006-8993(98)01295-5","volume":"818","author":"Prosser R.A.","year":"1999","unstructured":"Prosser R.A.; \nMelatonin inhibits \nin vitro\nserotonergic phase shifts of the suprachiasmatic circadian clock.\n Brain Res 1999,818(2),408-413","journal-title":"Brain Res"},{"key":"ref=683","doi-asserted-by":"publisher","first-page":"11537","DOI":"10.1074\/jbc.M114.559542","volume":"290","author":"Kamal M.","year":"2015","unstructured":"Kamal M.; Gbahou F.; Guillaume J.L.; Daulat A.M.; Benleulmi-Chaachoua A.; Luka M.; Chen P.; Kalbasi Anaraki D.; Baroncini M.; Mannoury la Cour C.; Millan M.J.; Prevot V.; Delagrange P.; Jockers R.; Convergence of melatonin and serotonin (5-HT) signaling at MT2\/5-HT2C receptor heteromers. J Biol Chem 2015,290(18),11537-11546","journal-title":"J Biol Chem"},{"key":"ref=684","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1124\/jpet.103.051797","volume":"306","author":"Millan M.J.","year":"2003","unstructured":"Millan M.J.; Gobert A.; Lejeune F.; Dekeyne A.; Newman-Tancredi A.; Pasteau V.; Rivet J.M.; Cussac D.; The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003,306(3),954-964","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=685","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1016\/j.bcp.2008.02.022","volume":"75","author":"Audinot V.","year":"2008","unstructured":"Audinot V.; Bonnaud A.; Grandcolas L.; Rodriguez M.; Nagel N.; Galizzi J.P.; Balik A.; Messager S.; Hazlerigg D.G.; Barrett P.; Delagrange P.; Boutin J.A.; Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors. Biochem Pharmacol 2008,75(10),2007-2019","journal-title":"Biochem Pharmacol"},{"key":"ref=686","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3109\/15622975.2011.595823","volume":"12","author":"Racagni G.","year":"2011","unstructured":"Racagni G.; Riva M.A.; Molteni R.; Musazzi L.; Calabrese F.; Popoli M.; Tardito D.; Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. World J Biol Psychiatry 2011,12(8),574-587","journal-title":"World J Biol Psychiatry"},{"key":"ref=687","doi-asserted-by":"publisher","first-page":"e21161","DOI":"10.1096\/fj.202000305R","volume":"35","author":"Gerbier R.","year":"2021","unstructured":"Gerbier R.; Ndiaye-Lobry D.; Martinez de Morentin P.B.; Cecon E.; Heisler L.K.; Delagrange P.; Gbahou F.; Jockers R.; Pharmacological evidence for transactivation within melatonin MT and serotonin 5-HT receptor heteromers in mouse brain. FASEB J 2021,35(1),e21161","journal-title":"FASEB J"},{"key":"ref=688","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0028-3908(01)00100-9","volume":"41","author":"Kishimoto K.","year":"2001","unstructured":"Kishimoto K.; Koyama S.; Akaike N.; Synergistic μ-opioid and 5-HT1A presynaptic inhibition of GABA release in rat periaqueductal gray neurons. Neuropharmacology 2001,41(5),529-538","journal-title":"Neuropharmacology"},{"key":"ref=689","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0304-3940(87)90218-7","volume":"83","author":"Daval G.","year":"1987","unstructured":"Daval G.; Vergé D.; Basbaum A.I.; Bourgoin S.; Hamon M.; Autoradiographic evidence of serotonin1 binding sites on primary afferent fibres in the dorsal horn of the rat spinal cord. Neurosci Lett 1987,83(1-2),71-76","journal-title":"Neurosci Lett"},{"key":"ref=690","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1523\/JNEUROSCI.12-02-00440.1992","volume":"12","author":"Pompeiano M.","year":"1992","unstructured":"Pompeiano M.; Palacios J.M.; Mengod G.; Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. J Neurosci 1992,12(2),440-453","journal-title":"J Neurosci"},{"key":"ref=691","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1146\/annurev.pharmtox.40.1.389","volume":"40","author":"Law P-Y.","year":"2000","unstructured":"Law P-Y.; Wong Y.H.; Loh H.H.; Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 2000,40(1),389-430","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=692","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1016\/j.cellsig.2012.04.010","volume":"24","author":"Cussac D.","year":"2012","unstructured":"Cussac D.; Rauly-Lestienne I.; Heusler P.; Finana F.; Cathala C.; Bernois S.; De Vries L.; \nμ-Opioid and 5-HT1A receptors heterodimerize and show signalling crosstalk\nvia \nG protein and MAP-kinase pathways.\n Cell Signal 2012,24(8),1648-1657","journal-title":"Cell Signal"},{"key":"ref=693","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S0165-6147(99)01404-2","volume":"21","author":"Milligan G.","year":"2000","unstructured":"Milligan G.; Insights into ligand pharmacology using receptor-G-protein fusion proteins. Trends Pharmacol Sci 2000,21(1),24-28","journal-title":"Trends Pharmacol Sci"},{"key":"ref=694","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/00005344-200411000-00001","volume":"44","author":"Ashton J.C.","year":"2004","unstructured":"Ashton J.C.; Appleton I.; Darlington C.L.; Smith P.F.; Immunohistochemical localization of cerebrovascular cannabinoid CB1 receptor protein. J Cardiovasc Pharmacol 2004,44(5),517-519","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=695","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/j.1476-5381.2010.00777.x","volume":"160","author":"Smith T.H.","year":"2010","unstructured":"Smith T.H.; Sim-Selley L.J.; Selley D.E.; Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? Br J Pharmacol 2010,160(3),454-466","journal-title":"Br J Pharmacol"},{"key":"ref=696","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/365061a0","volume":"365","author":"Munro S.","year":"1993","unstructured":"Munro S.; Thomas K.L.; Abu-Shaar M.; Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993,365(6441),61-65","journal-title":"Nature"},{"key":"ref=697","first-page":"2353-2366","author":"Latek D.","year":"2011","unstructured":"Latek D.; Kolinski M.; Ghoshdastider U.; Debinski A.; Bombolewski R.; Plazinska A.; Modeling of ligand binding to G protein coupled receptors: Cannabinoid CB 1, CB 2 and adrenergic β 2AR. J. Mol Mod 2011,2353-2366","journal-title":"Mol Mod"},{"key":"ref=698","doi-asserted-by":"publisher","first-page":"20851","DOI":"10.1074\/jbc.M111.335273","volume":"287","author":"Callén L.","year":"2012","unstructured":"Callén L.; Moreno E.; Barroso-Chinea P.; Moreno-Delgado D.; Cortés A.; Mallol J.; Casadó V.; Lanciego J.L.; Franco R.; Lluis C.; Canela E.I.; McCormick P.J.; Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J Biol Chem 2012,287(25),20851-20865","journal-title":"J Biol Chem"},{"key":"ref=699","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1007\/s00429-014-0823-8","volume":"220","author":"Sierra S.","year":"2015","unstructured":"Sierra S.; Luquin N.; Rico A.J.; Gómez-Bautista V.; Roda E.; Dopeso-Reyes I.G.; Vázquez A.; Martínez-Pinilla E.; Labandeira-García J.L.; Franco R.; Lanciego J.L.; Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. Brain Struct Funct 2015,220(5),2721-2738","journal-title":"Brain Struct Funct"},{"key":"ref=700","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0163-7258(97)82001-3","volume":"74","author":"Pertwee R.G.","year":"1997","unstructured":"Pertwee R.G.; Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997,74(2),129-180","journal-title":"Pharmacol Ther"},{"key":"ref=701","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bbi.2017.08.015","volume":"67","author":"Navarro G.","year":"2018","unstructured":"Navarro G.; Borroto-Escuela D.; Angelats E.; Etayo Í.; Reyes-Resina I.; Pulido-Salgado M.; Rodríguez-Pérez A.I.; Canela E.I.; Saura J.; Lanciego J.L.; Labandeira-García J.L.; Saura C.A.; Fuxe K.; Franco R.; Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB and CB receptors and relevance for Alzheimer\u2019s disease and levodopa-induced dyskinesia. Brain Behav Immun 2018,67,139-151","journal-title":"Brain Behav Immun"},{"key":"ref=702","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1523\/JNEUROSCI.20-09-03401.2000","volume":"20","author":"Beltramo M.","year":"2000","unstructured":"Beltramo M.; de Fonseca F.R.; Navarro M.; Calignano A.; Gorriti M.A.; Grammatikopoulos G.; Sadile A.G.; Giuffrida A.; Piomelli D.; Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J Neurosci 2000,20(9),3401-3407","journal-title":"J Neurosci"},{"key":"ref=703","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/7268","volume":"2","author":"Giuffrida A.","year":"1999","unstructured":"Giuffrida A.; Parsons L.H.; Kerr T.M.; Rodríguez de Fonseca F.; Navarro M.; Piomelli D.; Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 1999,2(4),358-363","journal-title":"Nat Neurosci"},{"key":"ref=704","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1124\/mol.104.006882","volume":"67","author":"Kearn C.S.","year":"2005","unstructured":"Kearn C.S.; Blake-Palmer K.; Daniel E.; Mackie K.; Glass M.; Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: A mechanism for receptor cross-talk? Mol Pharmacol 2005,67(5),1697-1704","journal-title":"Mol Pharmacol"},{"key":"ref=705","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/0006-8993(91)90970-7","volume":"547","author":"Herkenham M.","year":"1991","unstructured":"Herkenham M.; Lynn A.B.; de Costa B.R.; Richfield E.K.; Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 1991,547(2),267-274","journal-title":"Brain Res"},{"key":"ref=706","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S0028-3908(01)00012-0","volume":"40","author":"Meschler J.P.","year":"2001","unstructured":"Meschler J.P.; Howlett A.C.; Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacology 2001,40(7),918-926","journal-title":"Neuropharmacology"},{"key":"ref=707","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejphar.2003.08.101","author":"Van Der Stelt M.","year":"2003","unstructured":"Van Der Stelt M.; Di Marzo V.; In: European J 2003,133-150","journal-title":"In: European J"},{"key":"ref=708","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0306-4522(03)00070-8","volume":"119","author":"Julian M.D.","year":"2003","unstructured":"Julian M.D.; Martin A.B.; Cuellar B.; Rodriguez, De Fonseca, F.; Navarro, M.; Moratalla, R.; Garcia-Segura, L.M. Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience 2003,119(1),309-318","journal-title":"Neuroscience"},{"key":"ref=709","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fnbeh.2011.00049","volume":"5","author":"Terzian A.L.","year":"2011","unstructured":"Terzian A.L.; Drago F.; Wotjak C.T.; Micale V.; The dopamine and cannabinoid interaction in the modulation of emotions and cognition: Assessing the role of cannabinoid CB1 receptor in neurons expressing dopamine D1 receptors. Front Behav Neurosci 2011,5,49","journal-title":"Front Behav Neurosci"},{"key":"ref=710","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00213-020-05704-8","volume":"238","author":"Serrano A.","year":"2021","unstructured":"Serrano A.; Vadas E.; Ferrer B.; Bilbao A.; Granado N.; Suárez J.; Pavon F.J.; Moratalla R.; Rodríguez de Fonseca F.; Genetic deletion of dopamine D1 receptors increases the sensitivity to cannabinoid CB1 receptor antagonist-precipitated withdrawal when compared with wild-type littermates: studies in female mice repeatedly exposed to the Spice cannabinoid HU-210. Psychopharmacology (Berl) 2021,238(2),551-557","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=711","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/(SICI)1096-9861(20000626)422:2<159:AID-CNE1>3.0.CO;2-1","volume":"422","author":"Egertová M.","year":"2000","unstructured":"Egertová M.; Elphick M.R.; Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J Comp Neurol 2000,422(2),159-171","journal-title":"J Comp Neurol"},{"key":"ref=712","doi-asserted-by":"publisher","first-page":"8251","DOI":"10.1073\/pnas.0510797103","volume":"103","author":"Yin H.H.","year":"2006","unstructured":"Yin H.H.; Lovinger D.M.; Frequency-specific and D2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling. Proc Natl Acad Sci USA 2006,103(21),8251-8256","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=713","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/cne.20881","volume":"495","author":"Pickel V.M.","year":"2006","unstructured":"Pickel V.M.; Chan J.; Kearn C.S.; Mackie K.; Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens. J Comp Neurol 2006,495(3),299-313","journal-title":"J Comp Neurol"},{"key":"ref=714","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1002\/jnr.24716","volume":"98","author":"Bagher A.M.","year":"2020","unstructured":"Bagher A.M.; Young A.P.; Laprairie R.B.; Toguri J.T.; Kelly M.E.M.; Denovan-Wright E.M.; Heteromer formation between cannabinoid type 1 and dopamine type 2 receptors is altered by combination cannabinoid and antipsychotic treatments. J Neurosci Res 2020,98(12),2496-2509","journal-title":"J Neurosci Res"},{"key":"ref=715","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejphar.2017.07.034","volume":"813","author":"Bagher A.M.","year":"2017","unstructured":"Bagher A.M.; Laprairie R.B.; Toguri J.T.; Kelly M.E.M.; Denovan-Wright E.M.; Bidirectional allosteric interactions between cannabinoid receptor 1 (CB) and dopamine receptor 2 long (D) heterotetramers. Eur J Pharmacol 2017,813,66-83","journal-title":"Eur J Pharmacol"},{"key":"ref=716","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1124\/mol.116.103465","volume":"89","author":"Bagher A.M.","year":"2016","unstructured":"Bagher A.M.; Laprairie R.B.; Kelly M.E.M.; Denovan-Wright E.M.; Antagonism of dopamine receptor 2 long affects cannabinoid receptor 1 signaling in a cell culture model of striatal medium spiny projection neurons. Mol Pharmacol 2016,89(6),652-666","journal-title":"Mol Pharmacol"},{"key":"ref=717","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.expneurol.2013.12.021","volume":"253","author":"Pinna A.","year":"2014","unstructured":"Pinna A.; Bonaventura J.; Farré D.; Sánchez M.; Simola N.; Mallol J.; Lluís C.; Costa G.; Baqi Y.; Müller C.E.; Cortés A.; McCormick P.; Canela E.I.; Martínez-Pinilla E.; Lanciego J.L.; Casadó V.; Armentero M.T.; Franco R.; L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies. Exp Neurol 2014,253,180-191","journal-title":"Exp Neurol"},{"key":"ref=718","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.neuropharm.2013.10.036","volume":"79","author":"Bonaventura J.","year":"2014","unstructured":"Bonaventura J.; Rico A.J.; Moreno E.; Sierra S.; Sánchez M.; Luquin N.; Farré D.; Müller C.E.; Martínez-Pinilla E.; Cortés A.; Mallol J.; Armentero M.T.; Pinna A.; Canela E.I.; Lluís C.; McCormick P.J.; Lanciego J.L.; Casadó V.; Franco R.; L-DOPA-treatment in primates disrupts the expression of A(2A) adenosine-CB(1) cannabinoid-D(2) dopamine receptor heteromers in the caudate nucleus. Neuropharmacology 2014,79,90-100","journal-title":"Neuropharmacology"},{"key":"ref=719","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1124\/jpet.103.057620","volume":"308","author":"Jarrahian A.","year":"2004","unstructured":"Jarrahian A.; Watts V.J.; Barker E.L.; D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor. J Pharmacol Exp Ther 2004,308(3),880-886","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=720","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.1523\/JNEUROSCI.17-14-05327.1997","volume":"17","author":"Glass M.","year":"1997","unstructured":"Glass M.; Felder C.C.; Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 1997,17(14),5327-5333","journal-title":"J Neurosci"},{"key":"ref=721","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.neuropharm.2007.12.011","volume":"54","author":"Marcellino D.","year":"2008","unstructured":"Marcellino D.; Carriba P.; Filip M.; Borgkvist A.; Frankowska M.; Bellido I.; Tanganelli S.; Müller C.E.; Fisone G.; Lluis C.; Agnati L.F.; Franco R.; Fuxe K.; Antagonistic cannabinoid CB1\/dopamine D2 receptor interactions in striatal CB1\/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology 2008,54(5),815-823","journal-title":"Neuropharmacology"},{"key":"ref=722","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.neuropharm.2008.06.076","volume":"56","author":"Ferré S.","year":"2009","unstructured":"Ferré S.; Goldberg S.R.; Lluis C.; Franco R.; Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology 2009,56(Suppl. 1),226-234","journal-title":"Neuropharmacology"},{"key":"ref=723","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1111\/j.1460-9568.2004.03682.x","volume":"20","author":"Soria G.","year":"2004","unstructured":"Soria G.; Castañé A.; Berrendero F.; Ledent C.; Parmentier M.; Maldonado R.; Valverde O.; Adenosine A2A receptors are involved in physical dependence and place conditioning induced by THC. Eur J Neurosci 2004,20(8),2203-2213","journal-title":"Eur J Neurosci"},{"key":"ref=724","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1111\/j.1471-4159.2009.06282.x","volume":"110","author":"Tebano M.T.","year":"2009","unstructured":"Tebano M.T.; Martire A.; Chiodi V.; Pepponi R.; Ferrante A.; Domenici M.R.; Frank C.; Chen J.F.; Ledent C.; Popoli P.; Adenosine A2A receptors enable the synaptic effects of cannabinoid CB1 receptors in the rodent striatum. J Neurochem 2009,110(6),1921-1930","journal-title":"J Neurochem"},{"key":"ref=725","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0165-0270(01)00374-0","volume":"108","author":"Anderson W.W.","year":"2001","unstructured":"Anderson W.W.; Collingridge G.L.; The LTP Program: A data acquisition program for on-line analysis of long-term potentiation and other synaptic events. J Neurosci Methods 2001,108(1),71-83","journal-title":"J Neurosci Methods"},{"key":"ref=726","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1038\/sj.npp.1301375","volume":"32","author":"Carriba P.","year":"2007","unstructured":"Carriba P.; Ortiz O.; Patkar K.; Justinova Z.; Stroik J.; Themann A.; Müller C.; Woods A.S.; Hope B.T.; Ciruela F.; Casadó V.; Canela E.I.; Lluis C.; Goldberg S.R.; Moratalla R.; Franco R.; Ferré S.; Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology 2007,32(11),2249-2259","journal-title":"Neuropsychopharmacology"},{"key":"ref=727","first-page":"56","volume":"276","author":"Rodríguez de Fonseca F.","year":"1996","unstructured":"Rodríguez de Fonseca F.; Rubio P.; Menzaghi F.; Merlo-Pich E.; Rivier J.; Koob G.F.; Navarro M.; Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J Pharmacol Exp Ther 1996,276(1),56-64","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=728","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2174\/1568007033482670","volume":"2","author":"Castellano C.","year":"2003","unstructured":"Castellano C.; Rossi-Arnaud C.; Cestari V.; Costanzi M.; Cannabinoids and memory: Animal studies. Curr Drug Targets CNS Neurol Disord 2003,2(6),389-402","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"ref=729","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1369-1600.2008.00104.x","volume":"13","author":"Moreira F.A.","year":"2008","unstructured":"Moreira F.A.; Lutz B.; The endocannabinoid system: emotion, learning and addiction. Addict Biol 2008,13(2),196-212","journal-title":"Addict Biol"},{"key":"ref=730","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2011.02.035","volume":"181","author":"Maldonado R.","year":"2011","unstructured":"Maldonado R.; Berrendero F.; Ozaita A.; Robledo P.; Neurochemical basis of cannabis addiction. Neuroscience 2011,181,1-17","journal-title":"Neuroscience"},{"key":"ref=731","doi-asserted-by":"publisher","first-page":"e1002194","DOI":"10.1371\/journal.pbio.1002194","volume":"13","author":"Viñals X.","year":"2015","unstructured":"Viñals X.; Moreno E.; Lanfumey L.; Cordomí A.; Pastor A.; de La Torre R.; Gasperini P.; Navarro G.; Howell L.A.; Pardo L.; Lluís C.; Canela E.I.; McCormick P.J.; Maldonado R.; Robledo P.; Cognitive impairment induced by delta9- tetrahydrocannabinol occurs through heteromers between cannabinoid CB1 and serotonin 5-HT2A receptors. PLoS Biol 2015,13(7),e1002194","journal-title":"PLoS Biol"},{"key":"ref=732","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejphar.2005.04.019","volume":"516","author":"Gorzalka B.B.","year":"2005","unstructured":"Gorzalka B.B.; Hill M.N.; Sun J.C.; Functional role of the endocannabinoid system and AMPA\/kainate receptors in 5-HT2A receptor-mediated wet dog shakes. Eur J Pharmacol 2005,516(1),28-33","journal-title":"Eur J Pharmacol"},{"key":"ref=733","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0091-3057(00)00477-9","volume":"68","author":"Darmani N.A.","year":"2001","unstructured":"Darmani N.A.; Cannabinoids of diverse structure inhibit two DOI-induced 5-HT(2A) receptor-mediated behaviors in mice. Pharmacol Biochem Behav 2001,68(2),311-317","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=734","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0028-3908(98)00208-1","volume":"38","author":"Cheer J.F.","year":"1999","unstructured":"Cheer J.F.; Cadogan A.K.; Marsden C.A.; Fone K.C.F.; Kendall D.A.; Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology 1999,38(4),533-541","journal-title":"Neuropharmacology"},{"key":"ref=735","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1471-4159.2007.04768.x","volume":"103","author":"de Almeida J.","year":"2007","unstructured":"de Almeida J.; Mengod G.; Quantitative analysis of glutamatergic and GABAergic neurons expressing 5-HT(2A) receptors in human and monkey prefrontal cortex. J Neurochem 2007,103(2),475-486","journal-title":"J Neurochem"},{"key":"ref=736","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev-psych-113011-143739","volume":"64","author":"Mechoulam R.","year":"2013","unstructured":"Mechoulam R.; Parker L.A.; The endocannabinoid system and the brain. Annu Rev Psychol 2013,64(1),21-47","journal-title":"Annu Rev Psychol"},{"key":"ref=737","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00221-013-3512-6","volume":"230","author":"Bombardi C.","year":"2013","unstructured":"Bombardi C.; Di Giovanni G.; Functional anatomy of 5-HT2A receptors in the amygdala and hippocampal complex: relevance to memory functions. Exp Brain Res 2013,230(4),427-439","journal-title":"Exp Brain Res"},{"key":"ref=738","doi-asserted-by":"publisher","first-page":"6347","DOI":"10.1007\/s12035-017-0833-7","volume":"55","author":"Galindo L.","year":"2018","unstructured":"Galindo L.; Moreno E.; López-Armenta F.; Guinart D.; Cuenca-Royo A.; Izquierdo-Serra M.; Xicota L.; Fernandez C.; Menoyo E.; Fernández-Fernández J.M.; Benítez-King G.; Canela E.I.; Casadó V.; Pérez V.; de la Torre R.; Robledo P.; Cannabis users show enhanced expression of CB-5HT receptor heteromers in olfactory neuroepithelium cells. Mol Neurobiol 2018,55(8),6347-6361","journal-title":"Mol Neurobiol"},{"key":"ref=739","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.bbrc.2014.08.061","volume":"452","author":"Borroto-Escuela D.O.","year":"2014","unstructured":"Borroto-Escuela D.O.; Narvaez M.; Di Palma M.; Calvo F.; Rodriguez D.; Millon C.; Carlsson J.; Agnati L.F.; Garriga P.; Díaz-Cabiale Z.; Fuxe K.; Preferential activation by galanin 1-15 fragment of the GalR1 protomer of a GalR1-GalR2 heteroreceptor complex. Biochem Biophys Res Commun 2014,452(3),347-353","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=740","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyu064","volume":"18","author":"Millón C.","year":"2015","unstructured":"Millón C.; Flores-Burgess A.; Narváez M.; Borroto-Escuela D.O.; Santín L.; Parrado C.; A role for galanin N-terminal fragment (1-15) in anxiety-and depression-related behaviors in Ra. Int J Neuropsychopharmacol 2015,18(3),1-13","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=741","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fendo.2012.00127","volume":"3","author":"Fuxe K.","year":"2012","unstructured":"Fuxe K.; Borroto-Escuela D.O.; Romero-Fernandez W.; Tarakanov A.O.; Calvo F.; Garriga P.; Tena M.; Narvaez M.; Millón C.; Parrado C.; Ciruela F.; Agnati L.F.; Narvaez J.A.; Díaz-Cabiale Z.; On the existence and function of galanin receptor heteromers in the central nervous system. Front Endocrinol (Lausanne) 2012,3(OCT),127","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=742","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-020-01908-z","volume":"17","author":"Rivas-Santisteban R.","year":"2020","unstructured":"Rivas-Santisteban R.; Rodriguez-Perez A.I.; Muñoz A.; Reyes-Resina I.; Labandeira-García J.L.; Navarro G.; Angiotensin AT1and AT2receptor heteromer expression in the hemilesioned rat model of Parkinson\u2019s disease that increases with levodopa-induced dyskinesia. J Neuroinflammation 2020,17(1),1-16","journal-title":"J Neuroinflammation"},{"key":"ref=743","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/13543784.2017.1371133","volume":"26","author":"Perez-Lloret S.","year":"2017","unstructured":"Perez-Lloret S.; Otero-Losada M.; Toblli J.E.; Capani F.; Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson\u2019s disease. Expert Opin Investig Drugs 2017,26(10),1163-1173","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=744","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.expneurol.2014.08.019","volume":"261","author":"Muñoz A.","year":"2014","unstructured":"Muñoz A.; Garrido-Gil P.; Dominguez-Meijide A.; Labandeira-Garcia J.L.; Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson\u2019s disease. Involvement of vascular endothelial growth factor and interleukin-1β. Exp Neurol 2014,261,720-732","journal-title":"Exp Neurol"},{"key":"ref=745","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0163-7258(03)00038-X","volume":"98","author":"Pin J.P.","year":"2003","unstructured":"Pin J.P.; Galvez T.; Prézeau L.; Evolution, structure, and activation mechanism of family 3\/C G-protein-coupled receptors. Pharmacol Ther 2003,98(3),325-354","journal-title":"Pharmacol Ther"},{"key":"ref=746","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.neuropharm.2010.08.009","volume":"60","author":"Rondard P.","year":"2011","unstructured":"Rondard P.; Goudet C.; Kniazeff J.; Pin J.P.; Prézeau L.; The complexity of their activation mechanism opens new possibilities for the modulation of mGlu and GABAB class C G protein-coupled receptors. Neuropharmacology 2011,60(1),82-92","journal-title":"Neuropharmacology"},{"key":"ref=747","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1124\/pr.109.002501","volume":"63","author":"Urwyler S.","year":"2011","unstructured":"Urwyler S.; Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives. Pharmacol Rev 2011,63(1),59-126","journal-title":"Pharmacol Rev"},{"key":"ref=748","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/aps.2011.186","volume":"33","author":"Chun L.","year":"2012","unstructured":"Chun L.; Zhang W.H.; Liu J.F.; Structure and ligand recognition of class C GPCRs. Acta Pharmacol Sin 2012,33(3),312-323","journal-title":"Acta Pharmacol Sin"},{"key":"ref=749","doi-asserted-by":"publisher","first-page":"12154","DOI":"10.1074\/jbc.M611071200","volume":"282","author":"Binet V.","year":"2007","unstructured":"Binet V.; Duthey B.; Lecaillon J.; Vol C.; Quoyer J.; Labesse G.; Pin J.P.; Prézeau L.; Common structural requirements for heptahelical domain function in class A and class C G protein-coupled receptors. J Biol Chem 2007,282(16),12154-12163","journal-title":"J Biol Chem"},{"key":"ref=750","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/35039564","volume":"407","author":"Kunishima N.","year":"2000","unstructured":"Kunishima N.; Shimada Y.; Tsuji Y.; Sato T.; Yamamoto M.; Kumasaka T.; Nakanishi S.; Jingami H.; Morikawa K.; Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 2000,407(6807),971-977","journal-title":"Nature"},{"key":"ref=751","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1073\/pnas.052708599","volume":"99","author":"Tsuchiya D.","year":"2002","unstructured":"Tsuchiya D.; Kunishima N.; Kamiya N.; Jingami H.; Morikawa K.; Structural views of the ligand-binding cores of a metabotropic glutamate receptor complexed with an antagonist and both glutamate and Gd3+. Proc Natl Acad Sci USA 2002,99(5),2660-2665","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=752","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.tips.2008.10.006","volume":"30","author":"Conn P.J.","year":"2009","unstructured":"Conn P.J.; Lindsley C.W.; Jones C.K.; Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci 2009,30(1),25-31","journal-title":"Trends Pharmacol Sci"},{"key":"ref=753","doi-asserted-by":"publisher","first-page":"11097","DOI":"10.1073\/pnas.162138699","volume":"99","author":"Bessis A-S.","year":"2002","unstructured":"Bessis A-S.; Rondard P.; Gaven F.; Brabet I.; Triballeau N.; Prezeau L.; Acher F.; Pin J.P.; Closure of the Venus flytrap module of mGlu8 receptor and the activation process: Insights from mutations converting antagonists into agonists. Proc Natl Acad Sci USA 2002,99(17),11097-11102","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=754","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1124\/mol.59.1.46","volume":"59","author":"Romano C.","year":"2001","unstructured":"Romano C.; Miller J.K.; Hyrc K.; Dikranian S.; Mennerick S.; Takeuchi Y.; Goldberg M.P.; O\u2019Malley K.L.; Covalent and noncovalent interactions mediate metabotropic glutamate receptor mGlu5 dimerization. Mol Pharmacol 2001,59(1),46-53","journal-title":"Mol Pharmacol"},{"key":"ref=755","doi-asserted-by":"publisher","first-page":"28144","DOI":"10.1074\/jbc.M003226200","volume":"275","author":"Tsuji Y.","year":"2000","unstructured":"Tsuji Y.; Shimada Y.; Takeshita T.; Kajimura N.; Nomura S.; Sekiyama N.; Otomo J.; Usukura J.; Nakanishi S.; Jingami H.; Cryptic dimer interface and domain organization of the extracellular region of metabotropic glutamate receptor subtype 1. J Biol Chem 2000,275(36),28144-28151","journal-title":"J Biol Chem"},{"key":"ref=756","doi-asserted-by":"publisher","first-page":"34245","DOI":"10.1074\/jbc.M005581200","volume":"275","author":"Ray K.","year":"2000","unstructured":"Ray K.; Hauschild B.C.; Cys-140 is critical for metabotropic glutamate receptor-1 dimerization. J Biol Chem 2000,275(44),34245-34251","journal-title":"J Biol Chem"},{"key":"ref=757","doi-asserted-by":"publisher","first-page":"27642","DOI":"10.1074\/jbc.274.39.27642","volume":"274","author":"Ray K.","year":"1999","unstructured":"Ray K.; Hauschild B.C.; Steinbach P.J.; Goldsmith P.K.; Hauache O.; Spiegel A.M.; Identification of the cysteine residues in the amino-terminal extracellular domain of the human Ca(2+) receptor critical for dimerization. Implications for function of monomeric Ca(2+) receptor. J Biol Chem 1999,274(39),27642-27650","journal-title":"J Biol Chem"},{"key":"ref=758","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1073\/pnas.0611577104","volume":"104","author":"Muto T.","year":"2007","unstructured":"Muto T.; Tsuchiya D.; Morikawa K.; Jingami H.; Structures of the extracellular regions of the group II\/III metabotropic glutamate receptors. Proc Natl Acad Sci USA 2007,104(10),3759-3764","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=759","doi-asserted-by":"publisher","first-page":"24653","DOI":"10.1074\/jbc.M602277200","volume":"281","author":"Rondard P.","year":"2006","unstructured":"Rondard P.; Liu J.; Huang S.; Malhaire F.; Vol C.; Pinault A.; Labesse G.; Pin J.P.; Coupling of agonist binding to effector domain activation in metabotropic glutamate-like receptors. J Biol Chem 2006,281(34),24653-24661","journal-title":"J Biol Chem"},{"key":"ref=760","doi-asserted-by":"publisher","first-page":"16382","DOI":"10.1074\/jbc.M000277200","volume":"275","author":"Hu J.","year":"2000","unstructured":"Hu J.; Hauache O.; Spiegel A.M.; Human Ca2+ receptor cysteine-rich domain. Analysis of function of mutant and chimeric receptors. J Biol Chem 2000,275(21),16382-16389","journal-title":"J Biol Chem"},{"key":"ref=761","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/ncpendmet0388","volume":"3","author":"Brown E.M.","year":"2007","unstructured":"Brown E.M.; Clinical lessons from the calcium-sensing receptor. Nat Clin Pract Endocrinol Metab 2007,3(2),122-133","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"ref=762","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/BOR.0b013e32832cbc2a","volume":"21","author":"Deal C.","year":"2009","unstructured":"Deal C.; Future therapeutic targets in osteoporosis. Curr Opin Rheumatol 2009,21(4),380-385","journal-title":"Curr Opin Rheumatol"},{"key":"ref=763","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.ecl.2009.01.001","volume":"38","author":"Brown E.M.","year":"2009","unstructured":"Brown E.M.; Anti-parathyroid and anti-calcium sensing receptor antibodies in autoimmune hypoparathyroidism. Endocrinol Metab Clin North Am x2009,38(2),437-445","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref=764","first-page":"827","volume":"6","author":"Burger A.","year":"1963","unstructured":"Burger A.; Progress in Medicinal Chemistry. J Med Chem 1963,6(6),827","journal-title":"J Med Chem"},{"key":"ref=765","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41586-021-03691-0","volume":"595","author":"Gao Y.","year":"2021","unstructured":"Gao Y.; Robertson M.J.; Rahman S.N.; Seven A.B.; Zhang C.; Meyerowitz J.G.; Panova O.; Hannan F.M.; Thakker R.V.; Bräuner-Osborne H.; Mathiesen J.M.; Skiniotis G.; Asymmetric activation of the calcium-sensing receptor homodimer. Nature 2021,595(7867),455-459","journal-title":"Nature"},{"key":"ref=766","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ceca.2003.10.008","author":"Yano S.","year":"2004","unstructured":"Yano S.; Brown E.M.; Chattopadhyay N.; Calcium-sensing receptor in the brain 2004,257-264","journal-title":"Calcium-sensing receptor in the brain"},{"key":"ref=767","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.3390\/molecules24142546","volume":"24","author":"Giudice M.L.","year":"2019","unstructured":"Giudice M.L.; Mihalik B.; Dinnyés A.; Kobolák J.; The nervous system relevance of the calcium sensing receptor in health and disease. Molecules 2019,24(14),2546","journal-title":"Molecules"},{"key":"ref=768","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0896-6273(00)80510-3","volume":"21","author":"Berridge M.J.","year":"1998","unstructured":"Berridge M.J.; Neuronal calcium signaling. Neuron 1998,21(1),13-26","journal-title":"Neuron"},{"key":"ref=769","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a035212","volume":"12","author":"Schrank S.","year":"2020","unstructured":"Schrank S.; Barrington N.; Stutzmann G.E.; Calcium-handling defects and neurodegenerative disease. Cold Spring Harb Perspect Biol 2020,12(7),1-25","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=770","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3389\/fphar.2012.00061","volume":"3","author":"Kawamoto E.M.","year":"2012","unstructured":"Kawamoto E.M.; Vivar C.; Camandola S.; Physiology and pathology of calcium signaling in the brain. Front Pharmacol 2012,3,61","journal-title":"Front Pharmacol"},{"key":"ref=771","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/0197-4580(87)90073-X","volume":"8","author":"Khachaturian Z.S.","year":"1987","unstructured":"Khachaturian Z.S.; Hypothesis on the regulation of cytosol calcium concentration and the aging brain. Neurobiol Aging 1987,8(4),345-346","journal-title":"Neurobiol Aging"},{"key":"ref=772","doi-asserted-by":"publisher","first-page":"pp. 154-175","DOI":"10.1111\/j.1749-6632.1999.tb07824.x","author":"Mattson M.P.","year":"1999","unstructured":"Mattson M.P.; Pedersen W.A.; Duan W.; Culmsee C.; Camandola S.; In: Annals of the New York Academy of Sciences, 1999,pp. 154-175","journal-title":"In: Annals of the New York Academy of Sciences,"},{"key":"ref=773","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.bbrc.2016.08.168","volume":"483","author":"Surmeier D.J.","year":"2017","unstructured":"Surmeier D.J.; Schumacker P.T.; Guzman J.D.; Ilijic E.; Yang B.; Zampese E.; Calcium and Parkinson\u2019s disease. Biochem Biophys Res Commun 2017,483(4),1013-1019","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=774","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.1523\/JNEUROSCI.0739-06.2006","volume":"26","author":"Stutzmann G.E.","year":"2006","unstructured":"Stutzmann G.E.; Smith I.; Caccamo A.; Oddo S.; Laferla F.M.; Parker I.; Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer\u2019s disease mice. J Neurosci 2006,26(19),5180-5189","journal-title":"J Neurosci"},{"key":"ref=775","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ceca.2017.06.008","volume":"70","author":"Pchitskaya E.","year":"2018","unstructured":"Pchitskaya E.; Popugaeva E.; Bezprozvanny I.; Calcium signaling and molecular mechanisms underlying neurodegenerative diseases. Cell Calcium 2018,70,87-94","journal-title":"Cell Calcium"},{"key":"ref=776","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.pharmthera.2006.03.006","volume":"110","author":"Bettler B.","year":"2006","unstructured":"Bettler B.; Tiao J.Y.H.; Molecular diversity, trafficking and subcellular localization of GABAB receptors. Pharmacol Ther 2006,110(3),533-543","journal-title":"Pharmacol Ther"},{"key":"ref=777","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0304-3940(03)00242-8","volume":"342","author":"Sakamaki K.","year":"2003","unstructured":"Sakamaki K.; Nomura M.; Hatakenaka S.; Miyakubo H.; Tanaka J.; GABAergic modulation of noradrenaline release in the median preoptic nucleus area in the rat. Neurosci Lett 2003,342(1-2),77-80","journal-title":"Neurosci Lett"},{"key":"ref=778","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00702-008-0095-7","volume":"115","author":"Waldmeier P.C.","year":"2008","unstructured":"Waldmeier P.C.; Kaupmann K.; Urwyler S.; Roles of GABAB receptor subtypes in presynaptic auto- and heteroreceptor function regulating GABA and glutamate release. J Neural Transm (Vienna) 2008,115(10),1401-1411","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=779","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/25348","volume":"396","author":"Jones K.A.","year":"1998","unstructured":"Jones K.A.; Borowsky B.; Tamm J.A.; Craig D.A.; Durkin M.M.; Dai M.; Yao W.J.; Johnson M.; Gunwaldsen C.; Huang L.Y.; Tang C.; Shen Q.; Salon J.A.; Morse K.; Laz T.; Smith K.E.; Nagarathnam D.; Noble S.A.; Branchek T.A.; Gerald C.; GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature 1998,396(6712),674-679","journal-title":"Nature"},{"key":"ref=780","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/25360","volume":"396","author":"Kaupmann K.","year":"1998","unstructured":"Kaupmann K.; Malitschek B.; Schuler V.; Heid J.; Froestl W.; Beck P.; Mosbacher J.; Bischoff S.; Kulik A.; Shigemoto R.; Karschin A.; Bettler B.; GABA(B)-receptor subtypes assemble into functional heteromeric complexes. Nature 1998,396(6712),683-687","journal-title":"Nature"},{"key":"ref=781","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.schres.2010.12.025","volume":"128","author":"Fatemi S.H.","year":"2011","unstructured":"Fatemi S.H.; Folsom T.D.; Thuras P.D.; Deficits in GABA(B) receptor system in schizophrenia and mood disorders: A postmortem study. Schizophr Res 2011,128(1-3),37-43","journal-title":"Schizophr Res"},{"key":"ref=782","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ejphar.2003.08.006","volume":"478","author":"Nyitrai G.","year":"2003","unstructured":"Nyitrai G.; Kékesi K.A.; Emri Z.; Szárics E.; Juhász G.; Kardos J.; \nGABA(B) receptor antagonist CGP-36742 enhances somatostatin release in the rat hippocampus \nin vivo\nand \nin vitro\n.\n Eur J Pharmacol 2003,478(2-3),111-119","journal-title":"Eur J Pharmacol"},{"key":"ref=783","doi-asserted-by":"publisher","first-page":"13362","DOI":"10.1074\/jbc.274.19.13362","volume":"274","author":"Galvez T.","year":"1999","unstructured":"Galvez T.; Parmentier M.L.; Joly C.; Malitschek B.; Kaupmann K.; Kuhn R.; Bittiger H.; Froestl W.; Bettler B.; Pin J.P.; Mutagenesis and modeling of the GABAB receptor extracellular domain support a venus flytrap mechanism for ligand binding. J Biol Chem 1999,274(19),13362-13369","journal-title":"J Biol Chem"},{"key":"ref=784","doi-asserted-by":"publisher","first-page":"14649","DOI":"10.1073\/pnas.251554498","volume":"98","author":"Margeta-Mitrovic M.","year":"2001","unstructured":"Margeta-Mitrovic M.; Jan Y.N.; Jan L.Y.; Function of GB1 and GB2 subunits in G protein coupling of GABA(B) receptors. Proc Natl Acad Sci USA 2001,98(25),14649-14654","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=785","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s12035-014-8736-3","volume":"50","year":"2014","unstructured":"Li C jun, Lu Y, Zhou M, Zong X gang, Li C, Xu X lin. Activation of GABAB receptors ameliorates cognitive impairment via restoring the balance of HCN1\/HCN2 surface expression in the hippocampal CA1 area in rats with chronic cerebral hypoperfusion. Mol Neurobiol 2014,50(2),704-720","journal-title":"Mol Neurobiol"},{"key":"ref=786","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.neuron.2006.12.015","volume":"53","author":"Kuramoto N.","year":"2007","unstructured":"Kuramoto N.; Wilkins M.E.; Fairfax B.P.; Revilla-Sanchez R.; Terunuma M.; Tamaki K.; Iemata M.; Warren N.; Couve A.; Calver A.; Horvath Z.; Freeman K.; Carling D.; Huang L.; Gonzales C.; Cooper E.; Smart T.G.; Pangalos M.N.; Moss S.J.; Phospho-dependent functional modulation of GABA(B) receptors by the metabolic sensor AMP-dependent protein kinase. Neuron 2007,53(2),233-247","journal-title":"Neuron"},{"key":"ref=787","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/jnr.20674","volume":"82","author":"Dave K.R.","year":"2005","unstructured":"Dave K.R.; Lange-Asschenfeldt C.; Raval A.P.; Prado R.; Busto R.; Saul I.; Pérez-Pinzón M.A.; Ischemic preconditioning ameliorates excitotoxicity by shifting glutamate\/γ-aminobutyric acid release and biosynthesis. J Neurosci Res 2005,82(5),665-673","journal-title":"J Neurosci Res"},{"key":"ref=788","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1523\/JNEUROSCI.2343-09.2010","volume":"30","author":"Tu H.","year":"2010","unstructured":"Tu H.; Xu C.; Zhang W.; Liu Q.; Rondard P.; Pin J.P.; Liu J.; \nGABAB receptor activation protects neurons from apoptosis\nvia \nIGF-1 receptor transactivation.\n J Neurosci 2010,30(2),749-759","journal-title":"J Neurosci"},{"key":"ref=789","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.tips.2004.11.004","volume":"26","author":"Cryan J.F.","year":"2005","unstructured":"Cryan J.F.; Kaupmann K.; Don\u2019t worry \u2018B\u2019 happy!: A role for GABA(B) receptors in anxiety and depression. Trends Pharmacol Sci 2005,26(1),36-43","journal-title":"Trends Pharmacol Sci"},{"key":"ref=790","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.coph.2005.10.002","volume":"6","author":"Bowery N.G.","year":"2006","unstructured":"Bowery N.G.; GABAB receptor: A site of therapeutic benefit. Curr Opin Pharmacol 2006,6(1),37-43","journal-title":"Curr Opin Pharmacol"},{"key":"ref=791","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.brainresrev.2008.12.007","volume":"60","author":"Goudet C.","year":"2009","unstructured":"Goudet C.; Magnaghi V.; Landry M.; Nagy F.; Gereau R.W.; Pin J.P.; Metabotropic receptors for glutamate and GABA in pain. Brain Res Brain Res Rev 2009,60(1),43-56","journal-title":"Brain Res Brain Res Rev"},{"key":"ref=792","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.3390\/cells10051228","volume":"10","author":"Boczek T.","year":"2021","unstructured":"Boczek T.; Mackiewicz J.; Sobolczyk M.; Wawrzyniak J.; Lisek M.; Ferenc B.; Guo F.; Zylinska L.; The role of G protein-coupled receptors (GPCRs) and calcium signaling in schizophrenia. focus on GPCRs activated by neurotransmitters and chemokines. Cells 2021,10(5),1228","journal-title":"Cells"},{"key":"ref=793","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1146\/annurev.pharmtox.011008.145533","volume":"50","author":"Niswender C.M.","year":"2010","unstructured":"Niswender C.M.; Conn P.J.; Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 2010,50(1),295-322","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=794","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1146\/annurev.pharmtox.37.1.205","volume":"37","author":"Conn P.J.","year":"1997","unstructured":"Conn P.J.; Pin J-P.; Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997,37(1),205-237","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=795","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.neuropharm.2010.10.022","volume":"60","author":"Nicoletti F.","year":"2011","unstructured":"Nicoletti F.; Bockaert J.; Collingridge G.L.; Conn P.J.; Ferraguti F.; Schoepp D.D.; Wroblewski J.T.; Pin J.P.; Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology 2011,60(7-8),1017-1041","journal-title":"Neuropharmacology"},{"key":"ref=796","doi-asserted-by":"publisher","first-page":"694","DOI":"10.2174\/1567205011666140812115423","volume":"11","author":"Iyer A.M.","year":"2014","unstructured":"Iyer A.M.; van Scheppingen J.; Milenkovic I.; Anink J.J.; Lim D.; Genazzani A.A.; Adle-Biassette H.; Kovacs G.G.; Aronica E.; Metabotropic glutamate receptor 5 in Down\u2019s syndrome hippocampus during development: increased expression in astrocytes. Curr Alzheimer Res 2014,11(7),694-705","journal-title":"Curr Alzheimer Res"},{"key":"ref=797","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3389\/fnmol.2018.00414","volume":"11","author":"Spampinato S.F.","year":"2018","unstructured":"Spampinato S.F.; Copani A.; Nicoletti F.; Sortino M.A.; Caraci F.; Metabotropic glutamate receptors in glial cells: A new potential target for neuroprotection? Front Mol Neurosci 2018,11,414","journal-title":"Front Mol Neurosci"},{"key":"ref=798","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.neuroscience.2013.08.054","volume":"253","author":"Chen X.","year":"2013","unstructured":"Chen X.; Lin R.; Chang L.; Xu S.; Wei X.; Zhang J.; Wang C.; Anwyl R.; Wang Q.; Enhancement of long-term depression by soluble amyloid β protein in rat hippocampus is mediated by metabotropic glutamate receptor and involves activation of p38MAPK, STEP and caspase-3. Neuroscience 2013,253,435-443","journal-title":"Neuroscience"},{"key":"ref=799","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.neuron.2010.04.029","volume":"66","author":"Renner M.","year":"2010","unstructured":"Renner M.; Lacor P.N.; Velasco P.T.; Xu J.; Contractor A.; Klein W.L.; Triller A.; Deleterious effects of amyloid β oligomers acting as an extracellular scaffold for mGluR5. Neuron 2010,66(5),739-754","journal-title":"Neuron"},{"key":"ref=800","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1124\/mol.110.067488","volume":"79","author":"Caraci F.","year":"2011","unstructured":"Caraci F.; Molinaro G.; Battaglia G.; Giuffrida M.L.; Riozzi B.; Traficante A.; Bruno V.; Cannella M.; Merlo S.; Wang X.; Heinz B.A.; Nisenbaum E.S.; Britton T.C.; Drago F.; Sortino M.A.; Copani A.; Nicoletti F.; Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer\u2019s disease: selective activation of mGlu2 receptors amplifies β-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective. Mol Pharmacol 2011,79(3),618-626","journal-title":"Mol Pharmacol"},{"key":"ref=801","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/25354","volume":"396","author":"White J.H.","year":"1998","unstructured":"White J.H.; Wise A.; Main M.J.; Green A.; Fraser N.J.; Disney G.H.; Barnes A.A.; Emson P.; Foord S.M.; Marshall F.H.; Heterodimerization is required for the formation of a functional GABA(B) receptor. Nature 1998,396(6712),679-682","journal-title":"Nature"},{"key":"ref=802","doi-asserted-by":"publisher","first-page":"92-101","DOI":"10.1016\/j.neuropharm.2017.12.042","volume":"136","author":"Stewart G.D.","year":"2018","unstructured":"Stewart G.D.; Comps-Agrar L.; Nørskov-Lauritsen L.B.; Pin J.P.; Kniazeff J.; Allosteric interactions between GABAB1 subunits control orthosteric binding sites occupancy within GABAB oligomers. Neuropharmacology 2018,136((Pt A)),92-101","journal-title":"Neuropharmacology"},{"key":"ref=803","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.mce.2019.02.019","volume":"486","author":"Pin J.P.","year":"2019","unstructured":"Pin J.P.; Kniazeff J.; Prézeau L.; Liu J.F.; Rondard P.; GPCR interaction as a possible way for allosteric control between receptors. Mol Cell Endocrinol 2019,486,89-95","journal-title":"Mol Cell Endocrinol"},{"key":"ref=804","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41586-019-0881-4","volume":"566","author":"Koehl A.","year":"2019","unstructured":"Koehl A.; Hu H.; Feng D.; Sun B.; Zhang Y.; Robertson M.J.; Chu M.; Kobilka T.S.; Laeremans T.; Steyaert J.; Tarrasch J.; Dutta S.; Fonseca R.; Weis W.I.; Mathiesen J.M.; Skiniotis G.; Kobilka B.K.; Structural insights into the activation of metabotropic glutamate receptors. Nature 2019,566(7742),79-84","journal-title":"Nature"},{"key":"ref=805","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.tibs.2020.07.008","volume":"45","author":"Ellaithy A.","year":"2020","unstructured":"Ellaithy A.; Gonzalez-Maeso J.; Logothetis D.A.; Levitz J.; Structural and biophysical mechanisms of class C G protein-coupled receptor function. Trends Biochem Sci 2020,45(12),1049-1064","journal-title":"Trends Biochem Sci"},{"key":"ref=806","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1523\/JNEUROSCI.21-04-01189.2001","volume":"21","author":"Pagano A.","year":"2001","unstructured":"Pagano A.; Rovelli G.; Mosbacher J.; Lohmann T.; Duthey B.; Stauffer D.; Ristig D.; Schuler V.; Meigel I.; Lampert C.; Stein T.; Prezeau L.; Blahos J.; Pin J.; Froestl W.; Kuhn R.; Heid J.; Kaupmann K.; Bettler B.; C-terminal interaction is essential for surface trafficking but not for heteromeric assembly of GABA(b) receptors. J Neurosci 2001,21(4),1189-1202","journal-title":"J Neurosci"},{"key":"ref=807","doi-asserted-by":"publisher","first-page":"26361","DOI":"10.1074\/jbc.273.41.26361","volume":"273","author":"Couve A.","year":"1998","unstructured":"Couve A.; Filippov A.K.; Connolly C.N.; Bettler B.; Brown D.A.; Moss S.J.; Intracellular retention of recombinant GABAB receptors. J Biol Chem 1998,273(41),26361-26367","journal-title":"J Biol Chem"},{"key":"ref=808","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1074\/jbc.M108900200","volume":"277","author":"Duthey B.","year":"2002","unstructured":"Duthey B.; Caudron S.; Perroy J.; Bettler B.; Fagni L.; Pin J.P.; Prézeau L.; A single subunit (GB2) is required for G-protein activation by the heterodimeric GABA(B) receptor. J Biol Chem 2002,277(5),3236-3241","journal-title":"J Biol Chem"},{"key":"ref=809","doi-asserted-by":"publisher","first-page":"8043","DOI":"10.1523\/JNEUROSCI.21-20-08043.2001","volume":"21","author":"Robbins M.J.","year":"2001","unstructured":"Robbins M.J.; Calver A.R.; Filippov A.K.; Hirst W.D.; Russell R.B.; Wood M.D.; Nasir S.; Couve A.; Brown D.A.; Moss S.J.; Pangalos M.N.; GABA(B2) is essential for g-protein coupling of the GABA(B) receptor heterodimer. J Neurosci 2001,21(20),8043-8052","journal-title":"J Neurosci"},{"key":"ref=810","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1093\/emboj\/20.9.2152","volume":"20","author":"Galvez T.","year":"2001","unstructured":"Galvez T.; Duthey B.; Kniazeff J.; Blahos J.; Rovelli G.; Bettler B.; Prézeau L.; Pin J.P.; Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA(B) receptor function. EMBO J 2001,20(9),2152-2159","journal-title":"EMBO J"},{"key":"ref=811","doi-asserted-by":"publisher","first-page":"14643","DOI":"10.1073\/pnas.251554798","volume":"98","author":"Margeta-Mitrovic M.","year":"2001","unstructured":"Margeta-Mitrovic M.; Jan Y.N.; Jan L.Y.; Ligand-induced signal transduction within heterodimeric GABA(B) receptor. Proc Natl Acad Sci USA 2001,98(25),14643-14648","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=812","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/bcpt.13241","volume":"126","author":"Fritzius T.","year":"2020","unstructured":"Fritzius T.; Bettler B.; The organizing principle of GABA receptor complexes: Physiological and pharmacological implications. Basic Clin Pharmacol Toxicol 2020,126(S6)(Suppl. 6),25-34","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=813","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.bcp.2013.09.016","volume":"86","author":"Benke D.","year":"2013","unstructured":"Benke D.; GABAB receptor trafficking and interacting proteins: targets for the development of highly specific therapeutic strategies to treat neurological disorders? Biochem Pharmacol 2013,86(11),1525-1530","journal-title":"Biochem Pharmacol"},{"key":"ref=814","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1073\/pnas.1205798110","volume":"110","author":"Calebiro D.","year":"2013","unstructured":"Calebiro D.; Rieken F.; Wagner J.; Sungkaworn T.; Zabel U.; Borzi A.; Cocucci E.; Zürn A.; Lohse M.J.; Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization. Proc Natl Acad Sci USA 2013,110(2),743-748","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=815","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1021\/acschemneuro.0c00254","volume":"11","author":"Kent C.N.","year":"2020","unstructured":"Kent C.N.; Park C.; Lindsley C.W.; Classics in Chemical Neuroscience: Baclofen. ACS Chem Neurosci 2020,11(12),1740-1755","journal-title":"ACS Chem Neurosci"},{"key":"ref=816","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S2215-0366(18)30303-1","volume":"5","author":"Agabio R.","year":"2018","unstructured":"Agabio R.; Sinclair J.M.; Addolorato G.; Aubin H-J.; Beraha E.M.; Caputo F.; Chick J.D.; de La Selle P.; Franchitto N.; Garbutt J.C.; Haber P.S.; Heydtmann M.; Jaury P.; Lingford-Hughes A.R.; Morley K.C.; Müller C.A.; Owens L.; Pastor A.; Paterson L.M.; Pélissier F.; Rolland B.; Stafford A.; Thompson A.; van den Brink W.; de Beaurepaire R.; Leggio L.; Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry 2018,5(12),957-960","journal-title":"Lancet Psychiatry"},{"key":"ref=817","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1111\/j.1742-4658.2005.04728.x","volume":"272","author":"Pin J-P.","year":"2005","unstructured":"Pin J-P.; Kniazeff J.; Liu J.; Binet V.; Goudet C.; Rondard P.; Prézeau L.; Allosteric functioning of dimeric class C G-protein-coupled receptors. FEBS J 2005,272(12),2947-2955","journal-title":"FEBS J"},{"key":"ref=818","doi-asserted-by":"publisher","first-page":"16342","DOI":"10.1073\/pnas.1205838109","volume":"109","author":"El Moustaine D.","year":"2012","unstructured":"El Moustaine D.; Granier S.; Doumazane E.; Scholler P.; Rahmeh R.; Bron P.; Mouillac B.; Banères J.L.; Rondard P.; Pin J.P.; Distinct roles of metabotropic glutamate receptor dimerization in agonist activation and G-protein coupling. Proc Natl Acad Sci USA 2012,109(40),16342-16347","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=819","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1093\/hmg\/ddy264","volume":"27","author":"Morató X.","year":"2018","unstructured":"Morató X.; Luján R.; Gonçalves N.; Watanabe M.; Altafaj X.; Carvalho A.L.; Fernández-Dueñas V.; Cunha R.A.; Ciruela F.; Metabotropic glutamate type 5 receptor requires contactin-associated protein 1 to control memory formation. Hum Mol Genet 2018,27(20),3528-3541","journal-title":"Hum Mol Genet"},{"key":"ref=820","doi-asserted-by":"publisher","first-page":"14793","DOI":"10.1523\/JNEUROSCI.2038-14.2014","volume":"34","author":"García-Negredo G.","year":"2014","unstructured":"García-Negredo G.; Soto D.; Llorente J.; Morató X.; Galenkamp K.M.O.; Gómez-Soler M.; Fernández-Dueñas V.; Watanabe M.; Adelman J.P.; Shigemoto R.; Fukazawa Y.; Luján R.; Ciruela F.; Coassembly and coupling of SK2 channels and mGlu5 receptors. J Neurosci 2014,34(44),14793-14802","journal-title":"J Neurosci"},{"key":"ref=821","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/S0166-2236(99)01492-7","volume":"23","author":"Fagni L.","year":"2000","unstructured":"Fagni L.; Chavis P.; Ango F.; Bockaert J.; Complex interactions between mGluRs, intracellular Ca2+ stores and ion channels in neurons. Trends Neurosci 2000,23(2),80-88","journal-title":"Trends Neurosci"},{"key":"ref=822","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/j.1471-4159.2009.06348.x","volume":"111","author":"Canela L.","year":"2009","unstructured":"Canela L.; Fernández-Dueñas V.; Albergaria C.; Watanabe M.; Lluís C.; Mallol J.; Canela E.I.; Franco R.; Luján R.; Ciruela F.; The association of metabotropic glutamate receptor type 5 with the neuronal Ca-binding protein 2 modulates receptor function. J Neurochem 2009,111(2),555-567","journal-title":"J Neurochem"},{"key":"ref=823","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev.pharmtox.010909.105705","volume":"50","author":"Bockaert J.","year":"2010","unstructured":"Bockaert J.; Perroy J.; Bécamel C.; Marin P.; Fagni L.; GPCR interacting proteins (GIPs) in the nervous system: Roles in physiology and pathologies. Annu Rev Pharmacol Toxicol 2010,50(1),89-109","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=824","doi-asserted-by":"publisher","first-page":"24380","DOI":"10.1074\/jbc.M502642200","volume":"280","author":"Goudet C.","year":"2005","unstructured":"Goudet C.; Kniazeff J.; Hlavackova V.; Malhaire F.; Maurel D.; Acher F.; Blahos J.; Prézeau L.; Pin J.P.; Asymmetric functioning of dimeric metabotropic glutamate receptors disclosed by positive allosteric modulators. J Biol Chem 2005,280(26),24380-24385","journal-title":"J Biol Chem"},{"key":"ref=825","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1124\/mol.112.078501","volume":"82","author":"Kammermeier P.J.","year":"2012","unstructured":"Kammermeier P.J.; Functional and pharmacological characteristics of metabotropic glutamate receptors 2\/4 heterodimers. Mol Pharmacol 2012,82(3),438-447","journal-title":"Mol Pharmacol"},{"key":"ref=826","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1002\/pmic.201500400","volume":"16","author":"Pandya N.J.","year":"2016","unstructured":"Pandya N.J.; Klaassen R.V.; van der Schors R.C.; Slotman J.A.; Houtsmuller A.; Smit A.B.; Li K.W.; Group 1 metabotropic glutamate receptors 1 and 5 form a protein complex in mouse hippocampus and cortex. Proteomics 2016,16(20),2698-2705","journal-title":"Proteomics"},{"key":"ref=827","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cell.2009.01.050","volume":"137","author":"Hayashi M.K.","year":"2009","unstructured":"Hayashi M.K.; Tang C.; Verpelli C.; Narayanan R.; Stearns M.H.; Xu R.M.; Li H.; Sala C.; Hayashi Y.; The postsynaptic density proteins Homer and Shank form a polymeric network structure. Cell 2009,137(1),159-171","journal-title":"Cell"},{"key":"ref=828","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1124\/mol.114.094763","volume":"86","author":"Jong Y-J.I.","year":"2014","unstructured":"Jong Y-J.I.; Sergin I.; Purgert C.A.; O\u2019Malley K.L.; Location-dependent signaling of the group 1 metabotropic glutamate receptor mGlu5. Mol Pharmacol 2014,86(6),774-785","journal-title":"Mol Pharmacol"},{"key":"ref=829","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.1038\/sj.emboj.7601449","volume":"25","author":"Damian M.","year":"2006","unstructured":"Damian M.; Martin A.; Mesnier D.; Pin J.P.; Banères J.L.; Asymmetric conformational changes in a GPCR dimer controlled by G-proteins. EMBO J 2006,25(24),5693-5702","journal-title":"EMBO J"},{"key":"ref=830","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nchembio.396","volume":"6","author":"Albizu L.","year":"2010","unstructured":"Albizu L.; Cottet M.; Kralikova M.; Stoev S.; Seyer R.; Brabet I.; Roux T.; Bazin H.; Bourrier E.; Lamarque L.; Breton C.; Rives M.L.; Newman A.; Javitch J.; Trinquet E.; Manning M.; Pin J.P.; Mouillac B.; Durroux T.; Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nat Chem Biol 2010,6(8),587-594","journal-title":"Nat Chem Biol"},{"key":"ref=831","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1172\/JCI126361","volume":"130","author":"Sebastianutto I.","year":"2020","unstructured":"Sebastianutto I.; Goyet E.; Andreoli L.; Font-Ingles J.; Moreno-Delgado D.; Bouquier N.; Jahannault-Talignani C.; Moutin E.; Di Menna L.; Maslava N.; Pin J.P.; Fagni L.; Nicoletti F.; Ango F.; Cenci M.A.; Perroy J.; D1-mGlu5 heteromers mediate noncanonical dopamine signaling in Parkinson\u2019s disease. J Clin Invest 2020,130(3),1168-1184","journal-title":"J Clin Invest"},{"key":"ref=832","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.conb.2014.07.008","volume":"29","author":"Surmeier D.J.","year":"2014","unstructured":"Surmeier D.J.; Graves S.M.; Shen W.; Dopaminergic modulation of striatal networks in health and Parkinson\u2019s disease. Curr Opin Neurobiol 2014,29,109-117","journal-title":"Curr Opin Neurobiol"},{"key":"ref=833","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1042\/BST0380493","volume":"38","author":"Bagetta V.","year":"2010","unstructured":"Bagetta V.; Ghiglieri V.; Sgobio C.; Calabresi P.; Picconi B.; Synaptic dysfunction in Parkinson\u2019s disease. Biochem Soc Trans 2010,38(2),493-497","journal-title":"Biochem Soc Trans"},{"key":"ref=834","doi-asserted-by":"publisher","first-page":"18345","DOI":"10.1074\/jbc.M006960200","volume":"276","author":"Ciruela F.","year":"2001","unstructured":"Ciruela F.; Escriche M.; Burgueño J.; Angulo E.; Casadó V.; Soloviev M.M.; Canela E.I.; Mallol J.; Chan W.Y.; Lluis C.; McIlhinney R.A.; Franco R.; Metabotropic glutamate 1α and adenosine A1 receptors assemble into functionally interacting complexes. J Biol Chem 2001,276(21),18345-18351","journal-title":"J Biol Chem"},{"key":"ref=835","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jphs.2015.06.002","volume":"128","author":"Kamikubo Y.","year":"2015","unstructured":"Kamikubo Y.; Tabata T.; Sakairi H.; Hashimoto Y.; Sakurai T.; Complex formation and functional interaction between adenosine A1 receptor and type-1 metabotropic glutamate receptor. J Pharmacol Sci 2015,128(3),125-130","journal-title":"J Pharmacol Sci"},{"key":"ref=836","doi-asserted-by":"publisher","first-page":"18661","DOI":"10.1523\/JNEUROSCI.5567-12.2013","volume":"33","author":"Kamikubo Y.","year":"2013","unstructured":"Kamikubo Y.; Shimomura T.; Fujita Y.; Tabata T.; Kashiyama T.; Sakurai T.; Fukurotani K.; Kano M.; Functional cooperation of metabotropic adenosine and glutamate receptors regulates postsynaptic plasticity in the cerebellum. J Neurosci 2013,33(47),18661-18671","journal-title":"J Neurosci"},{"key":"ref=837","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0898-6568(01)00235-2","volume":"14","author":"Klinger M.","year":"2002","unstructured":"Klinger M.; Freissmuth M.; Nanoff C.; Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Cell Signal 2002,14(2),99-108","journal-title":"Cell Signal"},{"key":"ref=838","doi-asserted-by":"publisher","first-page":"44301","DOI":"10.1074\/jbc.M112.413161","volume":"287","author":"Moreno J.L.","year":"2012","unstructured":"Moreno J.L.; Muguruza C.; Umali A.; Mortillo S.; Holloway T.; Pilar-Cuéllar F.; Mocci G.; Seto J.; Callado L.F.; Neve R.L.; Milligan G.; Sealfon S.C.; López-Giménez J.F.; Meana J.J.; Benson D.L.; González-Maeso J.; Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A·mGlu2) receptor heteromerization and its psychoactive behavioral function. J Biol Chem 2012,287(53),44301-44319","journal-title":"J Biol Chem"},{"key":"ref=839","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature06612","volume":"452","author":"González-Maeso J.","year":"2008","unstructured":"González-Maeso J.; Ang R.L.; Yuen T.; Chan P.; Weisstaub N.V.; López-Giménez J.F.; Zhou M.; Okawa Y.; Callado L.F.; Milligan G.; Gingrich J.A.; Filizola M.; Meana J.J.; Sealfon S.C.; Identification of a serotonin\/glutamate receptor complex implicated in psychosis. Nature 2008,452(7183),93-97","journal-title":"Nature"},{"key":"ref=840","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","volume":"53","author":"González-Maeso J.","year":"2007","unstructured":"González-Maeso J.; Weisstaub N.V.; Zhou M.; Chan P.; Ivic L.; Ang R.; Lira A.; Bradley-Moore M.; Ge Y.; Zhou Q.; Sealfon S.C.; Gingrich J.A.; Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 2007,53(3),439-452","journal-title":"Neuron"},{"key":"ref=841","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2011.09.055","volume":"147","author":"Fribourg M.","year":"2011","unstructured":"Fribourg M.; Moreno J.L.; Holloway T.; Provasi D.; Baki L.; Mahajan R.; Park G.; Adney S.K.; Hatcher C.; Eltit J.M.; Ruta J.D.; Albizu L.; Li Z.; Umali A.; Shim J.; Fabiato A.; MacKerell A.D.; Brezina V.; Sealfon S.C.; Filizola M.; González-Maeso J.; Logothetis D.E.; Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 2011,147(5),1011-1023","journal-title":"Cell"},{"key":"ref=842","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.neuropharm.2008.12.010","volume":"56","author":"Schröder H.","year":"2009","unstructured":"Schröder H.; Wu D.F.; Seifert A.; Rankovic M.; Schulz S.; Höllt V.; Koch T.; Allosteric modulation of metabotropic glutamate receptor 5 affects phosphorylation, internalization, and desensitization of the micro-opioid receptor. Neuropharmacology 2009,56(4),768-778","journal-title":"Neuropharmacology"},{"key":"ref=843","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/1073858403261077","volume":"10","author":"Neugebauer V.","year":"2004","unstructured":"Neugebauer V.; Li W.; Bird G.C.; Han J.S.; The amygdala and persistent pain. Neuroscientist 2004,10(3),221-234","journal-title":"Neuroscientist"},{"key":"ref=844","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0165-6147(00)01694-1","volume":"22","author":"Spooren W.P.J.M.","year":"2001","unstructured":"Spooren W.P.J.M.; Gasparini F.; Salt T.E.; Kuhn R.; Novel allosteric antagonists shed light on mglu(5) receptors and CNS disorders. Trends Pharmacol Sci 2001,22(7),331-337","journal-title":"Trends Pharmacol Sci"},{"key":"ref=845","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3109\/07853899509031963","volume":"27","author":"Dickenson A.H.","year":"1995","unstructured":"Dickenson A.H.; Central acute pain mechanisms. Ann Med 1995,27(2),223-227","journal-title":"Ann Med"},{"key":"ref=846","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.brainresbull.2005.09.021","volume":"70","author":"Lee H.J.","year":"2006","unstructured":"Lee H.J.; Choi H.S.; Ju J.S.; Bae Y.C.; Kim S.K.; Yoon Y.W.; Ahn D.K.; Peripheral mGluR5 antagonist attenuated craniofacial muscle pain and inflammation but not mGluR1 antagonist in lightly anesthetized rats. Brain Res Bull 2006,70(4-6),378-385","journal-title":"Brain Res Bull"},{"key":"ref=847","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.brainres.2007.10.007","volume":"1187","author":"Gabra B.H.","year":"2008","unstructured":"Gabra B.H.; Smith F.L.; Navarro H.A.; Carroll F.I.; Dewey W.L.; \nmGluR5 antagonists that block calcium mobilization \nin vitro\nalso reverse (S)-3,5-DHPG-induced hyperalgesia and morphine antinociceptive tolerance \nin vivo\n.\n Brain Res 2008,1187(1),58-66","journal-title":"Brain Res"},{"key":"ref=848","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3109\/10799893.2010.506191","volume":"30","author":"Fuxe K.","year":"2010","unstructured":"Fuxe K.; Marcellino D.; Borroto-Escuela D.O.; Frankowska M.; Ferraro L.; Guidolin D.; Ciruela F.; Agnati L.F.; The changing world of G protein-coupled receptors: from monomers to dimers and receptor mosaics with allosteric receptor-receptor interactions. J Recept Signal Transduct 2010,30(5),272-283","journal-title":"J Recept Signal Transduct"},{"key":"ref=849","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3109\/10799893.2010.487492","volume":"30","author":"Agnati L.F.","year":"2010","unstructured":"Agnati L.F.; Guidolin D.; Albertin G.; Trivello E.; Ciruela F.; Genedani S.; Tarakanov A.; Fuxe K.; An integrated view on the role of receptor mosaics at perisynaptic level: focus on adenosine A(2A), dopamine D(2), cannabinoid CB(1), and metabotropic glutamate mGlu(5) receptors. J Recept Signal Transduct 2010,30(5),355-369","journal-title":"J Recept Signal Transduct"},{"key":"ref=850","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3109\/10799891003786226","volume":"30","author":"Agnati L.F.","year":"2010","unstructured":"Agnati L.F.; Guidolin D.; Vilardaga J.P.; Ciruela F.; Fuxe K.; On the expanding terminology in the GPCR field: the meaning of receptor mosaics and receptor heteromers. J Recept Signal Transduct 2010,30(5),287-303","journal-title":"J Recept Signal Transduct"},{"key":"ref=851","first-page":"183","volume":"60","author":"Agnati L.F.","year":"1982","unstructured":"Agnati L.F.; Fuxe K.; Zoli M.; Rondanini C.; Ogren S.O.; New vistas on synaptic plasticity: the receptor mosaic hypothesis of the engram. Med Biol 1982,60(4),183-190","journal-title":"Med Biol"},{"key":"ref=852","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00702-006-0589-0","volume":"114","author":"Fuxe K.","year":"2007","unstructured":"Fuxe K.; Canals M.; Torvinen M.; Marcellino D.; Terasmaa A.; Genedani S.; Leo G.; Guidolin D.; Diaz-Cabiale Z.; Rivera A.; Lundstrom L.; Langel U.; Narvaez J.; Tanganelli S.; Lluis C.; Ferré S.; Woods A.; Franco R.; Agnati L.F.; Intramembrane receptor-receptor interactions: A novel principle in molecular medicine. J Neural Transm (Vienna) 2007,114(1),49-75","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=853","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.pneurobio.2009.10.004","volume":"90","author":"Agnati L.F.","year":"2010","unstructured":"Agnati L.F.; Guidolin D.; Leo G.; Carone C.; Genedani S.; Fuxe K.; Receptor-receptor interactions: A novel concept in brain integration. Prog Neurobiol 2010,90(2),157-175","journal-title":"Prog Neurobiol"},{"key":"ref=854","first-page":"pp. 1-28","author":"Agnati L.F.","year":"2003","unstructured":"Agnati L.F.; Franzen O.; Ferré S.; Leo G.; Franco R.; Fuxe K.; Possible role of intramembrane receptor-receptor interactions in memory and learning via formation of long-lived heteromeric complexes: Focus on motor learning in the basal ganglia. In: J. Neural Transmission, Supplement, 2003,pp. 1-28"},{"key":"ref=855","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJM199103073241003","volume":"324","author":"Denning D.W.","year":"1991","unstructured":"Denning D.W.; Follansbee S.E.; Scolaro M.; Norris S.; Edelstein H.; Stevens D.A.; Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 1991,324(10),654-662","journal-title":"N Engl J Med"},{"key":"ref=856","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3109\/10799893.2010.506191","volume":"30","author":"Fuxe K.","year":"2010","unstructured":"Fuxe K.; Marcellino D.; Borroto-Escuela D.O.; Frankowska M.; Ferraro L.; Guidolin D.; Ciruela F.; Agnati L.F.; The changing world of G protein-coupled receptors: from monomers to dimers and receptor mosaics with allosteric receptor-receptor interactions. J Recept Signal Transduct Res 2010,30(5),272-283","journal-title":"J Recept Signal Transduct Res"},{"key":"ref=857","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1100\/tsw.2008.136","volume":"8","author":"Navarro G.","year":"2008","unstructured":"Navarro G.; Carriba P.; Gandía J.; Ciruela F.; Casadó V.; Cortés A.; Mallol J.; Canela E.I.; Lluis C.; Franco R.; Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer. Sci World J 2008,8,1088-1097","journal-title":"Sci World J"},{"key":"ref=858","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0306-4522(00)00552-2","volume":"103","author":"Dean B.","year":"2001","unstructured":"Dean B.; Sundram S.; Bradbury R.; Scarr E.; Copolov D.; Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001,103(1),9-15","journal-title":"Neuroscience"},{"key":"ref=859","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0074-7742(06)78001-1","volume":"78","author":"Guillin O.","year":"2007","unstructured":"Guillin O.; Abi-Dargham A.; Laruelle M.; Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol 2007,78,1-39","journal-title":"Int Rev Neurobiol"},{"key":"ref=860","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0091-679X(08)85019-4","volume":"85","author":"Kerppola T.K.","year":"2008","unstructured":"Kerppola T.K.; Bimolecular fluorescence complementation: visualization of molecular interactions in living cells. Methods Cell Biol 2008,85,431-470","journal-title":"Methods Cell Biol"},{"key":"ref=861","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nmeth.1229","volume":"5","author":"Carriba P.","year":"2008","unstructured":"Carriba P.; Navarro G.; Ciruela F.; Ferré S.; Casadó V.; Agnati L.; Cortés A.; Mallol J.; Fuxe K.; Canela E.I.; Lluís C.; Franco R.; Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nat Methods 2008,5(8),727-733","journal-title":"Nat Methods"},{"key":"ref=862","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/00001756-200303030-00003","volume":"14","author":"Deckert J.","year":"2003","unstructured":"Deckert J.; Brenner M.; Durany N.; Zöchling R.; Paulus W.; Ransmayr G.; Tatschner T.; Danielczyk W.; Jellinger K.; Riederer P.; Up-regulation of striatal adenosine A(2A) receptors in schizophrenia. Neuroreport 2003,14(3),313-316","journal-title":"Neuroreport"},{"key":"ref=863","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s00210-005-1074-2","volume":"371","author":"Sundram S.","year":"2005","unstructured":"Sundram S.; Copolov D.; Dean B.; Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn Schmiedebergs Arch Pharmacol 2005,371(5),428-433","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=864","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00213-009-1608-2","volume":"206","author":"Urigüen L.","year":"2009","unstructured":"Urigüen L.; García-Fuster M.J.; Callado L.F.; Morentin B.; La Harpe R.; Casadó V.; Lluis C.; Franco R.; García-Sevilla J.A.; Meana J.J.; Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology (Berl) 2009,206(2),313-324","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=865","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1111\/j.1471-4159.2009.06078.x","volume":"109","author":"Cabello N.","year":"2009","unstructured":"Cabello N.; Gandía J.; Bertarelli D.C.G.; Watanabe M.; Lluís C.; Franco R.; Ferré S.; Luján R.; Ciruela F.; Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells. J Neurochem 2009,109(5),1497-1507","journal-title":"J Neurochem"},{"key":"ref=866","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0893-133X(01)00256-1","volume":"25","author":"Popoli P.","year":"2001","unstructured":"Popoli P.; Pèzzola A.; Torvinen M.; Reggio R.; Pintor A.; Scarchilli L.; Fuxe K.; Ferré S.; The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors. Neuropsychopharmacology 2001,25(4),505-513","journal-title":"Neuropsychopharmacology"},{"key":"ref=867","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S0304-3940(02)00179-9","volume":"324","author":"Díaz-Cabiale Z.","year":"2002","unstructured":"Díaz-Cabiale Z.; Vivó M.; Del Arco A.; O\u2019Connor W.T.; Harte M.K.; Müller C.E.; Martínez E.; Popoli P.; Fuxe K.; Ferré S.; Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors. Neurosci Lett 2002,324(2),154-158","journal-title":"Neurosci Lett"},{"key":"ref=868","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.tins.2006.09.004","volume":"29","author":"Schwarzschild M.A.","year":"2006","unstructured":"Schwarzschild M.A.; Agnati L.; Fuxe K.; Chen J.F.; Morelli M.; Targeting adenosine A2A receptors in Parkinson\u2019s disease. Trends Neurosci 2006,29(11),647-654","journal-title":"Trends Neurosci"},{"key":"ref=869","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.pharmthera.2004.06.004","volume":"103","author":"Bockaert J.","year":"2004","unstructured":"Bockaert J.; Fagni L.; Dumuis A.; Marin P.; GPCR interacting proteins (GIP). Pharmacol Ther 2004,103(3),203-221","journal-title":"Pharmacol Ther"},{"key":"ref=870","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.semcdb.2003.12.018","volume":"15","author":"Fagni L.","year":"2004","unstructured":"Fagni L.; Ango F.; Perroy J.; Bockaert J.; Identification and functional roles of metabotropic glutamate receptor-interacting proteins. Semin Cell Dev Biol 2004,15(3),289-298","journal-title":"Semin Cell Dev Biol"},{"key":"ref=871","first-page":"273","volume":"4","author":"Kamal M.","year":"2011","unstructured":"Kamal M.; Maurice P.; Jockers R.; Expanding the concept of G protein-coupled receptor (GPCR) dimer asymmetry towards GPCR-interacting proteins. Pharm 2011,4(2),273-284","journal-title":"Pharm"},{"key":"ref=872","first-page":"649","volume":"7","author":"Bockaert J.","year":"2004","unstructured":"Bockaert J.; Dumuis A.; Fagni L.; Marin P.; GPCR-GIP networks: A first step in the discovery of new therapeutic drugs?. Curr Opin Drug Discov Devel 2004,7(5),649-657","journal-title":"Curr Opin Drug Discov Devel"},{"key":"ref=873","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/978-94-007-7423-0_9","volume":"796","author":"Kowalsman N.","year":"2014","unstructured":"Kowalsman N.; Niv M.Y.; Kowalsman N.; Niv \u2022 M Y, Filizola M. GPCR & Company: Databases and Servers for GPCRs and Interacting Partners. Adv Exp Med Biol 2014,796,185-204","journal-title":"Adv Exp Med Biol"},{"key":"ref=874","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/B978-0-12-385952-5.00001-4","volume":"62","author":"Maurice P.","year":"2011","unstructured":"Maurice P.; Guillaume J.L.; Benleulmi-Chaachoua A.; Daulat A.M.; Kamal M.; Jockers R.; GPCR-interacting proteins, major players of GPCR function. Adv Pharmacol 2011,62,349-380","journal-title":"Adv Pharmacol"},{"key":"ref=875","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1111\/j.1476-5381.2011.01552.x","volume":"165","author":"Magalhaes A.C.","year":"2012","unstructured":"Magalhaes A.C.; Dunn H.; Ferguson S.S.G.; Regulation of GPCR activity, trafficking and localization by GPCR-interacting proteins. Br J Pharmacol 2012,165(6),1717-1736","journal-title":"Br J Pharmacol"},{"key":"ref=876","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/nrm2803","volume":"10","author":"Ritter S.L.","year":"2009","unstructured":"Ritter S.L.; Hall R.A.; Fine-tuning of GPCR activity by receptor-interacting proteins. Nat Rev Mol Cell Biol 2009,10(12),819-830","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=877","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nri2473","volume":"9","author":"Shaw A.S.","year":"2009","unstructured":"Shaw A.S.; Filbert E.L.; Scaffold proteins and immune-cell signalling. Nat Rev Immunol 2009,9(1),47-56","journal-title":"Nat Rev Immunol"},{"key":"ref=878","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/nrm1527","volume":"5","author":"Wong W.","year":"2004","unstructured":"Wong W.; Scott J.D.; AKAP signalling complexes: focal points in space and time. Nat Rev Mol Cell Biol 2004,5(12),959-970","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=879","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1038\/emboj.2010.236","volume":"29","author":"Maurice P.","year":"2010","unstructured":"Maurice P.; Daulat A.M.; Turecek R.; Ivankova-Susankova K.; Zamponi F.; Kamal M.; Clement N.; Guillaume J.L.; Bettler B.; Galès C.; Delagrange P.; Jockers R.; Molecular organization and dynamics of the melatonin MT receptor\/RGS20\/G(i) protein complex reveal asymmetry of receptor dimers for RGS and G(i) coupling. EMBO J 2010,29(21),3646-3659","journal-title":"EMBO J"},{"key":"ref=880","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.semcdb.2006.03.002","volume":"17","author":"Neitzel K.L.","year":"2006","unstructured":"Neitzel K.L.; Hepler J.R.; Cellular mechanisms that determine selective RGS protein regulation of G protein-coupled receptor signaling. Semin Cell Dev Biol 2006,17(3),383-389","journal-title":"Semin Cell Dev Biol"},{"key":"ref=881","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jmb.2006.11.045","volume":"366","author":"Xie G.X.","year":"2007","unstructured":"Xie G.X.; Palmer P.P.; How regulators of G protein signaling achieve selective regulation. J Mol Biol 2007,366(2),349-365","journal-title":"J Mol Biol"},{"key":"ref=882","doi-asserted-by":"publisher","first-page":"5567","DOI":"10.1523\/JNEUROSCI.0026-21.2021","volume":"41","author":"Bockaert J.","year":"2021","unstructured":"Bockaert J.; Perroy J.; Ango F.; The complex formed by group i metabotropic glutamate receptor (mGluR) and homer1a plays a central role in metaplasticity and homeostatic synaptic scaling. J Neurosci 2021,41(26),5567-5578","journal-title":"J Neurosci"},{"key":"ref=883","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/35082096","volume":"411","author":"Ango F.","year":"2001","unstructured":"Ango F.; Prézeau L.; Muller T.; Tu J.C.; Xiao B.; Worley P.F.; \nAgonist-independent activation of metabotropic glutamate receptors by the intracellular protein. \nHomer.\n Nat 2001,411(6840),962-965","journal-title":"Nat"},{"key":"ref=884","doi-asserted-by":"publisher","first-page":"7238","DOI":"10.1523\/JNEUROSCI.20-19-07238.2000","volume":"20","author":"Kammermeier P.J.","year":"2000","unstructured":"Kammermeier P.J.; Xiao B.; Tu J.C.; Worley P.F.; Ikeda S.R.; Homer proteins regulate coupling of group I metabotropic glutamate receptors to N-type calcium and M-type potassium channels. J Neurosci 2000,20(19),7238-7245","journal-title":"J Neurosci"},{"key":"ref=885","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S0959-4388(00)00087-8","volume":"10","author":"Xiao B.","year":"2000","unstructured":"Xiao B.; Tu J.C.; Worley P.F.; Homer: A link between neural activity and glutamate receptor function. Curr Opin Neurobiol 2000,10(3),370-374","journal-title":"Curr Opin Neurobiol"},{"key":"ref=886","doi-asserted-by":"publisher","first-page":"R848","DOI":"10.1016\/S0960-9822(00)80043-3","volume":"9","author":"Ehlers M.D.","year":"1999","unstructured":"Ehlers M.D.; Synapse structure: glutamate receptors connected by the shanks. Curr Biol 1999,9(22),R848-R850","journal-title":"Curr Biol"},{"key":"ref=887","doi-asserted-by":"publisher","first-page":"pp. 269-283","DOI":"10.1039\/9781849733441-00269","author":"Bockaert J.","year":"2011","unstructured":"Bockaert J.; Fagni L.; Perroy J.; In: G Protein-Coupled Receptors, 2011,pp. 269-283","journal-title":"In: G Protein-Coupled Receptors,"},{"key":"ref=888","doi-asserted-by":"publisher","first-page":"107977","DOI":"10.1016\/j.pharmthera.2021.107977","volume":"231","author":"Ferré S.","year":"2022","unstructured":"Ferré S.; Ciruela F.; Dessauer C.W.; González-Maeso J.; Hébert T.E.; Jockers R.; Logothetis D.E.; Pardo L.; G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs). Pharmacol Ther 2022,231(Sep),107977","journal-title":"Pharmacol Ther"},{"key":"ref=889","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1021\/jm00349a016","volume":"25","author":"Erez M.","year":"1982","unstructured":"Erez M.; Takemori A.E.; Portoghese P.S.; Narcotic antagonistic potency of bivalent ligands which contain beta-naltrexamine. Evidence for bridging between proximal recognition sites. J Med Chem 1982,25(7),847-849","journal-title":"J Med Chem"},{"key":"ref=890","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/0024-3205(82)90362-9","volume":"31","author":"Portoghese P.S.","year":"1982","unstructured":"Portoghese P.S.; Ronsisvalle G.; Larson D.L.; Yim C.B.; Sayre L.M.; Takemori A.E.; Opioid agonist and antagonist bivalent ligands as receptor probes. Life Sci 1982,31(12-13),1283-1286","journal-title":"Life Sci"},{"key":"ref=891","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.drudis.2020.10.006","volume":"26","author":"Huang B.","year":"2021","unstructured":"Huang B.; St Onge C.M.; Ma H.; Zhang Y.; Design of bivalent ligands targeting putative GPCR dimers. Drug Discov Today 2021,26(1),189-199","journal-title":"Drug Discov Today"},{"key":"ref=892","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/cmdc.201100101","volume":"6","author":"Shonberg J.","year":"2011","unstructured":"Shonberg J.; Scammells P.J.; Capuano B.; Design strategies for bivalent ligands targeting GPCRs. ChemMedChem 2011,6(6),963-974","journal-title":"ChemMedChem"},{"key":"ref=893","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/s42003-021-02574-4","volume":"4","author":"Budzinski J.","year":"2021","unstructured":"Budzinski J.; Maschauer S.; Kobayashi H.; Couvineau P.; Vogt H.; Gmeiner P.; Roggenhofer A.; Prante O.; Bouvier M.; Weikert D.; Bivalent ligands promote endosomal trafficking of the dopamine D3 receptor-neurotensin receptor 1 heterodimer. Commun Biol 2021,4(1),1062","journal-title":"Commun Biol"},{"key":"ref=894","doi-asserted-by":"publisher","first-page":"8212","DOI":"10.1021\/acs.jmedchem.8b00671","volume":"61","author":"Qian M.","year":"2018","unstructured":"Qian M.; Wouters E.; Dalton J.A.R.; Risseeuw M.D.P.; Crans R.A.J.; Stove C.; Giraldo J.; Van Craenenbroeck K.; Van Calenbergh S.; Synthesis toward Bivalent Ligands for the Dopamine D and Metabotropic Glutamate 5 Receptors. J Med Chem 2018,61(18),8212-8225","journal-title":"J Med Chem"},{"key":"ref=895","doi-asserted-by":"publisher","first-page":"109648","DOI":"10.1016\/j.celrep.2021.109648","volume":"36","author":"Nasrallah C.","year":"2021","unstructured":"Nasrallah C.; Cannone G.; Briot J.; Rottier K.; Berizzi A.E.; Huang C.Y.; Quast R.B.; Hoh F.; Banères J.L.; Malhaire F.; Berto L.; Dumazer A.; Font-Ingles J.; Gómez-Santacana X.; Catena J.; Kniazeff J.; Goudet C.; Llebaria A.; Pin J.P.; Vinothkumar K.R.; Lebon G.; Agonists and allosteric modulators promote signaling from different metabotropic glutamate receptor 5 conformations. Cell Rep 2021,36(9),109648","journal-title":"Cell Rep"},{"key":"ref=896","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1111\/febs.15783","volume":"288","author":"Bock A.","year":"2021","unstructured":"Bock A.; Bermudez M.; Allosteric coupling and biased agonism in G protein-coupled receptors. FEBS J 2021,288(8),2513-2528","journal-title":"FEBS J"},{"key":"ref=897","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1111\/febs.15826","volume":"288","author":"Ma N.","year":"2021","unstructured":"Ma N.; Nivedha A.K.; Vaidehi N.; Allosteric communication regulates ligand-specific GPCR activity. FEBS J 2021,288(8),2502-2512","journal-title":"FEBS J"},{"key":"ref=898","doi-asserted-by":"publisher","first-page":"e2108776118","DOI":"10.1073\/pnas.2108776118","volume":"118","author":"Romantini N.","year":"2021","unstructured":"Romantini N.; Alam S.; Dobitz S.; Spillmann M.; De Foresta M.; Schibli R.; Schertler G.F.X.; Wennemers H.; Deupi X.; Behe M.; Berger P.; Exploring the signaling space of a GPCR using bivalent ligands with a rigid oligoproline backbone. Proc Natl Acad Sci USA 2021,118(48),e2108776118","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=899","doi-asserted-by":"publisher","first-page":"e2105848118","DOI":"10.1073\/pnas.2105848118","volume":"118","author":"Haubrich J.","year":"2021","unstructured":"Haubrich J.; Font J.; Quast R.B.; Goupil-Lamy A.; Scholler P.; Nevoltris D.; Acher F.; Chames P.; Rondard P.; Prézeau L.; Pin J.P.; A nanobody activating metabotropic glutamate receptor 4 discriminates between homo- and heterodimers. Proc Natl Acad Sci USA 2021,118(33),e2105848118","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=900","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.freeradbiomed.2021.09.005","volume":"176","author":"Wagner T.R.","year":"2021","unstructured":"Wagner T.R.; Rothbauer U.; Nanobodies - Little helpers unravelling intracellular signaling. Free Radic Biol Med 2021,176,46-61","journal-title":"Free Radic Biol Med"},{"key":"ref=901","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/363446a0","volume":"363","author":"Hamers-Casterman C.","year":"1993","unstructured":"Hamers-Casterman C.; Atarhouch T.; Muyldermans S.; Robinson G.; Hammers C.; Songa E.B.; Naturally occurring antibodies devoid of light chains. Nat 1993,363(6428),446-448","journal-title":"Nat"},{"key":"ref=902","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/s41467-020-14889-7","volume":"11","author":"Che T.","year":"2020","unstructured":"Che T.; English J.; Krumm B.E.; Kim K.; Pardon E.; Olsen R.H.J.; Wang S.; Zhang S.; Diberto J.F.; Sciaky N.; Carroll F.I.; Steyaert J.; Wacker D.; Roth B.L.; Nanobody-enabled monitoring of kappa opioid receptor states. Nat Commun 2020,11(1),1145","journal-title":"Nat Commun"},{"key":"ref=903","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7554\/eLife.54208","volume":"9","author":"Stoeber M.","year":"2020","unstructured":"Stoeber M.; Jullié D.; Li J.; Chakraborty S.; Majumdar S.; Lambert N.A.; Manglik A.; von Zastrow M.; Agonist-selective recruitment of engineered protein probes and of GRK2 by opioid receptors in living cells. eLife 2020,9,9","journal-title":"eLife"},{"key":"ref=904","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.neuron.2018.04.021","volume":"98","author":"Stoeber M.","year":"2018","unstructured":"Stoeber M.; Jullié D.; Lobingier B.T.; Laeremans T.; Steyaert J.; Schiller P.W.; Manglik A.; von Zastrow M.; A genetically encoded biosensor reveals location bias of opioid drug action. Neuron 2018,98(5),963-976.e5","journal-title":"Neuron"},{"key":"ref=905","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.cell.2017.12.011","volume":"172","author":"Che T.","year":"2018","unstructured":"Che T.; Majumdar S.; Zaidi S.A.; Ondachi P.; McCorvy J.D.; Wang S.; Mosier P.D.; Uprety R.; Vardy E.; Krumm B.E.; Han G.W.; Lee M.Y.; Pardon E.; Steyaert J.; Huang X.P.; Strachan R.T.; Tribo A.R.; Pasternak G.W.; Carroll F.I.; Stevens R.C.; Cherezov V.; Katritch V.; Wacker D.; Roth B.L.; Structure of a nanobody-stabilized active state of the kappa opioid receptor. Cell 2018,172(1-2),55-67.e15","journal-title":"Cell"},{"key":"ref=906","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.coemr.2020.08.005","volume":"16","author":"Johnson G.P.","year":"2021","unstructured":"Johnson G.P.; Agwuegbo U.; Jonas K.C.; New insights into the functional impact of G protein-coupled receptor oligomerization. Curr Opin Endocr Metab Res 2021,16,43-50","journal-title":"Curr Opin Endocr Metab Res"},{"key":"ref=907","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.mce.2019.01.021","volume":"484","author":"De Groof T.W.M.","year":"2019","unstructured":"De Groof T.W.M.; Bobkov V.; Heukers R.; Smit M.J.; Nanobodies: New avenues for imaging, stabilizing and modulating GPCRs. Mol Cell Endocrinol 2019,484,15-24","journal-title":"Mol Cell Endocrinol"},{"key":"ref=908","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrd.2018.103","volume":"17","author":"Dolgin E.","year":"2018","unstructured":"Dolgin E.; First GPCR-directed antibody passes approval milestone. Nat Rev Drug Discov 2018,17(7),457-459","journal-title":"Nat Rev Drug Discov"},{"key":"ref=909","doi-asserted-by":"publisher","first-page":"e01215","DOI":"10.1002\/brb3.1215","volume":"9","author":"Han L.","year":"2019","unstructured":"Han L.; Liu Y.; Xiong H.; Hong P.; CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta-analysis. Brain Behav 2019,9(2),e01215","journal-title":"Brain Behav"},{"key":"ref=910","doi-asserted-by":"publisher","first-page":"588662","DOI":"10.3389\/fncel.2020.588662","volume":"14","author":"DelaCuesta-Barrutia J.","year":"2020","unstructured":"DelaCuesta-Barrutia J.; Peñagarikano O.; Erdozain A.M.G.G.; Protein-coupled receptor heteromers as putative pharmacotherapeutic targets in autism. Front Cell Neurosci 2020,14,588662","journal-title":"Front Cell Neurosci"},{"key":"ref=911","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1124\/mol.105.012229","volume":"68","author":"So C.H.","year":"2005","unstructured":"So C.H.; Varghese G.; Curley K.J.; Kong M.M.C.; Alijaniaram M.; Ji X.; Nguyen T.; O\u2019dowd B.F.; George S.R.; D1 and D2 dopamine receptors form heterooligomers and cointernalize after selective activation of either receptor. Mol Pharmacol 2005,68(3),568-578","journal-title":"Mol Pharmacol"},{"key":"ref=912","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/S0893-133X(00)00144-5","volume":"23","author":"Franco R.","year":"2000","unstructured":"Franco R.; Ferré S.; Agnati L.; Torvinen M.; Ginés S.; Hillion J.; Casadó V.; Lledó P.; Zoli M.; Lluis C.; Fuxe K.; Evidence for adenosine\/dopamine receptor interactions: indications for heteromerization. Neuropsychopharmacology 2000,23(4)(Suppl.),S50-S59","journal-title":"Neuropsychopharmacology"},{"key":"ref=913","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0306-4522(02)00058-1","volume":"113","author":"Torvinen M.","year":"2002","unstructured":"Torvinen M.; Ginés S.; Hillion J.; Latini S.; Canals M.; Ciruela F.; Bordoni F.; Staines W.; Pedata F.; Agnati L.F.; Lluis C.; Franco R.; Ferré S.; Fuxe K.; Interactions among adenosine deaminase, adenosine A(1) receptors and dopamine D(1) receptors in stably cotransfected fibroblast cells and neurons. Neuroscience 2002,113(3),709-719","journal-title":"Neuroscience"},{"key":"ref=914","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejphar.2007.01.090","volume":"562","author":"Cao Y.","year":"2007","unstructured":"Cao Y.; Xie K.Q.; Zhu X.Z.; The enhancement of dopamine D1 receptor desensitization by adenosine A1 receptor activation. Eur J Pharmacol 2007,562(1-2),34-38","journal-title":"Eur J Pharmacol"},{"key":"ref=915","doi-asserted-by":"publisher","first-page":"5590","DOI":"10.1021\/jm900298c","volume":"52","author":"Soriano A.","year":"2009","unstructured":"Soriano A.; Ventura R.; Molero A.; Hoen R.; Casadó V.; Cortés A.; Fanelli F.; Albericio F.; Lluís C.; Franco R.; Royo M.; Adenosine A2A receptor-antagonist\/dopamine D2 receptor-agonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor heteromers. J Med Chem 2009,52(18),5590-5602","journal-title":"J Med Chem"},{"key":"ref=916","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1385\/JMN:26:2-3:209","volume":"26","author":"Fuxe K.","year":"2005","unstructured":"Fuxe K.; Ferré S.; Canals M.; Torvinen M.; Terasmaa A.; Marcellino D.; Goldberg S.R.; Staines W.; Jacobsen K.X.; Lluis C.; Woods A.S.; Agnati L.F.; Franco R.; Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function. J Mol Neurosci 2005,26(2-3),209-220","journal-title":"J Mol Neurosci"},{"key":"ref=917","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.1021\/ac049295f","volume":"76","author":"Ciruela F.","year":"2004","unstructured":"Ciruela F.; Burgueño F.; Casadó V.; Canals M.; Marcellino D.; Goldberg S.R.; Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope\u2212epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors. Anal Chem 2004,76(18),5354-5363","journal-title":"Anal Chem"},{"key":"ref=918","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1212\/01.WNL.0000073136.00548.D4","volume":"61","author":"Bara-Jimenez W.","year":"2003","unstructured":"Bara-Jimenez W.; Sherzai A.; Dimitrova T.; Favit A.; Bibbiani F.; Gillespie M.; Morris M.J.; Mouradian M.M.; Chase T.N.; Adenosine A(2A) receptor antagonist treatment of Parkinson\u2019s disease. Neurology 2003,61(3),293-296","journal-title":"Neurology"},{"key":"ref=919","first-page":"288(5463), 154-157","author":"Rocheville M.","year":"2000","unstructured":"Rocheville M.; Lange D.C.; Kumar U.; Patel S.C.; Patel R.C.; Patel Y.C.; Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity. Science (80) 2000,288(5463), 154-157","journal-title":"Science (80)"},{"key":"ref=920","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1073\/pnas.1712725115","volume":"115","author":"Damian M.","year":"2018","unstructured":"Damian M.; Pons V.; Renault P.; M\u2019Kadmi C.; Delort B.; Hartmann L.; Kaya A.I.; Louet M.; Gagne D.; Ben Haj Salah K.; Denoyelle S.; Ferry G.; Boutin J.A.; Wagner R.; Fehrentz J.A.; Martinez J.; Marie J.; Floquet N.; Galès C.; Mary S.; Hamm H.E.; Banères J.L.; GHSR-D2R heteromerization modulates dopamine signaling through an effect on G protein conformation. Proc Natl Acad Sci USA 2018,115(17),4501-4506","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=921","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1021\/acschemneuro.9b00426","volume":"11","author":"Cordisco G.S.","year":"2020","unstructured":"Cordisco G.S.; Mustafá E.R.; Rodriguez S.S.; Perello M.; Raingo J.; Dopamine receptor type 2 and ghrelin receptor coexpression alters Ca2.2 modulation by G protein signaling cascades. ACS Chem Neurosci 2020,11(1),3-13","journal-title":"ACS Chem Neurosci"},{"key":"ref=922","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11302-018-9638-z","volume":"15","author":"Morales-Figueroa G.E.","year":"2019","unstructured":"Morales-Figueroa G.E.; Rivera-Ramírez N.; González-Pantoja R.; Escamilla-Sánchez J.; García-Hernández U.; Galván E.J.; Arias-Montaño J.A.; Adenosine A and histamine H receptors interact at the cAMP\/PKA pathway to modulate depolarization-evoked [H]-GABA release from rat striato-pallidal terminals. Purinergic Signal 2019,15(1),85-93","journal-title":"Purinergic Signal"},{"key":"ref=923","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejphar.2007.02.040","volume":"566","author":"Lenard N.R.","year":"2007","unstructured":"Lenard N.R.; Daniels D.J.; Portoghese P.S.; Roerig S.C.; Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores. Eur J Pharmacol 2007,566(1-3),75-82","journal-title":"Eur J Pharmacol"},{"key":"ref=924","doi-asserted-by":"publisher","first-page":"19208","DOI":"10.1073\/pnas.0506627102","volume":"102","author":"Daniels D.J.","year":"2005","unstructured":"Daniels D.J.; Lenard N.R.; Etienne C.L.; Law P-Y.; Roerig S.C.; Portoghese P.S.; Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci USA 2005,102(52),19208-19213","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=925","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1042\/BST0320856","volume":"\u2022","author":"Zhang Y.Q.","year":"2004","unstructured":"Zhang Y.Q.; Limbird L.E.; Hetero-oligomers of α2A-adrenergic and μ-opioid receptors do not lead to transactivation of G-proteins or altered endocytosis profiles. Biochem Soc Trans 2004,\u2022,856-860","journal-title":"Biochem Soc Trans"},{"key":"ref=926","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1124\/mol.64.6.1317","volume":"64","author":"Jordan B.A.","year":"2003","unstructured":"Jordan B.A.; Gomes I.; Rios C.; Filipovska J.; Devi L.A.; Functional interactions between μ opioid and α 2A-adrenergic receptors. Mol Pharmacol 2003,64(6),1317-1324","journal-title":"Mol Pharmacol"},{"key":"ref=927","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/syn.10036","volume":"43","author":"Glass M.J.","year":"2002","unstructured":"Glass M.J.; Pickel V.M.; α(2A)-adrenergic receptors are present in μ-opioid receptor containing neurons in rat medial nucleus tractus solitarius. Synapse 2002,43(3),208-218","journal-title":"Synapse"},{"key":"ref=928","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/BF02244763","volume":"115","author":"Gabilondo A.M.","year":"1994","unstructured":"Gabilondo A.M.; Meana J.J.; Barturen F.; Sastre M.; García-Sevilla J.A.; μ-Opioid receptor and α 2-adrenoceptor agonist binding sites in the postmortem brain of heroin addicts. Psychopharmacology (Berl) 1994,115(1-2),135-140","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=929","doi-asserted-by":"publisher","first-page":"512558","DOI":"10.1101\/512558","author":"Fongang B.","year":"2019","unstructured":"Fongang B.; Cunningham K.A.; Rowicka M.; Kudlicki, A protein co-evolution strategies detect predicted functional interaction between the serotonin 5-HT2A and 5-HT2C receptors. bioRxiv 2019,512558","journal-title":"bioRxiv"},{"key":"ref=930","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1021\/cn300072u","volume":"4","author":"Cunningham K.A.","year":"2013","unstructured":"Cunningham K.A.; Anastasio N.C.; Fox R.G.; Stutz S.J.; Bubar M.J.; Swinford S.E.; Watson C.S.; Gilbertson S.R.; Rice K.C.; Rosenzweig-Lipson S.; Moeller F.G.; Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction. ACS Chem Neurosci 2013,4(1),110-121","journal-title":"ACS Chem Neurosci"},{"key":"ref=931","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/sj.npp.1301558","volume":"33","author":"Martín A.B.","year":"2008","unstructured":"Martín A.B.; Fernandez-Espejo E.; Ferrer B.; Gorriti M.A.; Bilbao A.; Navarro M.; Rodriguez de Fonseca F.; Moratalla R.; Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacology 2008,33(7),1667-1679","journal-title":"Neuropsychopharmacology"},{"key":"ref=932","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1096\/fj.10-163147","volume":"25","author":"Doumazane E.","year":"2011","unstructured":"Doumazane E.; Scholler P.; Zwier J.M.; Trinquet E.; Rondard P.; Pin J-P.; A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors. FASEB J 2011,25(1),66-77","journal-title":"FASEB J"},{"key":"ref=933","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2021_232","author":"Nieto A.","year":"2021","unstructured":"Nieto A.; Bailey T.; Kaczanowska K.; McDonald P.; GABAB receptor chemistry and pharmacology: Agonists, antagonists, and allosteric modulators. Curr Top Behav Neurosci 2021","journal-title":"Curr Top Behav Neurosci"},{"key":"ref=934","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/j.neuropharm.2012.01.010","volume":"62","author":"Delille H.K.","year":"2012","unstructured":"Delille H.K.; Becker J.M.; Burkhardt S.; Bleher B.; Terstappen G.C.; Schmidt M.; Meyer A.H.; Unger L.; Marek G.J.; Mezler M.; Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades. Neuropharmacology 2012,62(7),2184-2191","journal-title":"Neuropharmacology"},{"key":"ref=935","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1021\/acschemneuro.9b00044","volume":"10","author":"Shah U.H.","year":"2019","unstructured":"Shah U.H.; González-Maeso J.; Serotonin and glutamate interactions in preclinical schizophrenia models. ACS Chem Neurosci 2019,10(7),3068-3077","journal-title":"ACS Chem Neurosci"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X20666220327221830","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/202652\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X20666220327221830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T09:56:04Z","timestamp":1669110964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/202652\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":935,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x20666220327221830","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-09-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}